<SEC-DOCUMENT>0001731122-22-000196.txt : 20220209
<SEC-HEADER>0001731122-22-000196.hdr.sgml : 20220209
<ACCEPTANCE-DATETIME>20220209163039
ACCESSION NUMBER:		0001731122-22-000196
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220209
DATE AS OF CHANGE:		20220209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		22607648

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e3475_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:avxl="http://anavex.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2021_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_avxl_anavex.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20211001_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DCurrentFiscalYearEndDate_09/30 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">09/30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-09-30" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-01to2021-12-31" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-10-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20211001__20211231_zifwzZErv6V9"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 12pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--DocumentQuarterlyReport_c20211001__20211231_zyyE0SmfXq6g"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_906_edei--DocumentPeriodEndDate_c20211001__20211231_zrDUxBA8h8c3"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2021</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_90D_edei--DocumentTransitionReport_c20211001__20211231_zFRwHyYzsJb9"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_907_edei--EntityFileNumber_c20211001__20211231_zKHO0LQoHh97"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityRegistrantName_c20211001__20211231_zhodB74t2mA1"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20211001__20211231_zBrrI5DOfyej"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20211001__20211231_zlPcgl5q62Ua"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20211001__20211231_zQ8WbqaheAw6"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20211001__20211231_zHI2sBgTNila"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20211001__20211231_zyK8RCd5GC37"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20211001__20211231_zxZTfQnwjZRf"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressCountry_c20211001__20211231_zGXRyZYzdzv4"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">USA</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20211001__20211231_zzAxcpiGLUxh"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">1-<span id="xdx_90C_edei--CityAreaCode_c20211001__20211231_zfRo1SylVLVg"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90F_edei--LocalPhoneNumber_c20211001__20211231_zE0zodVWs5Bb"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Title
    of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    of Each Exchange on Which Registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20211001__20211231_z1R8WfcXSg78"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--TradingSymbol_c20211001__20211231_zxRdjtoYrO16"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The <span id="xdx_906_edei--SecurityExchangeName_c20211001__20211231_ztbft1GED9rb"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#9746;&#160;&#160;<span id="xdx_90B_edei--EntityCurrentReportingStatus_c20211001__20211231_zwOwvrnSaiL2"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#160;&#9744;&#160;&#160;No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#9746;&#160;&#160;<span id="xdx_903_edei--EntityInteractiveDataCurrent_c20211001__20211231_znNFFw2RRIV8"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#160;&#9744;&#160;&#160;No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 27%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--EntityFilerCategory_c20211001__20211231_zpwKYbu8Wb63"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
    <td style="width: 3%; text-align: justify">&#9746;</td>
    <td style="width: 41%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accelerated filer</span></td>
    <td style="width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-accelerated filer</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Smaller reporting company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntitySmallBusiness_c20211001__20211231_zUAYxDS0Dwjg"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Emerging growth company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20211001__20211231_zU2QZ06oPMGb"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#9744;&#160;&#160;Yes&#160;&#160;&#9746;&#160;&#160;<span id="xdx_904_edei--EntityShellCompany_c20211001__20211231" title="Entity Shell Company"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20220208_zQuy7M9FbL3i"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-02-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,174,887</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif">
shares of common stock outstanding as of February 8, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>TABLE OF CONTENTS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td colspan="2"><a href="#a_001">PART I - FINANCIAL INFORMATION&#9;PART I - FINANCIAL INFORMATION</a></td>
                                                                   <td style="text-align: right">4</td></tr>
                                                                                                                                                                 <tr style="vertical-align: top">
<td colspan="2">&#160;</td>
                                                                   <td style="text-align: right">&#160;</td></tr>
                                                                                                                                                                 <tr style="vertical-align: top">
<td style="width: 10%">Item 1.</td><td style="width: 85%"><a href="#a_002">FINANCIAL STATEMENTS</a>&#9;</td>
                                                                   <td style="text-align: right; width: 5%">4</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                                                                   <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 2.</td><td><a href="#a_003">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a>&#9;</td>
                         <td style="text-align: right">19</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 3.</td><td><a href="#a_004">Quantitative and Qualitative Disclosures about Market Risks.</a></td>
                         <td style="text-align: right">34</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 4.</td><td><a href="#a_005">Controls and Procedures.</a></td>
                                                                   <td style="text-align: right">34</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                                                                   <td style="text-align: right">&#160;</td></tr>
                                                                                                                 <tr style="vertical-align: top">
<td colspan="2"><a href="#a_006">PART II &#8211; OTHER INFORMATION</a></td>
                                                                   <td style="text-align: right">34</td></tr>

<tr style="vertical-align: top">
<td colspan="2">&#160;</td>
                                                                   <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 10%">Item 1.</td><td style="width: 85%"><a href="#a_007">Legal Proceedings.</a>&#9;</td>
                                                                   <td style="text-align: right; width: 5%">34</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                                                                   <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 1A.</td><td><a href="#a_008">Risk Factors.</a>&#9;</td>
                          <td style="text-align: right">34</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                          <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 2.</td><td><a href="#a_009">Unregistered Sales of Equity Securities and Use of Proceeds.</a>&#9;</td>
                         <td style="text-align: right">35</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right"></td></tr>
<tr style="vertical-align: top">
<td>Item 3.</td><td><a href="#a_010">Defaults Upon Senior Securities.</a>&#9;</td>
                         <td style="text-align: right">35</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 4.</td><td><a href="#a_011">Mine Safety Disclosures</a>&#9;</td>
                         <td style="text-align: right">35</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 5.</td><td><a href="#a_012">Other Information.</a>&#9;</td>
                         <td style="text-align: right">35</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                         <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Item 6. </td><td><a href="#a_013">Exhibits.</a></td>
                                                                    <td style="text-align: right">35</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td>
                                                                    <td style="text-align: right">&#160;</td></tr>
                                                                                                              <tr style="vertical-align: top">
<td colspan="2"><a href="#a_014">SIGNATURES</a></td>
                                                                    <td style="text-align: right">36</td></tr>
                                                                                                              </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_001"></span>PART I - FINANCIAL
INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_002"></span>Item 1. FINANCIAL
STATEMENTS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">Interim Condensed Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Interim Condensed Consolidated
Balance Sheets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">As at December 31,
2021 and September 30, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 218.65pt 0 0; text-align: center; text-indent: 4.6pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zvXsBTJYHjk2" summary="xdx: Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20211231" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20210930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">(Unaudited)</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsAbstract_iB_zqwHwIzwkVoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zyGPCXr7hy66" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzfop_zjC18kiRhNTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,146,355</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesReceivable_i02I_maCzfop_zp2xUreLTnA8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,372,153</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,136,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzfop_zM8UUioY1Fhl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">377,860</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,914</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzfop_zfSJBeNQ2ZFj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Total assets</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,896,368</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zO3sCQRBsbY3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i01B_zhzn2fmvzn97" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_maCzeNv_zAUgL1T6PFx6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,634,791</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,739,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzeNv_z2FSugKd2IZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities (Note 4)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,450,040</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,614,774</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeCurrent_i02I_maCzeNv_z5Of5WmU6ST7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtCzeNv_maCzfbu_zldrHGFcHgi6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total liabilities</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,528,662</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,798,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommitmentsAndContingencies_i01I_zveI5vIcNh4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_i01B_zmC0K8BvwZJc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_iI_zw80SrNf1K2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20210930_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pdd" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20210930_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,155,187</ix:nonFraction></ix:nonFraction></span></span> common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_iI_maSEzLXy_zLlj3aon3lQh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">(September 30, 2021 - <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20210930_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210930_zhqmeCI1IDq3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,156</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maSEzLXy_zjAHdz941KT3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,759,781</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzLXy_zQXXEW7TnA2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">208,468,231</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_iTI_maCzfbu_mtSEzLXy_zxBPNIlznwM1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,367,706</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzfbu_zRSpNzitWLD" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 20pt; text-align: left; text-indent: -10pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,896,368</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,616,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Anavex Life Sciences
Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Interim Condensed Consolidated</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Statements of Operations
and Comprehensive Loss</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">For the three months ended December 31,
2021 and 2020 (Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 177.85pt 0 0; text-align: center; text-indent: 15.6pt">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_zmGGH55zIQif" summary="xdx: Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20211001_20211231" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20201001_20201231" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpensesAbstract_iB_z6Cx0aURZsF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz4Bp_zHs40hRpKgy5" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,066,951</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,470,656</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz4Bp_zWUt1G4EGyhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Research and development</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,656,439</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,925,519</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_iNT_di_mtCz4Bp_msCz9JN_zMRyrvIAZWF6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,723,390</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,396,175</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zPnDxG2VdgBj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzJrT_zcjzLlCa0bn3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,730</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestIncomeExpenseNet_i01_maCzJrT_zq45u3DrbOX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income (expense), net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,910</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,559</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzJrT_zlvlOdlSOV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Foreign exchange gain, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,363</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,634</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NonoperatingIncomeExpense_iT_mtCzJrT_maCz9JN_zp45XiYs14R1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Total other income, net</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">871,003</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600,391</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCz9JN_maCzoAt_zDu3ZFuEhni7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,852,387</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,795,784</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzoAt_zoBZ0toqqFCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Income tax expense, current</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,980</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,281</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtCzoAt_zBOhgoxpiMS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net loss and comprehensive loss</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zZZ0SzSlsr53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zAj9ZM4VrmTe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Basic and diluted</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zeSnZ0jxdEok" style="vertical-align: bottom; background-color: White">
    <td>Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_z2Kqn3kANVjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,997,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,295,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Anavex Life Sciences
Corp.&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Interim Condensed Consolidated
Statement of Changes in Stockholders&#8217; Equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">For the three months ended December 31, 2021 and 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 97.85pt 0 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zomiAHqPztBe" summary="xdx: Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER&apos;S EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zk6qOTnLJeN3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zIszcw2gtdlh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zpib7fvffS7j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B1_zQBYDaaHlVWb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Additional</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Paid-in</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_433_c20211001__20211231_eus-gaap--StockholdersEquity_iS_zxOzp8iG2QSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; text-indent: -10pt">Balance, October 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL3NoV2Allej" title="Balance beginning, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsValue_zhYgxmiTZDse" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWABoZI87Ifl" title="Shares issued pursuant to exercise of stock options ,shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_z6WHXebkXW83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJe8Y7coS2C1" title="Shares issued under Sales Agreement, net of shares issue costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,149,602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,149,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zNoM2iwLfEAl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0194">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0196">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProfitLoss_zI3DAObMMuI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0200">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20211001__20211231_eus-gaap--StockholdersEquity_iE_zKXLVbNhGhz8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduHIjCA4op9" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,155,187</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,156</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,759,781</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">208,468,231</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,367,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20201001__20201231_eus-gaap--StockholdersEquity_iS_z3S5Z9gfkAMj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Balance, October 1, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2NqdDVFK8l8" title="Balance beginning, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--SharesOutstanding_zc3dtDReoT9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right">-&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right">-<span style="-sec-ix-hidden: xdx2ixbrl0218">&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right">-<span style="-sec-ix-hidden: xdx2ixbrl0221">&#160;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_zFDGXo6Yvgc8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_iP3us-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD0iTB1PHay3" title="Purchase shares ,shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,346,288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,458,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,461,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CommitmentSharesValue_iP3us-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_zYdXKWOAHc4k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--CommitmentSharesShares_iP3custom--CommitmentSharesValue_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Nt6v43YN1f" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under Sales Agreement, net of share issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwyDRuij99uf" title="Shares issued under Sales Agreement, net of shares issue costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,514,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,517,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,518,557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20201001__20201231_eus-gaap--StockholdersEquity_iE_zrYhLOL67Fqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt">Balance, December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4zYK4inwEyi" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,962,957</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,964</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,766,108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,532,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,300,777</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed
Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 7; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Anavex Life Sciences
Corp.&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Interim Condensed Consolidated
Statements of Cash Flows</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the three months ended
December 31, 2021 and 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 179pt 0 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_znMHvXNiaIak" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20211001__20211231_zTM7cRF5sUe5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20201001__20201231_z7fiFZ2T6Cld" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zBlb2o2p9IW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash flows used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maCzBTE_zXcNN9rhgti" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,882,367</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zb2vJB824ELb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_maCzBTE_zfgjYsr5F4Oe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z5IDJGxWpFDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in non-cash working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzBTE_zXU8HLV2VGhe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,764,678</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,728,467</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzBTE_zvrLLORIEGOg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,311</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzBTE_z7N8L0rjV653" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104,992</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,894</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzBTE_zkinKLZG4pRe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">164,734</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzBTE_maCz7tk_zHZBGgx4t4S" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,500,955</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,871,378</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zhTe5Jbejft2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash flows provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzbb5_z5hJTZhqia77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,312,785</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,243,419</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzbb5_zhGjcP9dbD79" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share issue costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,717</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,460</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzbb5_zHtMYvNp050l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,497</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzbb5_maCz7tk_z1VFMoWVaYUl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,539,565</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,979,959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_mtCz7tk_zZCOXGE0VFwk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease) increase in cash and cash equivalents during
    the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">961,390</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,108,581</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zgcPrAJBaz46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zA8INJVWjCWf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,146,355</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,357,599</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zIR3S5gerpQd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zhR8yB4eM1O9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local minimum income taxes</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zG4NB93uNQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1&#160;&#160;&#160;&#160;&#160;&#160; &#9;<span style="text-decoration: underline"><span id="xdx_827_zzJEo3RgaLhh">Description of Business and Basis of Presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Description of
Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221;
or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics
by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed
to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; text-indent: 2pt">Basis of Presentation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These accompanying unaudited interim condensed
consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management
are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2021 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes
thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2021 filed with the SEC on November
24, 2021. The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Operating results for the three months
ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Liquidity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company&#8217;s potential drug
compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful
or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience
negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zvFCXUkB6pLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 4 -->
    <div id="xdx_235_zZwj0i0lgq09" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zpEujEGa6iFe" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zGAqV4nAO9U7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_znTu0w4C2zGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_z2syj7xUmet7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zsifUe2sTP04" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zoBDIJdRQpf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_235_ztFfpRnzyeLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23C_z4bWk4uxdqm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zxhBbnjtkYcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 1&#160;&#160;&#160;&#160;&#160; &#9;<span style="text-decoration: underline">Description of Business and Basis of
Presentation</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_238_zkzUWp0N3Bfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current working
capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date
that these interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing
and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated
and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors
including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and
development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending
levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to the Sales
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Coronavirus Disease 2019 (COVID-19)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The recent global outbreak of COVID-19
has not had a material impact on the Company&#8217;s result of operations or financial condition as of December 31, 2021. However, the
pandemic continues to rapidly evolve as of the date these consolidated financial statements are issued and has created a dynamic and uncertain
situation in the global economy. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s
financial condition and future results of operations. Management is actively monitoring the global situation on its business, including
on its clinical trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses
to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations or financial
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Use
of Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial
statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting
period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and
loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other
factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other
sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To
the extent there are material differences between the estimates and the actual results, future results of operations will be
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23B_zHTi67HJdArh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 4 -->
    <div id="xdx_23F_zNnCVYHXLaUk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zDW7yf4FhpA" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zOfUrSrGLe6a" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zJfgA08i3Sli" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zy0MUCseZqNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zXBOV38uuQjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_233_zwvCgkCpnbb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_236_zMHUTVS5sQik" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23C_zEn8hiVJaST8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zYGAVl8vFPCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 1&#160;&#160;&#160;&#160;&#160;&#160; &#9;<span style="text-decoration: underline">Description of Business and Basis of
Presentation</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z6Fac7twUkE" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited. (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Fair
Value Measurements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value hierarchy under GAAP is
based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure
fair value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 - &#9;quoted
prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 - observable
inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value
drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 - &#9;assets
and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair
value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of cash and cash equivalents
and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At December 31, 2021 and September 30,
2021, the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common share is
computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during
the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum
of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of
options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes
of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation
of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of December 31, 2021, loss per share
excludes <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,403,769</ix:nonFraction></span> (September 30, 2021 &#8211; <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zWR0O7F3Y0k6" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,540,903</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zhgEcAAPbCF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 4 -->
    <div id="xdx_238_zGiF2upuEjse" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_z8JzfLpHE0qj" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zVrS0GLjA31b" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zTNHaglwUNyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zcp9t8s85uOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zJKLWeLC3uE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_235_zzzWOe9HvLrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z4KZoWLkfTkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_234_zSBKuDfgft0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_807_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zLlEni6ponre" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline"><span id="xdx_82D_zYSEBSrYZt01">Recent Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUO8BYw2NYma" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span id="xdx_863_zD5cBxvCJu8h">Recently Adopted
Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">Effective October
1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations, financial
condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_804_ecustom--OtherIncomeDisclosureTextBlock_zluVmor3G4sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 3&#9;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_828_zaV3cL0MM5V5">Other Income</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Grant Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the year
ended September 30, 2021, the Company received $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_z1AsLRT9ojul" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012021-12-31_custom_ParkinsonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s
Research. The grant will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to
Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">The grant income
is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2021 and 2020, the Company did not recognize any of this grant on its statements of operations. At
December 31, 2021, an amount of $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_ztn8klf9Fue2" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span> (September 30, 2021: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_zM2aXTHpLf33" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded as deferred grant income, representing
the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of
operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research and development
incentive income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research and development
incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the &#8220;R&amp;D
Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the three
months ended December 31, 2021, the Company recorded research and development incentive income of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zxIM8dcfeFPh" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">810,730</ix:nonFraction></span> (AUD <span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20211231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012021-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,362</ix:nonFraction></span>) (2020: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zetSwaPz1gl6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,269,316</ix:nonFraction></span>
(AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_zFB0I0xBKZJ5" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012020-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,735,962</ix:nonFraction></span>)) in respect of the R&amp;D Incentive Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zti2obruejZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 4&#9; &#160;&#160;&#160;&#160;&#9; <span style="text-decoration: underline"><span id="xdx_824_zVYsMgXVBcM7">Accrued liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consists of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zuDqTtFK1Pe4" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_zmtjbytSdBZh" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20211231_zompnbTVj6ec" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210930_z9MpFvF0PSd9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_407_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzxk9_zZoRKfFvKak2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,689,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,035,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzxk9_zk8vnRD0lay6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,205,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,201,903</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCzxk9_zpVFxt6N2Yv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">359,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">649,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzxk9_zGYcs2kVpfy" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,195,690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,727,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzxk9_zgWCmW0IOPH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 2.5pt">&#160;Total accrued liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,450,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,614,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_239_znPZP8eQ4Gei" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 4 -->
    <div id="xdx_23D_zgDQfbx1KZF" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zwE2NDTTph33" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zz83727rarza" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zhPeagdm9xh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zprFd91Nic5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zVNCCbdIngd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zgdO15KkLGtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zboIPD1qSQNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23D_zjltKH5g2V9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt; background-color: silver"><br /></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="avxl:EquityOfferingTextBlock"><p id="xdx_800_ecustom--EquityOfferingTextBlock_zl0TxZ1GVku8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline"><span id="xdx_82F_zl20FE9SSJ0j">Equity Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common shares are voting and are entitled
to dividends as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Preferred Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company&#8217;s Board of Directors
(the &#8220;Board&#8221;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with
Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer
and sell shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Upon delivery of a placement notice based
on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares
by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,
subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.
The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has agreed to pay the Sales
Agents commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement.
The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended
December 31, 2021, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zk8q2lcWl834" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,588</ix:nonFraction></span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_907_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFaMQJiBgp7d" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,312,785</ix:nonFraction></span> (net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,149,701</ix:nonFraction></span> after
deducting offering expenses) (December 31, 2020: <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,514,829</ix:nonFraction></span> shares were sold for gross proceeds of $<span id="xdx_90B_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,782,017</ix:nonFraction></span> (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,518,557</ix:nonFraction></span>)).
At December 31, 2021, an amount of $<span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20211231_zUptSGynmtw7" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,079,765</ix:nonFraction></span> (September 30, 2021: $<span id="xdx_903_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20210930_zFdVdAaChNf8" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,392,550</ix:nonFraction></span>) was registered pursuant to an effective registration
statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zPY9cYCNAPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 4 -->
    <div id="xdx_237_zqz22WWCR8p3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zzaxQ4M45YTa" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zyRgrtbbX6T3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zzp8VAzvxaEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zFR2UcZZymV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_z79dp2h9JEja" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zG4cb9TYyAYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_236_z2TeUG44MeG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_230_zPUCclQ496Hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_z5BuN0L6FBr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 5&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Equity Offerings</span> &#8211; (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zK3EdrlpMDie" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 7, 2019, the Company entered into
a $<span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdbSU8YLjkL7" title="Total number of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020, pursuant to
which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXVcp3FcTGi8" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> in value
of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In consideration for entering into the
2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September
30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTkAiWogLmT9" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At December 31, 2021 and September 30,
2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the three months ended December 31, 2020, the
Company issued to Lincoln Park an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zhtwFvurfetj" title="Share issued for aggregate, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,402,930</ix:nonFraction></span> shares of common stock including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgRJbbanxDAd" title="Additional common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,346,288</ix:nonFraction></span> shares of common stock for an aggregate
purchase price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues1_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXzMRXpmVMs7" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,461,402</ix:nonFraction></span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zWVTLdRcoidk" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,642</ix:nonFraction></span> commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zYuJPyeLiJ4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6 &#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline"><span id="xdx_82D_z4z315gt58wk">Commitments and Contingencies</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">a)</span></td><td><span style="font-size: 10pt; font-style: normal">Leases </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">During the
three months ended December 31, 2021, the Company incurred office lease expense of $<span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_pp0p0" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,845</ix:nonFraction></span> (2020: $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Operating Leases, Rent Expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,387</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-size: 11pt">b)</span></td><td><span style="font-size: 10pt">Employee 401(k) Benefit Plan</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The Company
has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2021, the Company made $<span id="xdx_906_eus-gaap--PensionContributions_c20211001__20211231_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,682</ix:nonFraction></span> (2020: $<span id="xdx_904_eus-gaap--PensionContributions_c20201001__20201231_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,556</ix:nonFraction></span>) in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">c)</span></td><td><span style="font-size: 10pt; font-style: normal">Litigation</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and
there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any
such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not
believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<ix:exclude><p id="xdx_238_zjDbhk7TVxpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 4 -->
    <div id="xdx_23F_zf6TyCUzM5Eh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_z8jX53gF6PRg" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zs5escza1NT1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zysxtaoI2b19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></p><ix:exclude><p id="xdx_23C_zNuqdhDFMTIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zqiQzuwur0s3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zK330P2z1WEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_231_zBbNIc7Vh4nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_234_zXQYs1io4Fe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zDJMuP5XQ1D4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_233_z3MFOQUaZv12" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">d)</span></td><td><span style="font-size: 10pt; font-style: normal">Share Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zR8tbH2IjLJ2" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zptmiuf4vbz6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; width: 40%; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zshCiUTvTg09" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 1pt solid; width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zffZoKhRxUwl" title="Weighted Average Exercise Price Balance, at beginning" style="border-bottom: Black 1pt solid; width: 20%; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmK5xj1o0nY4" title="Share Purchase Warrants Granted" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zX3ZX4j3Gj39" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zcP3u5JeiUB4" title="Share Purchase Warrants Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIzF2WN4Xq0j" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zjVAp4R6SIv8" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgxE64p4zeF" title="Weighted Average Exercise Price Balance, at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.69</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCrj4gWNDxOj" title="Share Purchase Warrants Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" contextRef="From2021-10-012021-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">50,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zItBURLrGIr4" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" contextRef="From2021-10-012021-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, December 31, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_znYsGskHwVf4" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zMbEm7RyKi56" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zz9Jlv3q2xpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt">At December 31, 2021,
the Company had share purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z9VRBT14uQY9" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B3_zMK5DP9P8Oyj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 44%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zhabp6Kbtqb8" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zVTvXlSl7sZf" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231_pdd" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_8A3_zlPXKFpFjCu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 14.05pt"><span style="font-size: 11pt; font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock&#8211;based Compensation Plan</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On September 18, 2015, the Company&#8217;s
Board approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The maximum number of our common shares reserved
for issue under the plan was <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization. At
December 31, 2021, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span> (September 30, 2021: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlDk8QefFfQ7" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span>) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_z86r3BbKu5z2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 4 -->
    <div id="xdx_23F_z7ulBzwZoHN3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zUX5k4TirV8f" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zbv2PZal2An7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zpMxN1QEEch4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zijCtCcAI9dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z76hi7N4dXI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_238_z5E9fn2BNIr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zu2QKMA0gJ02" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_233_z4fDomnfu4h2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_znnZeypGZP98" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zbNIT1aIYMrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On January 15, 2019, the Board approved the
2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to
directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zytI0TLx1wEg" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> additional shares
of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding
under the 2015 Plan or the Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under
the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The 2019 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At December 31,
2021, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zJ9yDVMkuGZb" title="Remaining stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">406,332</ix:nonFraction></span> (September 30, 2021: <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zrTcr8iXNUif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">456,332</ix:nonFraction></span>) options remain available for issue under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">A summary of the status of Company&#8217;s
outstanding stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zjNc9x8Nj2I3" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zNxMyvqlO6Ve" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Grant</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Date Fair</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2020</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z76JMhWmbfP5" title="Options Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgbgc8rWrId" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjyL7CjeODZ5" title="Aggregate intrinsic value Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,982,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zg8kDm2nkKgc" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,732,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbHgCahb0H3f" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzhsFA8zlgd1" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zydkA4JIAeo7" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,834</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFgaxSlKcDB9" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbYrcSCgB0E3" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMmqYd7ujKbe" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,421,529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1sAZmZBOP83" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.89</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkvDLFAjsqed" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVNyTicjux19" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,446,305</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9airy7jroe9" title="Options Outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zs30VwwFlObh" title="Weighted Average Exercise Price Outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zN2XW8aEfxB4" title="Aggregate intrinsic value Outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z7RVt3mDlfWi" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znomZGu57e8h" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.72</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zobnKnvMNfTe" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,276,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbh6nwP4tra6" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,243,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKhbYnfHQZO1" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT04pNiDM8Gc" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,001,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,294,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z501g5fLl7Cl" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,870,598</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>




</ix:nonNumeric><p id="xdx_8A8_zkiH39LqkZfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_234_zxh3gzb1PcV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 4 -->
    <div id="xdx_234_zrw4gBITt6Oe" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zSnNkv489XJj" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zjjtapwJ1bN2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zswVVjXwM0K" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z7Xt1xLnidQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zxByquYiAcEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_231_zoKrSQFLXG82" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_234_zlI6OeFqoCQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23C_zbJYz67X7Xrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z64l2gsgDhGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z8CTTHUI4YVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">The following summarizes information about
stock options at December 31, 2021 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1xG2dOoOy0g" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8BF_zoyRD3plMNz7" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zEhZCdW60Pq5" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,172,215</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zJYLigHP4Aj8" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.94</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,049,714</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,117,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIwNJcbuoUP3" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.08</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,837,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,397,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zF12E5ZYZwef" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,347,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z2LqBMyyzMi3" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.27</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.03</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.58</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,327,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zb09MQm3Cecf" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.58</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.24</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,243,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,294,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zVlENWz2IvMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">The weighted average grant date fair value
of options vested during the three months ended December 31, 2021 was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_pdd" title="weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></span> (2020: $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20201231_pdd" title="weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span>). At December 31, 2021, the weighted average
contractual life of options outstanding was <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zqOKm3mA3ZXk" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.54</ix:nonNumeric></span> years (September 30, 2021: <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zdoQ37djnXh9" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.79</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zYdMQr25P4i4" title="Options exercisable"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.31</ix:nonNumeric></span> years (September
30, 2021: <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_z1ZRdvmlBgg2" title="Options exercisable"><ix:nonNumeric contextRef="From2020-10-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.51</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the
options that were in-the-money at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">During the three months ended December 31,
2021, the Company recognized stock-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,908,771</ix:nonFraction></span> (2020: $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">939,314</ix:nonFraction></span>) in connection with the issuance and vesting
&#9;of stock options and warrants in exchange for services. These amounts have been included in general and &#9;administrative expenses
and research and development expenses on the Company&#8217;s statement of &#9;operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYZ4T48fmzl7" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B7_zVT9ZTgfIqRg" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,671,726</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">422,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,237,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">516,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Total share based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,908,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" title="Total share based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">939,314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zfF44lwTQFWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">An amount of approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20211231_zcbNuMzbgoN9" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,170,000</ix:nonFraction></span> in
stock-based compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zecbtcMpfKyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 4 -->
    <div id="xdx_230_zMF4GgMHuu5a" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zKIcpACgeX6" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zq9ggG1osnwd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zaipl77jWZ6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zE6ifvxwTyr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anavex Life Sciences Corp.</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zwkkFdZVjWOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Condensed Consolidated Interim Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_236_z9vu4E13O4Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">December 31, 2021</p></ix:exclude>

<ix:exclude><p id="xdx_238_zAJtmTBszIJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23D_zmlRpAYEj647" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zmDGjFH4trqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_235_zO1XAtsPvND5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2cm; text-align: justify; text-indent: 0pt">The fair value of each option
award granted during the three months ended December 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2021-10-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwPsLhoK7iT" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BA_zUq8JrD5JSwd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_zlmP78wcUCDa" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20201231_zoDBii2fv6h3" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.62</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znXlzJntB7E2" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.50</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zD7Q4Botjoo7" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2020-10-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.59</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_z2SwyH0RMdxb" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.79</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20201231_zgS3NgWIFXeb" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.16</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_znmFgHEvKVwe" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20201231_zRiN97It2KCb" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zhA8jAC66Gv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The fair value of stock compensation charges
recognized during the three months ended December 31, 2021 and 2020 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_819_zDahumA7YPW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify"><span id="a_003"></span>Item 2. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward-Looking Statements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;could,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify
forward-looking statements. Such forward-looking statements include, without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in our stock and in the markets in general;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 93%; padding-left: 1.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully conduct clinical and preclinical trials for our product candidates;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>

<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 outbreak and its effect on us;</span></td></tr>

<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate any revenue or to continue as a going concern;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to execute our research and development plan on time and on budget;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    products ability to demonstrate efficacy or an acceptable safety profile of our product candidates;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain the support of qualified scientific collaborators;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved
    for sale;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and obtain additional product candidates;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties in non-clinical and clinical studies;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to defend against product liability claims;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to safeguard against security breaches;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient intellectual property protection for our product candidates;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with our intellectual property licensing agreements;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to defend against claims of intellectual property infringement;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with the maintenance requirements of the government patent agencies;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our intellectual property rights throughout the world;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated start dates, durations and completion dates of our ongoing and future clinical studies;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated designs of our future clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of fast track designation on receipt of actual FDA approval;</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates,
    including any orphan drug or fast track designations; and</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated future cash position.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from the U.S. Food and Drug Administration,
(&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our financial condition, results
of operations, business strategy, preclinical and clinical trials, and financial needs. These forward-looking statements are subject to
a number of risks, uncertainties and assumptions including without limitation the risks described in &#8220;Risk Factors&#8221; in Part
I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 24, 2021. These risks are not
exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business
and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you
that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable laws including the securities laws
of the United States, we assume no obligation to update or supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q, the
terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Anavex&#8221; mean Anavex Life Sciences Corp., unless the context
clearly requires otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Current Business</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical studies to identify biomarkers, which we use to select patients that
will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead compound, ANAVEX<sup>&#174;</sup>2-73, is
being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including
rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding
protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two seed programs.
Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our
programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="image_001.jpg" alt="" style="height: 250.5pt; width: 468pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA; Dashed
lines indicate planned clinical studies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein with important
roles in cellular communication. S1R is also involved in transcriptional regulation at the nuclear envelope and restores homeostasis and
stimulates recovery of cell function when activated. In order to validate the ability of our compounds to activate quantitatively the
S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan in mice,
which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor occupancy (RO) with S1R in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 312pt; width: 468pt" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Source: Reyes S et al., Sci Rep. 2021 Aug 25; 11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett syndrome or infantile spasms, the chronic cellular
stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s and
Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles,
which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular
balance, i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A full genomic analysis of Alzheimer&#8217;s disease
(AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification of actionable genetic variants. A significant impact
of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 and COMT, a gene involved in memory function, on the
drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific biomarker hypothesis. It is expected that
<i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20% of the population) in prospective studies would
identify approximately 80%-90% patients that would display clinically significant improved functional and cognitive scores. The consistency
between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73, which are considered independent of AD pathology, as well
as multiple endpoints and time-points, provides support for precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using
genetic biomarkers identified within the study population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73
treatment in AD as well as indications like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>&#174;</sup>2-73
is currently studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Studies Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial met both primary and secondary endpoints and was designed to assess the safety and exploratory
efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors, which have
been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse the pathological
hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (PK) and pharmacodynamic (PD)
data from the Phase 2a study, which established a concentration-effect relationship between ANAVEX<sup>&#174;</sup>2-73 and study measurements.
These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive and functional scores
as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>&#174;</sup>2-73 activity is enhanced
by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately twice as long as the
parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing these Phase
2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 study enrolled 509 patients
for 48 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial commenced in Australia; and during
fiscal 2020 additional regions were added in the United Kingdom, The Netherlands, Germany and Canada. The ANAVEX<sup>&#174;</sup>2-73 Phase
2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. Primary
and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&#8217;s Disease Assessment
Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (CDR-SB). The
study completed enrollment in June 2021, exceeding the 450 patient enrollment target at 52 sites across North America, Europe and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open label
extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD study, for patients who have completed the 48-week Phase 2b/3
placebo-controlled trial referenced above. This study is expected to last two years and will give patients the opportunity to continue
their treatment. Upon request by patients, caretakers and investigators, this extension study was extended by one further year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The study was funded by the International Rett
Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017, we were awarded a financial grant from Rettsyndrome.org of a minimum
of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of
Rett syndrome. This award was received in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase 2 clinical
trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The studies will be conducted
in a range of patient age demographics and geographic regions, utilizing a convenient oral liquid once-daily formulation of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 study, (ANAVEX&#174;2-73-RS-001), which took place in the
United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability, pharmacokinetic
and efficacy study of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome over a 7-week
treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint of the trial
was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK (pharmacokinetics).
All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome
Behaviour Questionnaire (RSBQ AUC) Total scores, when compared to placebo, in the ITT cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73
treated subjects showed a statistically significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the
ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global
Impression Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014).
Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with
ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR study, commenced in June
2019.</span> This study took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 study for Rett
syndrome. The study was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Following the
successful completion of the U.S. Phase 2 Rett syndrome study (ANAVEX&#174;2-73-RS-001), and the knowledge gained from it, the endpoints
for the AVATAR study (ANAVEX&#174;2-73-RS-002) were appropriately updated according to ICH guidelines and were approved by the U.K. Medicines
and Healthcare products Regulatory Agency (MHRA) and in Australia by the Human Research Ethics Committees (HREC), where the AVATAR study
was conducted. Subsequently the AVATAR study was updated from a Phase 2 to a Phase 3 study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data of the AVATAR study was released in
February 2022. The study met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary
efficacy endpoint, RSBQ AUC (p = 0.037) response, and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037)
response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms.
Convenient once daily oral liquid doses of up to 30mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the study are eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open
label extension protocol, which is currently ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third study of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome, called the EXCELLENCE study. This Phase 2/3 study in pediatric patients with Rett syndrome will evaluate
the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period
incorporating ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. All patients who participate in the study will be eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicates that ANAVEX<sup>&#174;</sup>2-73 induces robust neurorestoration in experimental Parkinsonism. The encouraging results
we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&#8217;s disease trial, support the
notion that ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s Disease Dementia (PDD), to study
the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 study enrolled approximately
132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 PDD study design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s
disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Within this study ANAVEX<sup>&#174;</sup>2-73 was safe
and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically significant
improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73 also
resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-UPDRS Total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks
of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential global capability of slowing and reversing symptoms that progress
in Parkinson&#8217;s disease. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response
to ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we announced we were awarded a research
grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;(MJFF) to develop ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of
target engagement and pathway activation of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation for the treatment
of Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule targeting sigma-1 and
M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase 1
clinical trial was a prospective double-blind, randomized, placebo-controlled study. A total of 36 healthy male and female subjects were
included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability, and pharmacokinetics
(PK) of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The study met
its primary and secondary endpoints of safety, with no serious adverse events (SAEs) or dose-limiting toxicities observed. ANAVEX<sup>&#174;</sup>3-71
was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to 200 mg daily with no SAEs
and no significant lab abnormalities in any subject. In the study, ANAVEX<sup>&#174;</sup>3-71 exhibited linear pharmacokinetics. Its pharmacokinetics
was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no effect on the bioavailability
of ANAVEX<sup>&#174;</sup>3-71. The study also met the secondary objective of characterizing the effect of ANAVEX<sup>&#174;</sup>3-71 on
electrocardiogram (ECG) parameters. There were no clinically significant ECG parameters throughout the study. Participant QTcF measures
were normal across all dose groups with no difference between ANAVEX&#174;3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer&#8217;s disease, evaluating longitudinal
effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of these studies could serve as the basis for advancing into
respective registration studies in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical study indications, and several other compounds in different stages of clinical and pre-clinical
study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery Platform
produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may
be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s disease, as well
as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence the functioning
of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple viruses including SARS-CoV-2
(COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular processes, in order to ensure survival
and replication. Hence, it is possible that S1R could play a role in modulating the cellular response to viral infection and ameliorate
pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 may offer a disease-modifying
approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease
model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic visual
response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated
fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased
the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73
starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular
coordination, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease
model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In November 2019,
the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome. The RPD
designation provides priority review by the FDA to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted Fast Track
designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The FDA Fast Track program
is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious
and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates significant
improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant improvements were
seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s Disease Dementia (PDD),
to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 study enrolled
approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo.
The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a Alzheimer&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The study found that ANAVEX<sup>&#174;</sup>2-73 was
safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. We anticipate conducting further
clinical trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the study to the FDA
to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease (AD) animal models, ANAVEX<sup>&#174;</sup>2-73
has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive
therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition,
ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic
AD animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development
of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers
that is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in
the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing, we initiated
and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1 SAD trial, the maximum
tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse
models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters. ANAVEX<sup>&#174;</sup>2-73 was well
tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum tolerated
single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen with drugs
that target CNS conditions, including AD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, a Phase 2a clinical trial was initiated
for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed to assess
the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s disease. ANAVEX<sup>&#174;</sup>2-73
is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of Alzheimer&#8217;s. The Phase 2a study met both primary and secondary objectives
of the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes were analyzed using
unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data in patients exposed to ANAVEX<sup>&#174;</sup>2-73.
The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among them variants related to the Sigma-1
receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that study participants with the common SIGMAR1 wild type
gene variant, which is about 80 percent of the population worldwide, demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL)
scores. The results from this evaluation have been used to establish a precision medicine approach in subsequent clinical trials, since
these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s
disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the Human
Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week
safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in
Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates inclusion of genomic
precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The Phase 2b/3 study, which commenced in October 2018, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73
doses or placebo, completed enrollment in June 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data also validates ANAVEX<sup>&#174;</sup>2-73
as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett
syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and, more recently,
tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant improvements in all of these indications in the
respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a study sponsored by the Foundation for Angelman
Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results indicated that
ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures. In a study sponsored by FRAXA Research Foundation
regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived neurotrophic factor
(BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative pathologies.
BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression
could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative disorders like Angelman
and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>2-73
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data on ANAVEX<sup>&#174;</sup>2-73 related
to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further, data
also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes (&#8220;OL&#8217;s&#8221;) and oligodendrocyte
precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons in addition to helping repair by increasing OPC
proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrates that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increases survival and reduces seizures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug candidate
with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been shown to enhance
neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential disease modifying
treatment for cognitive impairments. It is highly effective in very small doses against the major Alzheimer&#8217;s hallmarks in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial
dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment
of Frontotemporal dementia (FTD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 demonstrates protective
effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis
of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase 1 clinical
trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The study took place in Australia and was a double-blind, randomized, placebo-controlled, Phase
1 trial to evaluate safety and tolerability, and pharmacokinetics (PK) of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers <span style="background-color: white">The study met its primary and secondary
endpoints of safety, respectively with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as more fully described
above under <i>Clinical Studies Overview &#8211; Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer&#8217;s disease, evaluating longitudinal
effect of treatment with ANAVEX<sup>&#174;</sup>3-71. Anavex believes the results of these studies, could serve as the basis for advancing
into respective registration studies in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems
through a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at
nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies,
this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy
cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility
that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed
in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through
tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of
new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compounds are in the pre-clinical and clinical
testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in human
testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value. Further, we
may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have developed compounds with potential application
to two broad categories and several specific indications. including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Alzheimer&#8217;s disease &#8211; In 2021, an estimated 5.7 million Americans were suffering from Alzheimer&#8217;s
disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that by 2050, this number will rise to nearly 14 million Americans.
Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or
its progression. There is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better
symptomatic treatments.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system
marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain
and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically
middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to expand to $11.5 billion by 2029, according to business
intelligence provider GBI Research.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental disorder
that affects the way the brain develops, including protein transcription, which is altered and as a result lead to severe disruptions
in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2
gene. Because males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating
ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting
nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures
and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization.
Pharmaceutical treatment for depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately
75% of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic
competition.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Epilepsy &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked
seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According
to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled,
but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs.
Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic
drugs and second generation anti-epileptic drugs.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation
of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not
respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category
of membrane stabilizing drugs or antidepressants.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes
found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes
surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc.
the worldwide malignant melanoma market is expected to grow to $6.4 billion by 2027.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate,
a gland in the male reproductive system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the
bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor
Healthcare.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt">&#9679;</td><td style="text-align: justify">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States,
approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately 44,000 patients will die as a result
of their cancer, according to the American Cancer Society. Sales predictions by FutureWise forecast that the market for the global pharmaceutical
treatment of pancreatic cancer will increase to $4.7 billion by 2027.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 29; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to fifteen U.S.
patents, sixteen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates, methods associated
therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent
is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own three issued U.S. patents each with
claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these three patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent any patent term extension
for regulatory delays. The third of these three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent
any patent term extension for regulatory delays. We also own two issued U.S. patents for seizure treatment. The first of these two patents
claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either:
(i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. The second
of these two patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug combined with (i)
ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;</sup> and ANAVEX 2-73<sup>&#174;</sup>. Both patents are expected to expire
in October 2035, absent any patent term extension for regulatory delays. We also own two issued U.S. patents with claims directed to treating
neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder or multiple sclerosis by administering
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to
ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. Both patents are expected to expire in January 2037, absent any patent term extension
for regulatory delays. In addition, we own one issued U.S. Patent with claims directed to methods of treating melanoma with a compound
related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February 2030, absent any patent term extension for regulatory
delays. We also own an issued U.S. patent that claims crystalline forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions
containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144, and methods of treatment for Alzheimer&#8217;s disease. This patent
is expected to expire in July 2036, absent any patent term extension for regulatory delays. Further, we own one issued U.S. Patent with
claims directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73 . This patent is expected to expire in July
2038, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related to ANAVEX<sup>&#174;</sup>1066.
The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066 isomer. The second
patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. Both patents are expected to expire
in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We also own other patent applications directed to
enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more of our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; &#8220; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on November 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Financial Highlights</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-style: normal">We are in
the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues until we
can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical studies and clinical supplies as well as clinical drug manufacturing and formulation.
Research and development expenses also include personnel related costs such as salaries and wages, and third-party contract research
organization (CRO) expenses in support of these clinical studies. Personnel costs include salaries and wages, benefits, and non-cash
stock-based compensation charges associated with options and other equity awards granted to employees and consultants who are directly
engaged in support of our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">General and administrative expenses consist
of personnel costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel costs
consist of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional services
and public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance,
expenses associated with patent research, applications and filings, investor and shareholder relations activities and other administrative
expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-style: normal"><b>Three months
ended December 31, 2021 compared to three months ended December 31, 2020</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-style: normal"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended December 31, 2021, we
completed our second randomized placebo-controlled clinical trial of <span style="background-color: white">ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome</span>, the AVATAR Phase 3 study, and reported positive top-line results from this study in February
2022, as described above under <i>Clinical Studies Overview &#8211; Rett Syndrome</i>. We continued to advance enrollment of our EXCELLENCE
international Phase 2/3 pediatric Rett syndrome clinical trial through the activation of additional clinical sites in new regions across
Canada.. We also completed the first in human Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71 with focus on the treatment of Frontotemporal
Dementia (FTD) and positive topline results were announced in January 2022, as described above under <i>Clinical Studies Overview &#8211;
Frontotemporal Dementia.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Operating Expenses</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Total operating expenses for the first quarter of
fiscal 2022 were $11.7 million, compared to $9.4 million for the comparable first quarter of fiscal 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">General and administrative expenses were $3.1 million
for the three months ended December 31, 2021, as compared to $1.5 million for the first quarter of fiscal 2021. The increase is primarily
related to an increase in non-cash stock option compensation charges of $1.3 million period over period in connection with the vesting
of milestone-based options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our research and development expenses for the first
quarter of fiscal 2022 were $8.7 million, as compared to $7.9 million for the first quarter of fiscal 2021. The increase is primarily
related to an increase in non-cash stock option compensation charges of $1.7 million period over period in connection with the vesting
of milestone-based options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">We will
continue to see an increase in our research and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73 clinical studies,
including extension studies to allow us to continue to gather longer term data, continuing to advance our other pipeline compounds such
as ANAVEX<sup>&#174;</sup>3-71, and as we continue to add additional staff to manage and support these clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Other income (net)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The net amount of other income for the first quarter
of fiscal 2022 was $0.9 million as compared to $1.6 million for the comparable first quarter of fiscal 2021. <span style="background-color: white">The
decrease in other income is attributable to a decrease in Australian research and development incentive income in connection with the
decrease in eligible clinical activities in Australia over the comparable period such as the completion of the </span>ANAVEX<sup>&#174;</sup>3-71
<span style="background-color: white">Phase 1 clinical study. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">Foreign exchange
gains during the period are primarily related to the fluctuations in the Australian dollar against the US dollar and its related impact
on incentive and tax receivables during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net loss</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the first quarter of fiscal 2022
was $10.9 million, or $0.14 per share, as compared to $7.9 million, or $0.12 per share in the comparative first quarter of fiscal 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Working Capital</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">156,896,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">161,616,490</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,528,662</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,798,386</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Working Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">146,367,706</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,818,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><br />
At December 31, 2021, we held $151.1 million in cash and cash equivalents, a decrease of $1.0 million from September 30, 2021. Cash expenditures
for the quarter of approximately $7.0 million were offset by a net reduction of incentive and tax receivables of $3.8 million, resulting
in a net cash used in operating activities of $3.5 million for the quarter. We received cash from financing activities of $2.5 million
primarily from the issuance of shares of common stock under the Sales Agreement (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">We intend to continue to use our
capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and to perform work necessary
to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Flows</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Three months ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,500,955</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(7,871,378</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,539,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,979,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease) increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(961,390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,108,581</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities for the
first quarter of fiscal 2022 was $3.5 million, compared to $7.9 million during the comparable period of fiscal 2021. The principal reason
for this decrease in net cash used in operating activities in the current period is due to the receipt of research and development incentive
tax refunds during the period, as compared to no such receipts during the comparable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash provided by financing activities for the
three months ended December 31, 2021 was $2.5 million, primarily attributable to cash received from the issuance of common shares at various
market prices under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Cash provided
by financing activities for the three months ended December 31, 2020 was $26.0 million, attributable to cash received from the issuance
of common shares at various market prices under the 2019 Purchase Agreement and the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Financing</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Controlled Equity Offering
Sales Agreement </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020, we entered into an Amended and Restated
Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;),
pursuant to which we may offer and sell shares of common stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon delivery of a placement notice based on our instructions
and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock by methods deemed to
be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to our prior written
consent. We are not obligated to make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the
At-the-Market Offering upon notice to the other party, subject to certain conditions. The Sales Agents will act as agents on a commercially
reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal law, rules and regulations
and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay the Sales Agents commissions
for their services of 3.0% of the gross proceeds from the sale of the shares pursuant to the Sales Agreement. We have also agreed to provide
the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the three months ended
December 31, 2021, 99,588 shares were sold pursuant to the At-the-Market Offering for gross proceeds of $2.3 million (net proceeds of
$2.2 million after deducting commissions and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We prepare our interim condensed
consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and make
estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related disclosures of
contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable in the circumstances.
Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 33; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September 30,
2021 as filed with the SEC on November 24, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Please refer to Note 2 &#8220;Recent
Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements included in this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-transform: uppercase"><b><span id="a_004"></span>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Not applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-transform: uppercase"><b><span id="a_005"></span>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Disclosure Controls and
Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We maintain disclosure controls
and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports
filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive
officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We carried out an evaluation,
under the supervision and with the participation of our management, including our principal executive officer and principal financial
officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a 15(e) under
the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the quarter ended
December 31, 2021, the Company implemented a new Enterprise Resource Planning (&#8220;ERP&#8221;) system and integrated and digitized
certain aspects of its internal controls over financial reporting within this ERP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Other than as noted above,
there were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a
15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal controls
over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_006"></span>PART II &#8211; OTHER
INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_007"></span>Item 1. Legal Proceedings.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company
or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors, officers
or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or has a material interest
adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_008"></span>Item 1A. Risk Factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to the risk factors
discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2021
filed with the SEC on November 24, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_009"></span>Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period covered by this Quarterly
Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously
reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_010"></span>Item 3. Defaults Upon
Senior Securities.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_011"></span>Item 4. Mine Safety
Disclosures</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_012"></span>Item 5. Other Information.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-weight: normal; text-transform: none">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-weight: normal; text-transform: none">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify"><span id="a_013"></span>Item 6. Exhibits.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><b>Exhibit <br />
Number </b></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><b><br />
Description</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>(3) </b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>Articles of Incorporation and Bylaws </b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">3.1 </td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">3.2 </td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>(31) </b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">31.1*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3475_ex31-1.htm">Certification of Christopher Missling, PhD.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">31.2*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3475_ex31-2.htm">Certification of Sandra Boenisch</a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>(32) </b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>Section 1350 Certifications</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">32.1*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e3475_ex32-1.htm">Certification of Christopher Missling, PhD and Sandra Boenisch.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>(101)</b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><b>XBRL</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.INS*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL INSTANCE DOCUMENT</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.SCH*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL TAXONOMY EXTENSION SCHEMA</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.CAL*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.DEF*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.LAB*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">101.PRE*</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Value: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span id="a_014"></span>SIGNATURES</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/Christopher Missling, PhD</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 40%; margin-top: 3pt; margin-bottom: 3pt" />
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Christopher Missling, PhD</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 219.75pt; text-indent: -219.75pt; background-color: white">Chief
Executive Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: February 9, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/Sandra Boenisch</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 40%; margin-top: 3pt; margin-bottom: 3pt" />
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sandra Boenisch, CPA, CGA</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 219.75pt; text-indent: -219.75pt; background-color: white">Principal
Financial Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: February 9, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">36</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e3475_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended December 31, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: February 9, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">/s/Christopher Missling, PhD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<HR COLOR="Black" ALIGN="LEFT" NOSHADE SIZE="1" STYLE="width: 40%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT>Christopher
Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e3475_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended December 31, 2021 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: February 9, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U STYLE="text-decoration: none">/s/Sandra Boenisch</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<HR COLOR="Black" ALIGN="LEFT" NOSHADE SIZE="1" STYLE="width: 40%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sandra Boenisch, CPA, CGA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 219.75pt; text-indent: -219.75pt; background-color: white">Principal
Financial Officer, Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e3475_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended December 31, 2021 as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the date indicated below,
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(1) the Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">(2) the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">Dated: February 9, 2022</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: justify">/<U STYLE="text-decoration: none">s/Christopher Missling, PhD </U></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">Christopher Missling, PhD</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;Chief Executive Officer, President, Secretary</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD>(Principal Executive Officer) &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><U STYLE="text-decoration: none">/s/Sandra Boenisch</U></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">Sandra Boenisch, CPA, CGA</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">Principal Financial Officer, Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *+!, # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 5!<WMK9*K75S# K'"F60*"?;-3T4 9_]O:/_ -!:Q_\  A/\:/[>T?\
MZ"UC_P"!"?XUH44 9_\ ;VC_ /06L?\ P(3_ !H_M[1_^@M8_P#@0G^-:%%
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MH_\ T%K'_P "$_QH_M[1_P#H+6/_ ($)_C6A10!G_P!O:/\ ]!:Q_P# A/\
M&C^WM'_Z"UC_ .!"?XUH44 9_P#;VC_]!:Q_\"$_QH_M[1_^@M8_^!"?XUH4
M4 9_]O:/_P!!:Q_\"$_QH_M[1_\ H+6/_@0G^-:%% &?_;VC_P#06L?_  (3
M_&C^WM'_ .@M8_\ @0G^-:%% &?_ &]H_P#T%K'_ ,"$_P :/[>T?_H+6/\
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M^!"?XT?V]H__ $%K'_P(3_&M"B@#/_M[1_\ H+6/_@0G^-']O:/_ -!:Q_\
M A/\:T** ,_^WM'_ .@M8_\ @0G^-']O:/\ ]!:Q_P# A/\ &M"B@#/_ +>T
M?_H+6/\ X$)_C1_;VC_]!:Q_\"$_QK0HH S_ .WM'_Z"UC_X$)_C1_;VC_\
M06L?_ A/\:T** ,_^WM'_P"@M8_^!"?XT?V]H_\ T%K'_P "$_QK0HH S_[>
MT?\ Z"UC_P"!"?XT?V]H_P#T%K'_ ,"$_P :T** ,_\ M[1_^@M8_P#@0G^-
M']O:/_T%K'_P(3_&M"B@#/\ [>T?_H+6/_@0G^-']O:/_P!!:Q_\"$_QK0HH
M S_[>T?_ *"UC_X$)_C1_;VC_P#06L?_  (3_&M"B@#/_M[1_P#H+6/_ ($)
M_C1_;VC_ /06L?\ P(3_ !K0HH S'UC0Y'C9]2TYFC;<A:="4;!&1SP<$CZ$
MTUM5T!VD9[_36:5!'(3-&2ZC.%//(^9N/<^M:M% &1_:/AWR)(/MNE^3)G?'
MYL>UL]<C.#5-8O!:)>HL>@!+\[KM0(<7!R3F3^_R2><]371T4 8$#>$;;3'T
MRW;1(M/D!#VL9B6)@>N4'!SWXI^FS^%=&MVM]+ET:Q@9R[1VK11*6P!DA<#.
M !GV%;E% &?_ &]H_P#T%K'_ ,"$_P :/[>T?_H+6/\ X$)_C6A10!G_ -O:
M/_T%K'_P(3_&C^WM'_Z"UC_X$)_C6A10!G_V]H__ $%K'_P(3_&C^WM'_P"@
MM8_^!"?XUH44 9_]O:/_ -!:Q_\  A/\:/[>T?\ Z"UC_P"!"?XUH44 9_\
M;VC_ /06L?\ P(3_ !H_M[1_^@M8_P#@0G^-:%% &?\ V]H__06L?_ A/\:/
M[>T?_H+6/_@0G^-:%% &?_;VC_\ 06L?_ A/\:/[>T?_ *"UC_X$)_C6A10!
MG_V]H_\ T%K'_P "$_QH_M[1_P#H+6/_ ($)_C6A10!G_P!O:/\ ]!:Q_P#
MA/\ &C^WM'_Z"UC_ .!"?XUH44 9_P#;VC_]!:Q_\"$_QI@UC0Q,9AJ6G"5E
M"E_/3<5&2!G/3D_F:TZ* ,DZGX?*%#?:84,@E*^;'@N&W!NO7(!SZC--:_\
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M"B@#/_M[1_\ H+6/_@0G^-']O:/_ -!:Q_\  A/\:T** ,_^WM'_ .@M8_\
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M(=EW'<RK;G>QX3!VXSSQFE;#V3<%KY(+XF[2F]/-E/\ X6)XJ_Z"G_DO%_\
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MJE3H1W@ON74F-3$2VF_O?0?_ ,+$\5?]!3_R7B_^)H_X6)XJ_P"@I_Y+Q?\
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MM,G^S2AT$B75I;B/RBO7^%20<XY'I5V'5],L;S4+5K9;,QLL4>&>(LJ\?,Z
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MQ>1O^TM&V=^-NUMWISFO8_\ A7?A7_H%_P#DQ+_\51_PKOPK_P! O_R8E_\
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MC_A7?A7_ *!?_DQ+_P#%4?VM1[/\/\P_LFMW7X_Y'A%%>[_\*[\*_P#0+_\
M)B7_ .*H_P"%=^%?^@7_ .3$O_Q5']K4>S_#_,/[)K=U^/\ D>$45[O_ ,*[
M\*_] O\ \F)?_BJ/^%=^%?\ H%_^3$O_ ,51_:U'L_P_S#^R:W=?C_D>$45[
MO_PKOPK_ - O_P F)?\ XJC_ (5WX5_Z!?\ Y,2__%4?VM1[/\/\P_LFMW7X
M_P"1X117N_\ PKOPK_T"_P#R8E_^*H_X5WX5_P"@7_Y,2_\ Q5']K4>S_#_,
M/[)K=U^/^1X117N__"N_"O\ T"__ "8E_P#BJ/\ A7?A7_H%_P#DQ+_\51_:
MU'L_P_S#^R:W=?C_ )'A%%>[_P#"N_"O_0+_ /)B7_XJC_A7?A7_ *!?_DQ+
M_P#%4?VM1[/\/\P_LFMW7X_Y'A%%>[_\*[\*_P#0+_\ )B7_ .*H_P"%=^%?
M^@7_ .3$O_Q5']K4>S_#_,/[)K=U^/\ D>$45[O_ ,*[\*_] O\ \F)?_BJ/
M^%=^%?\ H%_^3$O_ ,51_:U'L_P_S#^R:W=?C_D>$45[O_PKOPK_ - O_P F
M)?\ XJC_ (5WX5_Z!?\ Y,2__%4?VM1[/\/\P_LFMW7X_P"1X117N_\ PKOP
MK_T"_P#R8E_^*H_X5WX5_P"@7_Y,2_\ Q5']K4>S_#_,/[)K=U^/^1X117N_
M_"N_"O\ T"__ "8E_P#BJ/\ A7?A7_H%_P#DQ+_\51_:U'L_P_S#^R:W=?C_
M )'A%%>[_P#"N_"O_0+_ /)B7_XJC_A7?A7_ *!?_DQ+_P#%4?VM1[/\/\P_
MLFMW7X_Y'A%%>[_\*[\*_P#0+_\ )B7_ .*H_P"%=^%?^@7_ .3$O_Q5']K4
M>S_#_,/[)K=U^/\ D>$45[O_ ,*[\*_] O\ \F)?_BJ/^%=^%?\ H%_^3$O_
M ,51_:U'L_P_S#^R:W=?C_D>$45[O_PKOPK_ - O_P F)?\ XJC_ (5WX5_Z
M!?\ Y,2__%4?VM1[/\/\P_LFMW7X_P"1X117N_\ PKOPK_T"_P#R8E_^*H_X
M5WX5_P"@7_Y,2_\ Q5']K4>S_#_,/[)K=U^/^1X117N__"N_"O\ T"__ "8E
M_P#BJ/\ A7?A7_H%_P#DQ+_\51_:U'L_P_S#^R:W=?C_ )'A%%>[_P#"N_"O
M_0+_ /)B7_XJC_A7?A7_ *!?_DQ+_P#%4?VM1[/\/\P_LFMW7X_Y'A%%>[_\
M*[\*_P#0+_\ )B7_ .*H_P"%=^%?^@7_ .3$O_Q5']K4>S_#_,/[)K=U^/\
MD>$45[O_ ,*[\*_] O\ \F)?_BJ/^%=^%?\ H%_^3$O_ ,51_:U'L_P_S#^R
M:W=?C_D>$45[O_PKOPK_ - O_P F)?\ XJC_ (5WX5_Z!?\ Y,2__%4?VM1[
M/\/\P_LFMW7X_P"1X117N_\ PKOPK_T"_P#R8E_^*H_X5WX5_P"@7_Y,2_\
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MI#YMI%Y*D@_.F,8;GG]*;%K]S'<WTSQ0S&]!659 V,>@P01^=>Q?\*[\*_\
M0+_\F)?_ (JC_A7?A7_H%_\ DQ+_ /%4?VEAOY7_ %\P_LW$_P R_KY'C/\
M;#QVDUM:VT%HLQ7S&A+[B!T&68X'TJ+4=1EU.X6>=(Q,$",Z#!DQQN;GK7M?
M_"N_"O\ T"__ "8E_P#BJ/\ A7?A7_H%_P#DQ+_\5369X=.ZB_Z^8GEF(:LY
M+^OD>,V.KO86<]LMK;R+/Q(S[PQ']W*L./:J4\B2RET@CA7^Y&6(_P#'B3^M
M>Y_\*[\*_P#0+_\ )B7_ .*H_P"%=^%?^@7_ .3$O_Q5"S2@G=)_U\Q/*\0U
M9M?U\CQ6XU2:XM[. I$D5HN(U5>"<Y)8'()-3RZY*UM<PP6EI:BYQYI@1@6
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M(966)05(Z$'%27-G:WUPUQ=VT-Q,V-TDJ!V..!DGFIJ!1[.'\J^Y?Y![2?\
M,_O?^8Q[>"2QCLGAC:TC;<D#*#&IYY"] >3^9HM+>"P=VLX8[9G78YA4(67T
M..HJ2BCV<.R^Y?Y![2?=_>_\SUQ?A?X)1E9/#ULK _*REA@_G5BZ^&_A/4+@
MSWFBQ7$Q !>:5Y&P/<MFK0?5K2^E1G7[,QW)(R%@/;BKBR7<YVF^1?\ KWCY
M_'.:^'6.F^Y]N\'!=C./PW\)FR6Q;1T-HK;Q 9)#&&]0N[ /)J./X?\ @_1
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M?&.UOIQ;VFF0W,Q!Q%#>AR<=> F:BD^-6FJ6AEL+-64X=&OU!!'8C;Q7I/\
MPDNA?]!O3?\ P*3_ !H_X270O^@WIO\ X%)_C7#>'_/C_P!*.[EG_P __P#T
MD\^N/C!;:;Y:W.CQ6N]=T8EO FY?493D4Z/XR036<EY'I4;VL1Q),MZ"B'T+
M;,#J/SKO_P#A)="_Z#>F_P#@4G^-'_"2Z%_T&]-_\"D_QHO#_GQ_Z4'+/_G_
M /\ I)YY:_&>SO;E;>TTR">=\[8XKX.[8&3@!,] :)?C?803/%+8VT<B,5='
MU!05(X((V\&O0_\ A)="_P"@WIO_ (%)_C1_PDNA?]!O3?\ P*3_ !HYH?\
M/C_TH.6?_/\ _P#23@+KXQV]FD3W>D10+,NZ)I;T*'7U7*<CGM20_&&WGMI;
MF#2(I+>'_6RI> HG^\0F!7H'_"2Z%_T&]-_\"D_QH_X270O^@WIO_@4G^-%X
M7O[#_P!*#EG;^/\ ^DGGEM\9[*[G2"VTZWGF<X6..^5F;Z +DT3?&G3[>9X9
M]/M8I4)5XWOE5E/<$%>#7H?_  DNA?\ 0;TW_P "D_QH_P"$ET+_ *#>F_\
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M9Q!?W<%K,5W".>0(V/7!/3BO;O\ A)="_P"@WIO_ (%)_C1_PDNA?]!O3?\
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MX!Y''N*2SU33]0N%M[*_M;F=LE8H9E=CCD\ YKV?_A)="_Z#>F_^!2?XT?\
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M?_D5_P#&C_A%]&_Y\_\ R*_^-:]%'U+#?\^X_<@^LUOYW][,C_A%]&_Y\_\
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M37NK[CE4\$^#Y)"B6 8CKMN)#T_X%33X-\&Y'^A*.,_\?$O_ ,56Y,L5G/\
M+%]]2Q*BJ:/9,\2?96/F.0#M. ?>I>/Q*TYG][-(X'#O7D7W(HCP3X/[V '&
M?FGE'_LU(W@OP<HS]@!Y XN)._\ P*M0W%L&/F6[GYO*RR']/:HUN+(NFVV9
M6+X'RGJ.]2\QQ/\ ._O8U@*'\B^Y%0> _"956_LW*L< _:)?_BJB_P"$*\(;
MF7^SB2IVD">7.?\ OJM/[;;8";)04RX&WCIFE:ZMPS-Y3!^7)"GD\4WF-?\
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M1@C/<"J==!XN*3:M]IAG@EB9$4&*97.0.> <BN?K:G)R@FS&I%1FT@HHHJR
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M*^BJ*/[7G_*OQ#^QX?SO[D?.O_"-:[_T!-2_\!7_ ,*/^$:UW_H":E_X"O\
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M(UKO_0$U+_P%?_"OHJBC^UY_RK\0_L>'\[^Y'SK_ ,(UKO\ T!-2_P# 5_\
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M?^ K_P"%?15%']KS_E7XA_8\/YW]R/G7_A&M=_Z FI?^ K_X4?\ "-:[_P!
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MO_0$U+_P%?\ PH_X1K7?^@)J7_@*_P#A7T511_:\_P"5?B']CP_G?W(^=?\
MA&M=_P"@)J7_ ("O_A1_PC6N_P#0$U+_ ,!7_P *^BJ*/[7G_*OQ#^QX?SO[
MD?.O_"-:[_T!-2_\!7_PH_X1K7?^@)J7_@*_^%?15%']KS_E7XA_8\/YW]R/
MG7_A&M=_Z FI?^ K_P"%'_"-:[_T!-2_\!7_ ,*^BJ*/[7G_ "K\0_L>'\[^
MY'SK_P (UKO_ $!-2_\  5_\*/\ A&M=_P"@)J7_ ("O_A7T511_:\_Y5^(?
MV/#^=_<CYU_X1K7?^@)J7_@*_P#A1_PC6N_] 34O_ 5_\*^BJ*/[7G_*OQ#^
MQX?SO[D?.O\ PC6N_P#0$U+_ ,!7_P */^$:UW_H":E_X"O_ (5]%44?VO/^
M5?B']CP_G?W(\(TKPEJ'[V[U+2[]+:!0^P6SL\F21@* 6.,<@#N*Z*WF>[GC
MMH-,U=&;A?-TJXB0?5FC"C\37JM%83S&K-W:1O#+:4%9-GD5U--;W$D+Z7K+
M.C%28]*N74GV98R"/<'%)>0WEK!;S2:9JC+.NY!%I\TC <?>54)0\]& /7T-
M>O45*Q]1=$4\OIOJSQJ*VOKJWGGCTK5 D RXDT^:-C_NJR@MT_A!JG%%>W5P
MD,>D:R&<X!DTNXC7\69 !]2:]QHJEF57LB7EM+NSP>[M=0MKAX'T?6&=#@F+
M3+B1?P94(/X&FW.EZK!;0W#Z/JI28941V$SL/]Y54LOX@5[U15+-*O9$O*Z3
MZO\  ^?H='U>[BGDBT750L*[F$MA+&2.?NAE!8\=%R?SJDFF:M/,D2:'K09V
M"@OIDZ+D^I*  >YXKZ.HJEFU9=%^/^9+RFB^K_#_ "/G2?2=7M+AH)=#UAG7
M&3%IT\B],\,J$'\#4[Z-K$-I%=/HNJF.4X4)82LX^J!2R_B!7T)11_:U;LOQ
M_P Q?V11[O\ #_(\ L](U:[$ICT;55\I=S>=8319'MN4;C[#)ID-IJ,DJ1KH
MFM!F8*"VE7"CGU)3 'N:^@J*7]JUNR_'_,?]DT>[_#_(\&N;#4K*X:"71]79
MUQDPZ=/*O/HR(0?SJ9M/U*.PCO&TC5/*D;:JK83-(#SUC"[@.#R0!T]17N=%
M']J5>R_$?]E4>[_ \1L;'4;YW6+2=44HNX^?830C'L749/L.:CC^U,ZJ-'UL
M$G SI%R!^9CXKW*BE_:=7LA_V72[L\:GT_5XKU;&#1[Z2[? 0FVD$(SW:7;L
M '?G/L3Q7I^A:%;:/:QMY,!OVB5+BXC3!D(Y[Y.W).!GC-:U%<U?%U*VDMCH
MP^$IT-8[A1117,=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5PGQ8_Y%:U_Z_4_] >N[KA/BQ_R*UK_U^I_Z ]=6"_WB'K_F<N-_
MW>?I_D>.4]H94C21XW5),[&*D!L'!P>],KK;CQ1%J-G9V*6\J.98][F0<X;C
M)Q\^>IZ<\U]/.4HVLKGR\(QE>[L<E17H&M2%HM9"S/<E9X5:&7I;CCYDY.<Y
MQV[UF>*M2FM]:NT@U74(Y%*XA3*QCY1T(?\ '[M9PK.;22_K3_,UG04$VW_6
MO^1R5%=5K^IW\-GH[17URADLU9RLK#<?4\\FH_%UY=&>U@-S,87LXF>/>=K'
MGDCN:J-1MK3>_P"!,J:2>NUOQ.9HKK;"^EU*QM['2[HV=U# 4:W9 8Y^Y8'G
M#<9Y'?@]:?=7L4>AMK<:D7U_&+5ST"D9#L/J *7M7>UA^Q5KW./HKTQX8K_Q
M<EQ$ MS82>7,/[T;(2K?@21^58FK:C?:?9Z*UE-(K'S<HI)5SOZ$=^M1'$<S
M22U*EA^5-MZ''45Z/-%;V*-##=26$;:J@_<+P"8E)0\C"D_4#CBLS5Y9=/TV
M]N[2,6MU-?M%,T7WD4#( 8 $ X#?C3CB.9V2W"6'Y5=O8XNBO0M'N2UE8ZK<
M#?>+:S@L?O2HA&"3WZ8S[U7L=.@TO7VU( -;3RQ+9=/F,IY(_P!T9I?6-TUL
M'U?9I[G"T5W>KW/V;2MWVZ[M,ZA<#=;+DM\[<'YEKAG=I)&=F9F8DEFZD^IK
M6G4YU>QE5I\CM<T?#^DC7-;M].-Q]G$N\F79NV[5+=,CT]:EU"PT.TU!K*WU
MJ>\E3[S168V#\?,J;P9;O>>*+>V23RWFBGC#_P!TF%QFMK0M+TG1K>;2?%.E
MNDK.0)UMW?>,\'>H.*\W'8FK2J*,)65CULMPE&M2<JBN[E'P[X9T?Q+))#:>
M('CN8\[H9;/#<=<?O.:TK+X?Z;J+E+7Q,DC %L?9,9 ."1E_6MR#P'';>-M+
MUK2%6'3XX"9,<,QVX&._/4U ?#>M+;66^.618^BAE_= R.74C.&!!3KZ5Q/'
MXC^?\$=_]FX7^7\65&^%ULAP_B.-6P#@VXZ$X'\=3#X2J3QKRGZ6O_V=6#X3
MNYFE>33_ #0T#JIF5/\ GX5@,#I\H) 'TK4?3;NUA>6.W>)K>,R(S,.&&, X
M^\.O7I64\RQ,=I?@B99=AEM'\689^$JYQ_;Z[O3[+_\ 9U&?A7"LZ0'Q HD<
M$@?9?3&?X_>NG@TJ[:![AHV:>14E!W#*LS!FQZ=ZJ?V/?2/I^^R831JXN90P
M&X$\#@\\5G_:F*_F_!?Y$_4,/_)^+,?_ (5(G/\ Q/U_\!?_ +.@?"1"<#7U
M)]K7_P"SK>N-*OV58H;9U<7+M(X8 -&6X'TQVJS<Z1=+YSVT&R3[4IC*X&$V
M\X]!FC^U,5W_  7^0?V?A_Y/Q9S'_"I%/W=>#8ZXM<X_\?I1\(LG']N?^2G_
M -G6[#9ZK9VZ^5%<*7$:S;=HYR-Y&#UQGFJ-U-XAL[%IKN2<,[R^6JL"<93R
M^G;[U:QS'$M7YOP12R[#/[/XL\LU*S_L_5+NRW[_ +/,\6_&-VUB,X[=*K5I
M^)/^1HU?_K]F_P#0S697TL&W!-]E^1\U424VEW?YA1115$A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6E+H5_;N$F6WC<@$*]U$&P>G!;-9M=CXHL[JY
MOU6#2&FW0Q@7*I(2#Z9!V_F*SG-QDEW-804HM]CFSI-\'NT-N5-H,S[B $_'
M/.>V.O:IO^$>U3&/LPW^7YAC,J>8%]2F=P_*NMFE22S@M!<B6XTR6&2_ '^L
M5<;N?XMO?Z5B:CH^HS^(I[M8C+;-+YZW&X>68R<C#'@\8&.M91K-[V7]?KN:
M2HI;7?\ 7Z;&7-H=_!-Y,JP+-N"^5]IC+Y.,#;NSW%1QZ3?2ZA)8I!FYCR73
M>O&.O.<5T^L6]PWBT2#22(A<PG[6$DY&5[YV^W2I[.QNT\;W\[6LZPN)0LAC
M(5LCC!Z&E[=\M]-K_P!:C]@N:VN]OZT./M--NKZ*:6!$\N';YCO*J!<\#EB/
M2I#HU\+6:Y6))(8<>8\4J.%S_NDUMZ/87MOH&M)-I<TCOY&R"6)QOPYS@#!.
M.O%3V%S+I.A74T]B8$-VBRVS*P#1E<,,,<\C/4]:J59W?+W)C1C9<VFC.<CT
M;4)3:B.V9S= F':0=P'4]>/QQ4R>'=4EV^5;I(K;L.DR,O'4%@V ?8UVDT5O
M%8P6%K*A>XL9DM'+8W9*D+D]R"/RK$\*Z7?6>IF:YM7B62"1423Y68@#/R_>
MQ[X[U'UAN+EV+^KI24=[_@<S<VDEKM\QH6W9QY4R2?GM)Q^-2'3+P::-1,!^
MR%MHDR.OTZU+>6EUY\"-I1LFE.U$V2+O.?\ ;)]176EK-[N7PVL[G-J+=5,0
MV>:H+;MV[KDGM^-:SJN*5M?\C.%)2;OI_F<?+I-]#]D\R K]L ,!W#Y\XQWX
MZCKZT^'1-1N+Z:RBMB]Q "9$#+\N/?.*ZY)4DO-*TB\^0BUMYH">J2KU'X@$
M?A1?3PZ'-<7<LLD<MW?;QY<8<M'&>F"PP">]9>WELEK_ ,$T]A#=O3_@?YG$
MO97"64=XT?\ H\C%%?<#\PZC'45:70=1>W\_R8UB\M9-[SH@"L2%)RPQG!KI
M_P"SX;S4+[1]X%O>;+^U<=L_>Q]1D?04ANCJ47B,V]J+J-#;Q0P ,0RJQ'&T
M@^IZTW7D]OZO;_@_<)4(]?Z:O_P/O.3FTJ\A@$Y1'B+B,-#*D@W$9 ^4GFK\
M7A74F#F98X-K!?G)?DC/\ ;  QDG &16MH.='DN+[4[<V5K*\<:6[1GE\@A@
M').%Y.??BJ-QJFJ:#?7-G.RW&9?.#.7 ;/<;6&0>,@Y'%4ZDY-QC;^O\A*G"
M*4I7_K_,H_\ ".:H9GB%NN5E\G+2JH9NN%W$9X]*SO(D^T>0P"2!MA#L%P>G
M)/ _&NATNUN[^\D\07<$TZ1R[U2%"6ED'0#'11QD^V.:R[V:)YKAKVSNDOW9
MF<F4*H8G/W"F<<],U<9R;L_Z?WD2A%*Z_I?< T._>%Y8TAE1"H8Q7$;D%C@#
M"L3R>E-NM&OK*!IIH5\M)/*=DE5]K>AVDX/UK5O87LM(T_18E'VJZ87$ZLVW
MD\(I)X'YU9FA\CPS<1ZA8-8+'<@K#"Y3[0>AY?<3CKD<?SJ/:RT]2O91U]#G
M;33;J^BFE@1/+AV^8[RJ@7/ Y8CTJ?\ L#4Q++&UML,6W>SR*JC=T^8G!S[&
MM72YK-/#^MR1V;O"OV??%/-NW?.>ZA2/\_2M._.H2S2-#8C4M(NDB=80=K(N
M/E V\K@@\X^M*5:2DU_70<:,7%/^NIQ=Q:SVMT]K-$R3HVUD/7/]:N3:#J<$
M<CO;?ZK;YBI(K,F[IE021GW%:,D.CZ1XDB@ N)1!.A:4W"A5.02"-G;OSV[5
MNZ=%)I?B'5]0U#]W9R/\DCGY7W."N#WP/RISK-*Z[?>$**;L^_W'(S:!J<".
MSVN=A575'5V4MT!4$D9]Q3+O1;^R@>:>%1&C^6[)*K[&]#M)Q^-=.+&ZMKCQ
M%)<+LCNLQ0,[8$K.V5P3P>OX53N8)8/"U]%=60TTI<(412<7#="/F))  SD'
M%*-9MK;I^(2HI)[]?P.5HHHKI.8**** "BBB@ HHHH U- U^]\.ZDMY9MQTD
MB)^61?0_X]J]WT+7;+Q#IJ7EF_'22,_>C;T-?.E=/X#.LCQ'$-'YSC[0'SY?
ME]]W].^:\_'X2%6#GLUU_P ST,!BYTIJGNGT_P CW>BBBOFSZ4**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X3XL?\BM:_P#7ZG_H
M#UW=%:T*GLJBG:]C*O2]K3<+VN?,-.C=HI%D0X92&!]"*^G**]7^U_[GX_\
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M -_\/^"?,-%?3U%']L?W/Q_X ?V/_?\ P_X)\PT5]/44?VQ_<_'_ ( ?V/\
MW_P_X)\PT5]/44?VQ_<_'_@!_8_]_P##_@GS#17T]11_;']S\?\ @!_8_P#?
M_#_@GS#17T]11_;']S\?^ ']C_W_ ,/^"?,-%?3U%']L?W/Q_P" ']C_ -_\
M/^"?,-%?3U%']L?W/Q_X ?V/_?\ P_X)\PT5]/44?VQ_<_'_ ( ?V/\ W_P_
MX)\PT5]/44?VQ_<_'_@!_8_]_P##_@GS#17T]11_;']S\?\ @!_8_P#?_#_@
MGS#17T]11_;']S\?^ ']C_W_ ,/^"?,-%?3U%']L?W/Q_P" ']C_ -_\/^"?
M,-%?3U%']L?W/Q_X ?V/_?\ P_X)\PT5]/44?VQ_<_'_ ( ?V/\ W_P_X)\P
MT5]/44?VQ_<_'_@!_8_]_P##_@GS#17T]11_;']S\?\ @!_8_P#?_#_@GS#1
M7T]11_;']S\?^ ']C_W_ ,/^"?,-%?3U%']L?W/Q_P" ']C_ -_\/^"?,-%?
M3U%']L?W/Q_X ?V/_?\ P_X)\PT5]/44?VQ_<_'_ ( ?V/\ W_P_X)\PT5]/
M44?VQ_<_'_@!_8_]_P##_@GS#17T]11_;']S\?\ @!_8_P#?_#_@GS#17T]1
M1_;']S\?^ ']C_W_ ,/^"?,-%?3U%']L?W/Q_P" ']C_ -_\/^"?,-%?03^(
MI#K-QIUKH>I7?V:1(YKB)K=8T+*&_CE5C@,"<*?;-;E']L?W/Q_X ?V/_?\
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M9'B!E'V)(VFE'_39#MV_BV/KS3]O:3BT+ZO>*DF<117I&KS^5;ZQ,;F>V/\
MH_[R 989';D?SKSZ\F:XNGD:XFN,]))OOD>_)_G5TJKJ:V(JTE3TN%E:27]_
M;V<159+B58E+'@%B ,^W-:^K^&#HDZV][K.EK<-TB1Y&;]$JIX<_Y&C2,?\
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M5RK".W0?.OEXYVL<'S #ZE10!P]E::<GB>=M3T*\GUPZ@[V^H"R=@L)Y0K<
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M ,S4_P"$EUW_ *#>I?\ @4_^-'_"2Z[_ -!O4O\ P*?_ !K+HH]E#^5?<O\
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M>TI]8+\._H5[.ITF_P >U^YRW_"2Z[_T&]2_\"G_ ,:/^$EUW_H-ZE_X%/\
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M,$^_6OHNBC^U8_\ /O\ '_@!_94O^?GX?\$^<CKFI&=9OM.&2,Q* BA50C!
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M , /['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_ .'_  3YAHKZ>HH_MC^Y^/\
MP _L?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\ X?\ !/F&BOIZBC^V/[GX_P#
M#^Q_[_X?\$^8:*^GJ*/[8_N?C_P _L?^_P#A_P $^8:*^GJ*/[8_N?C_ , /
M['_O_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_ .'_  3YAHKZ>HH_MC^Y^/\ P _L
M?^_^'_!/F&BOIZBC^V/[GX_\ /['_O\ X?\ !/F&BOIZBC^V/[GX_P# #^Q_
M[_X?\$^8:*^GJ*/[8_N?C_P _L?^_P#A_P $^8:*^GJ*/[8_N?C_ , /['_O
M_A_P3YAHKZ>HH_MC^Y^/_ #^Q_[_ .'_  3YAHKZ>HH_MC^Y^/\ P _L?^_^
M'_!/F&BOIZBC^V/[GX_\ /['_O\ X?\ !/F.-VBD61" RD,,C/(JU_:M[_:?
M]I>>?M>[=YFT=<8Z8QTKZ2HI/-D]X?C_ , :RAK:?X?\$^;?[5O19SV@G(MY
MW\R1 H 9N.>G'0=*;<:C=W5Q%/++F2%56,A0-H7H  *^E**/[5C_ ,^_Q_X
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M5Z:IU'!.]CZRA4=6FIM6N%%%%9&H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)J7_ ("O_A7L?_"Q/"O_ $%/_)>7_P")H_X6)X5_Z"G_ )+R_P#Q-'U[%?\
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M\SI:*Y-/B3X7DD5%NKX%B -VEW0'XDQX%37GQ \-V-P8);NY9P <PV%Q*O\
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M9ND@N([L?87B:26X:/'DE>JD9Z],<\U#K-RUU+))_:XNXC*S1P[I24!)[,H
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M_B*Z;^V/B+_T =-_[['_ ,=I?[7^(Q_Y@&F_]]C_ ..TOK6)_GA]Z']5PO\
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M5/KO_/WIO_?Q_P#XBC_A;&N_\^FF_P#?M_\ XNC_ (6QKO\ SZ:;_P!^W_\
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MY-]$DL"S""W60 K(6Y!YZX7G\:ETG1[<FZ,]AYT=Y=20(PBW"!%W#<./E^;
M[=*YX^);\OI[-Y;?8?\ 5@@_-QC+<\G J#4=:NM2EMY)!'%Y _=B($ '.2W)
M/)/\J3I59/5[_H-5:45HMOU.@M-'MI/#YL+B&*/4'N9(HIMN#YB\A2<9P<$5
M#JEU%I%I;6B68C>[T^#SV7"G )W9&/O'H2:RM1\0WFI(JR)#$5E\X-$"IW8
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M&/S(J_HL$EVK:G)('>6(Q+&5P$P3G/OGBD32;V*2 PV]BAMT*1,!]Q3R5 _
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "J&K:-I^N6JVVHV_GPJXD"[V7# $9RI!Z$U?K!\9
MZC=:3X3O;VRE\JXB\O8^T-C+J#P01T)K2DI.:479W,ZKBH-S5U8K?\*[\*_]
M O\ \F)?_BJ/^%=^%?\ H%_^3$O_ ,57F'_"Q/%7_04_\EXO_B:/^%B>*O\
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M_P 31_PL3Q5_T%/_ "7B_P#B:/J6-_Y^?BP^NX+_ )]_@CT__A7?A7_H%_\
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M>BCZS6_G?WL/JU'^1?<CF/\ A7?A7_H%_P#DQ+_\51_PKOPK_P! O_R8E_\
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MDS[R;]Q'/3.*++X=^%["8RPZ?,S%=N)[V>9<?[KN1GCKC-=113]K4_F?WO\
MS%[*G_*ON7^1QP^%WA($'[#><>NJ71_]J5/>?#CPM?3^=-I\RMC;B"]GA7_O
ME' S[XKJJ*7M:G\S^]_YA[*G_*ON7^1RO_"N?"OV$V?]G2^46W;OMD_F9_ZZ
M;]V/;.*2T^&WA2RG\Z+3I6;&,37L\J_]\NY'Z5U=%/VM3^9_>_\ ,/8T_P"5
M?<O\CC6^%GA!F+'3[O).>-3NA_[4J>\^&WA2^E62;39%95V@0WD\0Q[A' )Y
MZ]:ZNBCVM3^9_>_\P]E3_E7W+_(Y1?AOX42Q>S&FR>4[;BQO)S)GCHY?<!QT
M!QU]326GPU\)V=P)HM.F9P",37T\J_\ ?+N1^E=911[6I_,_O?\ F'L:?\J^
MY?Y''/\ "[PC)(SFPN@6))VZE<J/P DP*GN_AQX5O3&9=.E78NT>3>3Q9'OL
M<9/N>:ZJBCVM3^9_>_\ ,/94_P"5?<O\CE8_ASX5BLY;5=.E,<ARS->3LX^C
ME]R].Q%-M?AKX4L[A)XM/G9US@2W]Q(O(QRK.0?Q%=911[6I_,_O?^8>RI_R
MK[E_D<A+\,?"<TSRM8709V+$)J5RHR?0"0 #V'%37/PZ\+7:0K)I\JB)=J^5
M>SQDC_:*N-Q]SDUU-%'M:G\S^]_YA[*G_*ON7^1RT/P[\+P6LUNFGRE)?O%[
MV=W'^ZQ<LOX$4RV^&OA6UN$GCL;DNAR!+J%Q(OXJTA!_$5UE%'M:G\S^]_YA
M[*G_ "K[E_D<E/\ #3PI<3O,]C=!G)8B/4;E%_!5D  ]@*EN/AYX8NH8(I+"
M95@7:ABO9XV(X^\RN"QXZL2>OJ:ZBBCVM3^9_>_\P]E3_E7W+_(Y>W^'GABV
M@GACL)BDPPQDO9Y&'7[K,Y*]>JD5'!\-O"UM.DR65T60Y DU&Y=?Q5I"#^(K
MK**/:U/YG][_ ,P]E3_E7W+_ ".4N/AOX6N;AYI+*Z5W.2(]1N8U_!5D 'X"
MI)_A]X9N+:&W>QG"0C"F.]G1C_O,KAF_$FNGHI>UJ?S/[W_F'LJ?\J^Y?Y',
M6OP^\-6D<T<=C.PF7:QEO9Y"!S]TLY*GGJN#^510_#;PM!-'*EG>%D8, ^I7
M+J2/53(01[$8KK**/:S_ )G][_S'[*G_ "K[E_D<M=?#KPQ=W+SR6=TKOC(B
MU"XB7ICA5D 'X"GR^ /#<UG%:M93B.(Y5DO9U<_[SAPS?B37344>UJ?S/[W_
M )B]E3_E7W+_ ".:M/ 'ANR\WRK.=O,7:WG7L\N![;W.T^XP:@C^&WA>*5)%
MM;XLC!@&U2Z89'J#)@CV-=911[6?\S^]_P"8_90_E7W+_(YB[^'OAJ]N6GEM
M+I7;&1#J%Q$O''"I( /RIS^ ?#DEA'9&SN!%&VY66^G60GGK('WL.3P21T]!
M72T4>UG_ #/[W_F'LH?RK[E_D<W9> O#EA([PVEPQ==I\^^GF&/8.Y /N.:K
MI\-O#".K"VO\J<C.JW1'Y&3FNLHH]I/^9_>_\P]E#^5?<O\ (YJ\\ ^'+ZX,
M\UK=*Y &(+^XA7_OE' _2E/@/PZVGK9&TN/*5MP87TXDS[R;]Y'/3.*Z2BCV
ML_YG][#V4/Y5]R_R.;L? ?A[3YS-!:W+,5VXGOIYEQ_NNY&>.N,U7_X5OX9!
MSY&H_P#@VN__ ([7644>TGW?WO\ S#V</Y5]R_R,"7P7X?FU&&^DL"TL)!1#
M/)Y60<@F/=L)!YR1G@>@K?HHJ7)R=VRE%15DK!1112&%%%% !1110 4444 %
M%%% !1110 5Y5+\:$65A%H1= ?E9KO:2/IL.*]5KRCX*_P#,<_[8?^U*ZJ$8
M<DYS5[6.3$2J>TA"#M>_X!_PNK_J7_\ R<_^UT?\+J_ZE_\ \G/_ +77J]%'
MM:'_ #[_ !8>QQ'_ #\_!'E'_"ZO^I?_ /)S_P"UT?\ "ZO^I?\ _)S_ .UU
MZO11[6A_S[_%A['$?\_/P1Y1_P +J_ZE_P#\G/\ [71_PNK_ *E__P G/_M=
M>KT4>UH?\^_Q8>QQ'_/S\$>4?\+J_P"I?_\ )S_[71_PNK_J7_\ R<_^UUZO
M11[6A_S[_%A['$?\_/P1Y1_PNK_J7_\ R<_^UT?\+J_ZE_\ \G/_ +77J]%'
MM:'_ #[_ !8>QQ'_ #\_!'E'_"ZO^I?_ /)S_P"UT?\ "ZO^I?\ _)S_ .UU
MZO11[6A_S[_%A['$?\_/P1Y1_P +J_ZE_P#\G/\ [71_PNK_ *E__P G/_M=
M>KT4>UH?\^_Q8>QQ'_/S\$>4?\+J_P"I?_\ )S_[71_PNK_J7_\ R<_^UUZO
M11[6A_S[_%A['$?\_/P1Y1_PNK_J7_\ R<_^UT?\+J_ZE_\ \G/_ +77J]%'
MM:'_ #[_ !8>QQ'_ #\_!'E'_"ZO^I?_ /)S_P"UT?\ "ZO^I?\ _)S_ .UU
MZO11[6A_S[_%A['$?\_/P1Y1_P +J_ZE_P#\G/\ [71_PNK_ *E__P G/_M=
M>KT4>UH?\^_Q8>QQ'_/S\$>51?&A&E42Z$40GYF6[W$#Z;!FO5:\H^-7_,#_
M .V__M.O5Z*\8<D)P5KW##RJ>TG";O:WXA1117*=84444 %%%% !5&\UG2].
MF$-]J5G:RE=P2>=48CIG!/3@_E5ZO$OC""?%]H ,DV*?^C)*WPU%5JG(W8Y\
M36=&GSI7/5_^$H\/?]!W3/\ P+C_ ,:/^$H\/?\ 0=TS_P "X_\ &OG6?1-4
MMH$GEL9UC?@'9G!SMP1_"<\8.*&T/5D +:7>KDX&;=QS^5=_]GT_Y_R//_M*
MI_)^9]%?\)1X>_Z#NF?^!<?^-'_"4>'O^@[IG_@7'_C7S?=:=>V2JUW9W%N&
M.%,L3)GZ9%/FTK4;: SSZ?=10C&9'A95&>G)%']G4_YOR#^TJG\GYGT;_P )
M1X>_Z#NF?^!<?^-'_"4>'O\ H.Z9_P"!<?\ C7S:]E=QO"CVLRO, 8E:,@R
M]-OKGVJS_8.L'II-]_X#O_A1_9U/^;\@_M*I_)^9]$_\)1X>_P"@[IG_ (%Q
M_P"-'_"4>'O^@[IG_@7'_C7SFFD:G+))''IUV[QD!U6!B5/N,<4L>C:I+O\
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M&R/HRBJ>EZI9ZSI\5]8S"6"09!'4'N".Q'I5RO,::=F>JFFKH****0PHHHH
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MXFW1IO.$/J!V-#I-VU&JR5]-SO-/D;P^AO-1FM[:ZO[]S.LBOAHE)#!0%/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKP9_T&;[_O\ W?\ C1:?_/C\&%X_\_\ \4<__P )S\0?^A5_\I]Q_P#%4?\
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M%O\ _'J/J6(_D?\ 7S#Z]AOYU_7R/2Z*\T_X3_PQ_P \?$'_ (%O_P#'J/\
MA/\ PQ_SQ\0?^!;_ /QZCZEB/Y'_ %\P^O8;^=?U\CTNBO-/^$_\,?\ /'Q!
M_P"!;_\ QZC_ (3_ ,,?\\?$'_@6_P#\>H^I8C^1_P!?,/KV&_G7]?(]+HKS
M3_A/_#'_ #Q\0?\ @6__ ,>H_P"$_P##'_/'Q!_X%O\ _'J/J6(_D?\ 7S#Z
M]AOYU_7R/2Z*\T_X3_PQ_P \?$'_ (%O_P#'J/\ A/\ PQ_SQ\0?^!;_ /QZ
MCZEB/Y'_ %\P^O8;^=?U\CTNBO-/^$_\,?\ /'Q!_P"!;_\ QZC_ (3_ ,,?
M\\?$'_@6_P#\>H^I8C^1_P!?,/KV&_G7]?(]+HKS3_A/_#'_ #Q\0?\ @6__
M ,>H_P"$_P##'_/'Q!_X%O\ _'J/J6(_D?\ 7S#Z]AOYU_7R/2Z*\T_X3_PQ
M_P \?$'_ (%O_P#'J/\ A/\ PQ_SQ\0?^!;_ /QZCZEB/Y'_ %\P^O8;^=?U
M\CTNBO-/^$_\,?\ /'Q!_P"!;_\ QZC_ (3_ ,,?\\?$'_@6_P#\>H^I8C^1
M_P!?,/KV&_G7]?(]+HKS3_A/_#'_ #Q\0?\ @6__ ,>H_P"$_P##'_/'Q!_X
M%O\ _'J/J6(_D?\ 7S#Z]AOYU_7R/2Z*\T_X3_PQ_P \?$'_ (%O_P#'J/\
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M16?_ &-:_P#/6^_\#Y__ (NC^QK7_GK??^!\_P#\70!H45G_ -C6O_/6^_\
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M_L:U_P">M]_X'S__ != &A16?_8UK_SUOO\ P/G_ /BZ/[&M?^>M]_X'S_\
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M*BBI6B%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP#N_^%3Z[_S]Z=_W\?\ ^(H_X5/KO_/WIW_?Q_\ XBN$HI^SQ'_/Q?\ @/\
MP1>TPW_/M_\ @7_ .[_X5/KO_/WIW_?Q_P#XBC_A4^N_\_>G?]_'_P#B*X2B
MCV>(_P"?B_\  ?\ @A[3#?\ /M_^!?\  .[_ .%3Z[_S]Z=_W\?_ .(H_P"%
M3Z[_ ,_>G?\ ?Q__ (BN$HH]GB/^?B_\!_X(>TPW_/M_^!?\ [O_ (5/KO\
MS]Z=_P!_'_\ B*/^%3Z[_P _>G?]_'_^(KA**/9XC_GXO_ ?^"'M,-_S[?\
MX%_P#N_^%3Z[_P _>G?]_'_^(H_X5/KO_/WIW_?Q_P#XBN$HH]GB/^?B_P#
M?^"'M,-_S[?_ (%_P#N_^%3Z[_S]Z=_W\?\ ^(H_X5/KO_/WIW_?Q_\ XBN$
MHH]GB/\ GXO_  '_ ((>TPW_ #[?_@7_  #N_P#A4^N_\_>G?]_'_P#B*/\
MA4^N_P#/WIW_ '\?_P"(KA**/9XC_GXO_ ?^"'M,-_S[?_@7_ .[_P"%3Z[_
M ,_>G?\ ?Q__ (BC_A4^N_\ /WIW_?Q__B*X2BCV>(_Y^+_P'_@A[3#?\^W_
M .!?\ [O_A4^N_\ /WIW_?Q__B*/^%3Z[_S]Z=_W\?\ ^(KA**/9XC_GXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Q^$'_,9_P"V
M'_M2O3J\Q^$'_,9_[8?^U*[:'^[5?^W?S.&O_O-+_M[\CTZBBBN([@HHHH *
MYSQSHFH^)/"UQHVG7$5N;QTCN)9&(*P;@9-N <L0,8/')Y%='10!YOKWPTE^
MWQWGANX\II--N=,NUU"^GFWPR(1&%+ER KX.!@=:J:_\+M0O[7PM+I]W;0W^
MFQ6D&H*\C"*YCAP01A3E@P."0.&/(Z5ZG10!Y=_PJB:[\%ZC!?W[GQ)>3RWQ
MGAOIQ;+<EMR'R\A2  HW%"<#CH*L:U\.]4USQ9I&K3W5I%:R1V[:Y;(S$7$L
M!+)L^7D;CCG;P!QVKTFB@#A[;0?$FC^._$VN6%KI5Y:ZQ]EV)/?20/'Y,6PY
M A<'))[]O?C-U'P#KVIZC-XHDO[6#Q5!<H^F[)7:VM[=0086.T%@X9RQV]3Q
MQG/I5% #4+F-3(JJ^!N"G(![X.!G\JXC4="\377Q"L?$$5EI!M+.WEM5C?4)
M \B.P^<CR"%.!]W)^M=S10!R6H_#GP]=K;_8+2+1I()TG\S3+6"-I&7E0^Z-
M@R@X;!&,@'L*SO#GA'Q#X9D\17*7\6IR:E>O-%#<3K"C*P \R1D@)$G&,*-G
MMGFN^HH Y'X<Z#K'A;PE:Z%JT=B?L8(CGM+AY/-W.S'*M&NW&0."V>>E==11
M0 4444 %%%% 'F/Q?_Y@W_;?_P!IUZ=7F/Q?_P"8-_VW_P#:=>G5VU_]VI?]
MO?F<-#_>:O\ V[^04445Q'<%%%% !1110 5X[\6/^1IM?^O)/_0WKV*O'?BQ
M_P C3:_]>2?^AO7H97_O"]&>=FG^[/U1Q=DTT=]!);QF29)%9$"EMQ!R!@=:
MW=37^T-+O-3B>ZML7&+FTE<E#(>,KTY''!''X5SBLR,&5BK Y!!P0:GN+^\N
MU"W-W/,JG($DA8 _B:^AE!N2:/GHS2BTSLV_Y*!IG_7L/_0&J;2#;R1:;]E!
M\A9YLB5MS)/M.!G@8QG' [=ZX7[==_:%N/M4_GH,+)YAW >@/6FK=7"1F-)Y
M50L'*AR 6'0X]?>L'AVU:_3_ #_S-EB4FW;K_E_D=#X?-QYVLF^\WR/LT@NB
M^?O]L_[77WZUI^*3*]G,+ KE GVY5'SE=H*G_<Z_C7'W&HWUU'Y=Q>7$R9SM
MDE9AGUP32"^NQ.9Q=3B5EVF3S#N(],^E4Z+<^?\ K^O^ 2JR4.3^OZ_X)O>,
M6M?[6=3#-]H\J/$GFC9T'\.W/3WKF:N/JVHR1-%)J%TT;#:5:9B"/3&:IUK3
MBX1469U9J<G)!1115F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !112JK.P5068G  &230 L1D$J&+=YFX;-O7/;'O7T+X
M:.JG0;8ZT%%[M^;'7';=_M>M<QX%\"KI2IJFJ1AKXC,41Y$(]3_M?RKO:^?S
M'%0JOD@KVZ_Y'T.6X2=)<\W:_3_,****\L]4**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O,?A!_S&?^V'_M2O3J\4\"^*['PL=0%]#<N;CR]HA53C;NSG)'
M]X5Z&%A*="K&*N]/S//Q4XTZ]*4W9:_D>UT5PG_"V-"_Y]-1_P"_:?\ Q='_
M  MC0O\ GTU'_OVG_P 76/U+$?R/^OF;?7L-_.OZ^1W=%<)_PMC0O^?34?\
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MHSNVXQ@G^Z:]KK;%0E"A2C)6>OYF.%G&I7JR@[K3\@HHHKSST HHHH ****
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M[_OV_P#\77.:GI-II;+%+>SO,\(E4+;C;R. 3OS^E6[GPE);ZS:6/VH-%<Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM12&:TDD5G:-V61&;.Y<#.?8X_"O0_\ A4^A?\_>H_\ ?Q/_ (BC_A4^A?\
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M"Y _,&J7VK3[;3]>M8)]RW#Q&V^1AN4.2>HXP#WKT3_A4^A?\_>H_P#?Q/\
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M &:NJA&')*<U>UCDQ$JGM(0@[7N9_P#;&C_]"S8_]\I_\11_;&C_ /0LV/\
MWRG_ ,17>44>UH?\^_Q8>QK_ //S\$<'_;&C_P#0LV/_ 'RG_P 11_;&C_\
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M/_?*?_$4?VQH_P#T+-C_ -\I_P#$5WE%'M:'_/O\6'L:_P#S\_!'!_VQH_\
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MUZ4@L[@F<"/F $R<CY:/JU'^F+ZS6_I&G]H\-_\ 0%@_\!8Z/M'AO_H"P?\
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M^ Z?X4?V#H__ $";'_P'3_"M"B@#/_L'1_\ H$V/_@.G^%']@Z/_ - FQ_\
M =/\*T** ,_^P='_ .@38_\ @.G^%']@Z/\ ] FQ_P# =/\ "M"B@#/_ +!T
M?_H$V/\ X#I_A1_8.C_] FQ_\!T_PK0HH S_ .P='_Z!-C_X#I_A1_8.C_\
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M'_Z!-C_X#I_A1_8.C_\ 0)L?_ =/\*T** ,_^P='_P"@38_^ Z?X4?V#H_\
MT";'_P !T_PK0HH S_[!T?\ Z!-C_P" Z?X4?V#H_P#T";'_ ,!T_P *T**
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MBXD5)6@+98=]OOC\ZYZBL_8OHS3VRZHW-/M+B"QO5DM]S/&I6(]2,GJ <BB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_!/_+]_VS_]FKK*
MY/P3_P OW_;/_P!FKJI?P*GR_,Y*W\>G\_R.LHHHKE.L**** $9@JEF("@9)
M/05X)>+K>K:9J/Q'L]/MG2'51J-M<&Z99C:6X,?EB/RR-I4.Q.\=2<>OOE%
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M1%.3]TL/YBK!TFU.IC8FZV(92NX_*X'3U]Z3C070:EB'U%_X2C_IS_\ (O\
M]:C_ (2C_IS_ /(O_P!:N=HK;ZM2[&'UJKW.B_X2C_IS_P#(O_UJ/^$H_P"G
M/_R+_P#6KG:*/JU+L'UJKW.B_P"$H_Z<_P#R+_\ 6H_X2C_IS_\ (O\ ]:N=
MHH^K4NP?6JO<Z+_A*/\ IS_\B_\ UJ/^$H_Z<_\ R+_]:N=HH^K4NP?6JO<Z
M+_A*/^G/_P B_P#UJM6&O17D_DR1^2Q^[EL@GTZ5R=%*6%IM62*CBJB=V[GH
M=%86C:SYVVUNF_>=$<_Q>Q]ZW:\VI3E3E9GI4ZD:D>:(4445!84444 %%%%
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M3_\ ?L_X4?8+W_GTG_[]G_"CGCW#DEV*]%6/L%[_ ,^D_P#W[/\ A1]@O?\
MGTG_ ._9_P *.>/<.278KT58^P7O_/I/_P!^S_A1]@O?^?2?_OV?\*.>/<.2
M78KT58^P7O\ SZ3_ /?L_P"%6[#1;BZGQ-')#$.6+*03[#-3*I"*NV.-.<G9
M(9I>ER:A+DY6%3\S_P!![UV2C:H49P!CDYIL,,<$2Q1*%11@ 4^O+K5G4?D>
MK1HJE'S"BBBL38**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /2!6\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR'3/^3G=:_[!B?\ H$= &7\:-,BUKXC^"M,FDDCBNW\EGC.&4-(HR#ZUL?\
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M.<UZK0!E^''UJ30+1_$45K%JQ#>>EJ28U^8[<9)_AQGGKFO,/BQ_R4_X=?\
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MXR0"#R.HX% %O]HF"$^"=-NBJ_:8M218G[@,CE@/KM7\A3?CN\DGPMTEYO\
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M9/&([S:9KH @XE;D@D<$@87(_NTOQ(\,-XM\":EI<,8DNRGFVH) _>KR "<
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M(TQ9%M82Q7S'W-EF+')^I->.?%)[KXE^-(?!6@1PR'2HY+BYN6 ^63;]S=U
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M9P#@#.<5?T?X5:A<>)K/Q#XS\1RZU>69W6]NJ;(D8<@_3.#@ <@9R.*]/HH
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M_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\
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M17B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\ \-(^'/\
MH#:K_P"0_P#XJC_AI'PY_P! ;5?_ "'_ /%4 >T45XO_ ,-(^'/^@-JO_D/_
M .*H_P"&D?#G_0&U7_R'_P#%4 >T45XO_P -(^'/^@-JO_D/_P"*H_X:1\.?
M] ;5?_(?_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4
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M^&D?#G_0&U7_ ,A__%4 >T45XO\ \-(^'/\ H#:K_P"0_P#XJC_AI'PY_P!
M;5?_ "'_ /%4 >T45XO_ ,-(^'/^@-JO_D/_ .*H_P"&D?#G_0&U7_R'_P#%
M4 >T45XO_P -(^'/^@-JO_D/_P"*H_X:1\.?] ;5?_(?_P 50![117B__#2/
MAS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\ \-(^'/\ H#:K_P"0
M_P#XJC_AI'PY_P! ;5?_ "'_ /%4 >T45XO_ ,-(^'/^@-JO_D/_ .*H_P"&
MD?#G_0&U7_R'_P#%4 >T45XO_P -(^'/^@-JO_D/_P"*H_X:1\.?] ;5?_(?
M_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\
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MB@#X=\;?\C[XB_["ES_Z-:L*MWQM_P C[XB_["ES_P"C6K"H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*P$HI:*+ )12XI<4U!L!M%.VT;:KV<A7&T4[%&*3IM#N-HI<48J; )12T46
M2BEHHY0$HI:.*+ )1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHQ2TT 8HHHJK %%%%)(04N*3%. K6,;@ 7V
MI=OM3@*F2%G' KMIX7FZ$N217VCTI-HJVUJX&<5 R$'!%.IA'%7L)33(L4AI
MY&*97G3BTRQ**#168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BEI#3 **** %HH%%"0!11BEK1(08I*=257*%Q*#114-
M#$HHQ146 6BBB@ I*6DH ****0!7K/[/'_)2)O\ L'2_^AI7DU>L_L\?\E(F
M_P"P=+_Z&E 'U-1110 4444 %%%% 'P[XV_Y'WQ%_P!A2Y_]&M6%6[XV_P"1
M]\1?]A2Y_P#1K5A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+24M,
MHHHJD 4444Q!112]Z:U  *<!0*L0V[2GBNRAAW,F4DB'%&VM5-*9@#3SI3 U
MWK":&+KP[F.5II%:TFFL!Q5"6!HSR*RJX5VT*C4C+9E?%(:>5IF*\R<'%FPE
M%+BBHL E%%%*P!24M)4L HHHJ1A1110 4444 %%%% !1110 4444 %%%% !2
MTE** "DIV!FE JU&X#<48IVTTX(2>AK6-&3Z";& 4\*.]3QVLCGA35V+2W;&
M5-=]+!MJ[1E*M&.[,S8/2DV>U=!%HY/5#4K:-\O^K%=?U!-;&/UN%]SF2M-Q
M6M=Z9)%DA3BLYD(X(KBK81PZ&\*D9JZ9%BDQ4NP^E-*\URRH26Z+3&8HIQ&#
M2$5@XV*&XHI<T5%@$HHHI %%%% !1110 4444 %%%% !1110 4444 %%% H0
M"T4452 ****H04M%%- *!3@*:*GAC,D@45V8>ESRLA2=D7+&Q>=Q\O&:Z:TT
M4E1E*LZ!I)?:2O>NRATO8GW:^AITHTU:9\YC<PY9<J9QLNB';PM8][HS*#\E
M>H#3MW&TU!<Z$)(S\AJYND_=N<E+,W%ZL\6N;9X7((XS54BN]U_0O)#':1S7
M$2QF-RI'->/C<)RZH^DPN)C6C=%<@TE./%-KQ)*SL=@4445(!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44M%.PA*4BBEJN48@I
M<4H%."UK3HRD*XT"G!:ECMW<\*<5<BLCGYA7HT<(WN92J)%#8<9Q32*W/L>5
M^[5&YLV0Y"UM4PFET1&M%NQGD4F*D84W'/->55I.+.A,8:2G'%)6%AA11118
M HHHHL &DI:2I: *]9_9X_Y*1-_V#I?_ $-*\FKUG]GC_DI$W_8.E_\ 0TI
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M!0)CCUKX;+<YQ;JI<SW.W-\FHX2ESTV<[=V00Y'2J*PG=6S?$X%4%QGFOUW
M8F<\.I29\]3F^48EN2:T+>S&,D5#&>>*THCF.N/,,54C!M&=2;&B*,<;<_A4
M<EG#("&C'/M5E, TZ0BOAGG&,C72C)F\:*]GS7U.#\3Z#&869$'0UY'JEF8)
MVXQS7OFO#-LRCN#7CGB"V/G.<'K7Z?@YRQ.$4I[GO9+B)/W6SDS334CJ0<$5
M&:\RO!Q9]4G<;12FFUQ-E"TE%%2 4444 %%%% !1110 4444 %%%% !1110
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M;I*<:;7CS21[X&DI325B]QA1112 **** "BBB@ HHHH **** "BBB@ HHHH
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M*X:'5P@P16E;W\4HR#@U^59QPE6C)S@C3!9IB<%[J^$W[L>?\V<UDRQA@48
MBI5N&(X(JG=WL<$;,[<UYN49?CZ5>,81:5S/'8FEB7S1^(\N\?6T<<K$* <G
M^5>8,.:[WQQJBW%PX4]S_*N";.:_4<;=0C&6]CZK*82CAUS#2.*::<3Q3:\=
MGJL****EH0E>L_L\?\E(F_[!TO\ Z&E>35ZS^SQ_R4B;_L'2_P#H:5 SZFHH
MHH **** "BBB@#X=\;?\C[XB_P"PI<_^C6K"K=\;?\C[XB_["ES_ .C6K"H
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M4E+28J6 5ZS^SQ_R4B;_ +!TO_H:5Y-7K/[/'_)2)O\ L'2_^AI4@?4U%%%
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MLIQ?8E :+[G;_@!XZ]*W-=N?%GQ T;2->\!:[=^:EHD&HZ7;W_DO%*,_/M+
M'.2,]P!C/./G\,P! ) /49ZTL<CQ.'C=D8=&4X(H ]5\<6&M:!X'2U\4^,-3
MNM>O9AG1_MQFB2($$-(,GG(R.<9(QT-:%C<#X*^$;6]:"*3QAK.V3R91G[+:
MA@=K#J"V,'W_ -RO&68LQ9B23U)I* /2_B;X<LKNTM/'OAR/_B3:L<W$2_\
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M141ZU;O5VSD54->1BU:1]I!WC<;24M)7G,U"DI:*SL E%*:2D 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IU-IU7  I124M;P)8X5>T]PLXS[51J6)MK@^]=^&E9D5%=6/5_#<JX
M7&.M>B6!S"#[5X[X;O"LB D]:]9TB;S8!SVK7.(N6'YUT/A,VI.,[FGFBF=Z
M<*^'C4<CQK 30HR:0TY#BO-S"4N70Z<,ES:CRO%1 =14I;(J(=:Y,I<_;*YT
M8Q1LK&+> "6I[)PIQ3KBU+R9J:"RV<DBOTBIB:2H6;.>4X\EBS+*/*)'I7GO
MBD[D<>XKT!H5:,J*X3Q3#M5_PK3(94WS<IT9=95D>0WXQ<O5(]:T-1&+EJSS
MUJL<ES'Z%2^%"4E*:2O-:-0HHHJ; %(:6D-)C"BBBI **** "BBB@ HHHH *
M*** '4H-)171=H1(AYKM_"<@\Y![BN&2NI\+W&VY09_B%>SE\[V1P9A#FHL]
MTTHYM%^E7P:Q]"FWVJC/:M?I7S69IPQ4C\ZK*TVA<<4P=>:<6IH&37A9A.'(
M]1T4W(GC -/; %.@B)[5))%Q7QE2:=0^DI49>RO8HN>:1:?(A!Z5&#BOH\LJ
M121X>+C+FU'&D'I2<FC&"*]!XN/M4D<RIOEN<1XP"I&]>.:B0;EA[FO8/'#;
M89#]*\8NW+7#G/>OT24[86#?8^RR*-Z5RN33:#17BRE=GT0AI*4TE82W&%%%
M%2 4444 %%%% !1110 4444 %%%% !2BDI13CN H%+116\=!#UJW9C][5-35
MBW<K*,5Z6%DFS.HO=.\T)P-H]J[^T.]!Q7 >' KLN?2O4M-MHVB&:]+&UE3H
M79\5FDE&90FA.*RI@0:Z6^B54.VN7G+&3%/*ZWM(W..A+F+%HA9Q]:Z6TM%\
ML%JPM/3YP3ZUT\/^I6O+S[%3@[1,,5)WLB-[<!3@5EW*;0>*VQ52]@4Q[J\C
M+<:Y5$I&%.=GJ<S*V#Q4EM(<BFW"8D('K3K9?FK[6;C[$]!VY329=\-<IK]J
M"C'V-=:S!817(^(;H+&PR.AKBP-WS7V*P5_:*QYAJT6RXK+85IZI,9)ZS6KA
MQR5]#[JA?D5R.BE-)7CM,W"BBBD,#24II*E[@%%%%( HHHH **** "BBB@ H
MHHH ****  4M(*6JB M/6F4X&NFE.S$;.DR#S5![$5Z?X?<%%KR73WVW"\]Z
M]-\/SX5>>U?2X=\].Q\]F]/W3N' \H5S^H@ FM7[23'UK'OF+ U.!I2A.1\W
M0BU+4JVJ[I,5NV]KN4<5DV$?[RNLLXEV XI9EB71@K%8JIR[&=)8G'2JYM"A
MZ5T;(OI5::)<=!7F4<RF_=9RQKLS80J=:L&YA4<U2NW\L''%9RN\KXR:]&.%
M55<[9NJ?/JS0N)T?.VN4UHG:U=4EK\F:YGQ HC5OI771Y(P:B=>#:51)'G.J
M',I^M9;5?U!RT[#/>J!->-C7=GVE%>XAE!I:::\F2-PHHHJ& E>L_L\?\E(F
M_P"P=+_Z&E>35ZS^SQ_R4B;_ +!TO_H:5F,^IJ*** "BBB@ HHHH ^'?&W_(
M^^(O^PI<_P#HUJPJW?&W_(^^(O\ L*7/_HUJPJ "BBB@ HHHH **** "BBB@
M JUIMA+JNJV>G6Y037<Z01ESA0S,%&?;)JK6YX,_Y'KP_P#]A*V_]&K0!VTO
MP'\1P2F*76?#T<B]4>]8$?@4KE/%O@#Q!X+,+:K;(;:?_574#^9$Y]-W8^QQ
M7I/Q,^%/C+Q'\1-6U72]*6:RN&C,<AN8ESB)%/!8$<@]JJ^*K*^\"?!2+PKK
MQ,VI7]]]HA107CM8QM)7?]W=E3P"?OF@#QFBO6M*\!^#+7X>:'XP\2:AJ$4%
MR94FM[<J6FD$C*BH,<#:C$Y/Y5BZ5X8\':MK.NZBVL75GX6TQ5>-7*&[N,C[
MJ X_BSS@XR,^M 'G];NC>$]0US0=:UFUDMUMM(1)+A9&(9@V[&T $'[IZD5W
MGA_PK\/?'LUQI'AYM<TW6%@:6W:]:-XY2O9MO.?IC\>E<YX4\)6.L^"O&&K7
M<EREUH\43P+&X",6+YW @Y^Z.A% '$T5Z=HG@/PQ-\,[7Q?KFI7MK$MT\5Q'
M!M9I0"0J1 CAB><DD8!XIUYX/\'^(O ^J^(/!L^JP7.CA6N[/4-C;D/\0*].
M QZG[I&!P: /+ZW_  IX,UOQG?R6NCVPD\E=\TTC;(XAV+,?7TZ\'T-8%>K_
M  SN].UCP/XB\$2ZK%I.HZG(DMM<RG:LH&W,9/\ P'&.X8]>E %)O@GK\L;#
M3-8T#5+E%+/;6=]ND&.V" /U%>?_ -F7QU4:7]DF^WF;R/LVP[_,SC;CKG/&
M*]!E^%GQ!\%ZI;ZO9Z=]K:SD69)K"3S,X.?NC#D'OQTI?"_B&T\3_&JSUCQ%
M9R6]U<74 ABT]0BK<JZ*A<.2=N =V.<T >?:IIEWHVIW&G7\7DW=NVR6/<#M
M;TR.*J5ZK\0M$TWQ/\6VT7P[%?C6+J]D2^:Z*&$'"G='MYV@!R<\\"H[W2?A
M3HNJOH-]>^(+JYA?R;G4K?RQ#'(.&VI@DJ#UZGCC- 'EU%>B#X;)I_Q7TWPI
MJ-R\^GWS+)#=V^%,T+ D,N<@'(([]#6PWA'X::3XJ_X174]1UNYU*6Y^SFYM
M?+6"W9FPBDD9)&0&.,9SP.P!Y'17JNH^#_ 7@76WTCQ;J&JZA>,Y(&FJJQV\
M1/R&3=R7(PQ X&>_&>7^(WA"+P5XL?3;:Y:XLY84N;:1_O&-LXSCC(((SWH
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MTM--838P-)2T8KG>I0AI*4TE9O< HHHI %%%% !1110 4444 %%%% !1110
MHIPIM+6T&(=244N*V6HA0:DC<HP(J*G@UU4I-$M&U::@4(PU;EKJI&,/7&*3
MGBM"W=@1S7K4JKL<%?#1>IVJ:J2!EZLIJ*G&6%<C',1U-2_:#V-=,:QYTL)$
M[B"_B(ZBDGU&)1U%<:MZR#.?UJ&>^+\;C^=7]8T,E@$Y'2OJ\>[[PJM=:BCQ
MG!%<H\KYSDT"=@.2:R==G5'!16J%U.XW$X-8S$DU9NGW/54UYF*G<]:C#EC8
M::;2TE>3-FZ"EIM%9W&*:2BBI; 2O6?V>/\ DI$W_8.E_P#0TKR:O6?V>/\
MDI$W_8.E_P#0TK,9]34444 %%%% !1110!\.^-O^1]\1?]A2Y_\ 1K5A5N^-
MO^1]\1?]A2Y_]&M6%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z=3>
M].K2 F+2XI*6NF-A!2BDI:TBA"TN:2BMTQ#@Q%3QW<B8Y-5Q3L5O&4ELR7%/
M<T8M4<<$D5<CU8_WS6#1DUO&O)&,L/!]#I1JY_O&FR:KN7[QKG=Q]32ESCJ:
MOZPVB/JL+ERZNS(< U08YI2:;7+5J.6AT0@HJR"DI:*YFKF@VD-*:0USS0T(
M:2E-)7+(H****0!2&EI#28!1114@%%%% !1110 4444 %%%% $F:44VG@5Z%
M.[9+%%+4D<1;I2O&5KT8TW8SNB+- ;%!%-K)MQ8RS%<.A&":WM.U J1EJYD&
MK,,Q0@9XKKHUF85J*FK'J&F:V$49>M"XUT%.'KS6VNV7O5E]0;;UKLYX[M7/
M#GEL7.YJ:MK+,6P]<C=7C2N><TMW=,[$9JB.M<V)Q#>B/7PN&C31*CDOS6U8
MP*X&16+ A>05U6G6Q" T8=.6X8J:BM".XLT"=!TKG;N,)(<5U]VA$9KEKY/G
M)]ZUKQT,L)-MZF<:0TXTTUX\XGI(8W:FTY^U-KS*OQLM!11168PHHHH ****
M "BBB@ HHHH **** "E%)2BJCN X4HI!2UUP)%%+2"EKHC%,5PI0*7%%;QA8
M5QZ.RGBK\%TR#DUG!L4;JZ8U$D9R@I&XNHG'6D:^8]ZQE#$\5/@XY-:^T;,'
M0BBT]Z?[U,^VGUJDXYIE1*HS14HEJ2Z+=#55CDYI,TTFL*E30UC%+8":0FBC
M%<4KLL**,4&AZ(!*0TM-K";&+2445FQB&DI325C+<84445(!1110 4444 %%
M%% !1110 4M)2TT 4M)2UI$0HIU-I0:Z(,0N*<!2 THKK@DR1W>KEN_R\U2J
M1)"OTKLIRMH1-71?,I'2@3FJGG CO2"0$UMS&/LRVTYQUJ SG/6C(I-H-*XU
M%(D20L>:G(4IG-42VPTOV@XP11<'![HCF^^:A-2,<G-,-<E;4WCHAAIM.-(:
M\Z:+0VBE-)7.QA1114W&)7K/[/'_ "4B;_L'2_\ H:5Y-7K/[/'_ "4B;_L'
M2_\ H:5 'U-1110 4444 %%%% 'PYXU(;QWXA(Z'4[D_^16K#K;\9?\ (\>(
M/^PE<?\ HQJQ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C)HHIW8"Y
M-&3244<S[@+N/K1N/K244^>7<!=[>M&X^M)13]I/N%AV]O6C>WK3:*?M9]V*
MR';V]:/,;UIM%'MJG\S"R';V]:-[>M-HH]M4_F860[>WK2;V]:2BE[2?=A87
M>WK1O;UI**/:3[CL+N/K1DTE%)SD^H!FBBBE=@%%%%( HHHH **** "BBB@
MHHHH **** "BBB@!VX^@I1(1V%,HK159K9BL6$O'C& J_C2M>R-U5:K45I];
MK?S,7)'L2&8DYP*3S#Z"F45+Q%5[R'9#_,/H*42L.PJ.BA8BJMI!9%I+Z5.@
M6AK^5NRU5HJ_KE?^9D^SAV)&F9CD@4GF'T%,HJ'B*KWD59%B*[>$Y55/UK2B
M\2W<*X6*'\0?\:Q:*N.,Q$=ILSG1IS^)7-F7Q+>2C!CA'T!_QJA+?2S9W*O/
MI56BF\;B'O-A&C3C\*'^8?04F\^@IM%9.O4>[-+(4MNI***S;;=V,****0!1
M110 4444 %%%% !1110 4444 % .***$[ +NI=QIM%7SR[A8=O-+YA]!3**I
M5JBV8K(D\T^@H\T^@J.BJ^LU?Y@LA_F'TI1*?05'12^L5>X61.+HKT1:#=.>
MPJ"BJ^MUOYA<D>Q(9F/4"CS3Z"HZ*7UFM_,/E0_S#Z"C>?2F44G7J/J%D/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGWX29"(4V[B<YYX[#)KG* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1I(O))PV$.0,+DY'3'IFLCXDV%AI?Q%URSTQ%2TBN3L1.%0D LH'8!B1CVH
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MZAJ#>'X_&]NWB<*V;1+1S")%!+1^;G!(P>1Z'@U%IWPQT"/4H="\0>,8M/\
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M\"23!(0;LC!/(&<BO._#O_(S:3_U^0_^ABNO^-SLWQ=UL,20H@ ]AY$9_J:
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MOC8=*TJ'?,]I"7=N$B3'+L>P'_UAR:Y/XKWD,OCYM,M6S9Z-!#IL'L(UP?\
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M%%% !1110 4444 ?#?C+_D>/$'_82N/_ $8U8E;?C+_D>/$'_82N/_1C5B4
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M-%4  *"20./7J36CX*\?:GX%DOVTZTL+D7T:QS)>1LZ[1G@!67KDYSFN5HH
M]._X7?JW_0K>$_\ P7O_ /'*QM5^)5YJ^MZ3JEQH&@(^F.SQPPVKI%(QQ@R
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M&EK)>WT<C9597P4!V],'. /[H[$5Y%8>*O$.EVOV73]=U.TM_P#GE!=R(H_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M5/V??^2FC_KRE_FM>5UZI^S[_P E-'_7E+_-: /JNBBB@ HHHH **** /AOQ
ME_R/'B#_ +"5Q_Z,:L2MOQE_R/'B#_L)7'_HQJQ* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD] #0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% "-]P_2HK3_CTB_W14K?</TJ*T_X](O\
M=% $U%%% !1110 4444 %%%% !1110 4444 -D_U;_0TRU_X]8O]P?RI\G^K
M?Z&F6O\ QZQ?[@_E0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %06G^I;_?;^=3U!:?ZEO]]OYT 3T444 %%%% !1110
M4444 %%%% !1110 5!:?ZEO]]OYU/4%I_J6_WV_G0!/1110 4444 %%%% !1
M110 4444 %%%% "-]P_2HK3_ (](O]T5*WW#]*BM/^/2+_=% $U%%% !1110
M 4444 %%%% !1110 4444 -D_P!6_P!#3+7_ (]8O]P?RI\G^K?Z&F6O_'K%
M_N#^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO4T]PEZT#BW8]!)M.T_GB@"87,!N#;B>,S 9,>\;L?3K3WD2)&>1U1%&2S'
M%?-.[PHW@NWTVQAN%^)(N50,"XN/M?F#<QE/R[<9[X_'FO2_$-JWBCXEZ#X4
MU@B>PM=+;5+RW4D1W$N[RUW =0&R0/>@#TN.6.:-9(G5T89#*<@_C3J\UTNR
MM_!OQ=CT728_L^D:SISW!M$)\N.XC;EE'097@@5Z50 53MO^0E??5/\ T&KE
M9\4RQ:E>A@QSLZ*3_#0!H45!]KC_ +LG_?LT?:X_[LG_ '[- $]%0?:X_P"[
M)_W[-'VN/^[)_P!^S0!/14'VN/\ NR?]^S1]KC_NR?\ ?LT 3T5!]KC_ +LG
M_?LT?:X_[LG_ '[- $]%0?:X_P"[)_W[-'VN/^[)_P!^S0!/14'VN/\ NR?]
M^S1]KC_NR?\ ?LT 3U!!_KKC_?\ Z"C[7'_=D_[]FH8;E%EF)#\OGA#Z"@"[
M14'VN/\ NR?]^S1]KC_NR?\ ?LT 3T5!]KC_ +LG_?LT?:X_[LG_ '[- $]%
M0?:X_P"[)_W[-'VN/^[)_P!^S0!/14'VN/\ NR?]^S1]KC_NR?\ ?LT 3T5!
M]KC_ +LG_?LT?:X_[LG_ '[- $]%0?:X_P"[)_W[-'VN/^[)_P!^S0!/4$'^
MNN/]_P#H*/M<?]V3_OV:AAN4668D/R^>$/H* +M%0?:X_P"[)_W[-'VN/^[)
M_P!^S0!/14'VN/\ NR?]^S1]KC_NR?\ ?LT 3T5!]KC_ +LG_?LT?:X_[LG_
M '[- $]%0?:X_P"[)_W[-'VN/^[)_P!^S0!/14'VN/\ NR?]^S1]KC_NR?\
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M*T_X](O]T4UKN,J?EDZ?W#4=M<HMM&I63(4=$- %RBH/M<?]V3_OV:/M<?\
M=D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[
M]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@">BH/M<?]V3_OV:/M<?\ =D_[]F@"
M>BH/M<?]V3_OV:/M<?\ =D_[]F@"63_5O]#3+7_CUB_W!_*HWNHS&PVR=#_
M:;;W2+;QJ5DR% X0T 6Z*@^UQ_W9/^_9I5N4=@H#Y/JA% $U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0JCH , 4M !5.V_Y"5]]4_\ 0:N53MO^0E??5/\ T&@"Y1110 4444 %%%%
M!1110 4444 %%%% !4$'^NN/]_\ H*GJ"#_77'^__04 3T444 %%%% !1110
M 4444 %%%% !1110 5!!_KKC_?\ Z"JFIP:Q+)&=,O;6W0#YQ/ 9"3[888KG
MM,E\47M]J<":EIR&UN!$S&T8[CL!R/GXZT =G12+N" ,06QR0.]+0 4444 %
M%%% !1110 4444 %%%% !4%I_J6_WV_G4]06G^I;_?;^= $]%%% !1110 44
M44 %%%% !1110 4444 %06G^I;_?;^=3U!:?ZEO]]OYT 3T444 %%%% !111
M0 4444 %%%% !1110 C?</TJ*T_X](O]T5*WW#]*BM/^/2+_ '10!-1110 4
M444 %%%% !1110 4444 %%%% &'K6@6E\)[R6:\241' BNG1>!QP#BLWPCH5
ML^C:5JCW%\]RT*2'==R%22/[N<8]JZ>]_P"/"Y_ZY-_(UE^#_P#D3M(_Z]4_
ME0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%I_J6_WV_G53^T;T?>TBX_"1#_6H;;4YDC(.EWA^=N5"GO\ [U'UFGY_<_\
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MC-MO<****8@HHHH *@M/]2W^^W\ZGJ"T_P!2W^^W\Z )Z*** "BBB@ HHHH
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MYVCM7SE3(JTL0VI+E;O>^O\ PY[$<TIJE9KWK;=#IJ***^J/""BBB@ HHHH
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M !H\^3_GVD_,?XT 3T5!Y\G_ #[2?F/\://D_P"?:3\Q_C0!/4$'^NN/]_\
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M(4KN ]L5W-% ',>"?#=YH%EJ$^ISPRZGJEZ][=?9P1$C-@!$SR0 !R>373@
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M*H  X ':EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KEH/"!T_Q]+XCTRZ6WM[V#R]1LMGRSN/N2CGAAWXYY[DUU-%
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MU'FY<V=N?^6,3?.P_P!INWT%7[:U@LXA%;Q+&GHHZ_7UJ:BKA1C!\V[[O?\
MX'HK$RJ.2MLNW]?J%%%%;&84444 %%%% &;J<^L121C3+*UN$(^<SSF,@^V%
M.:Y[3(O%%E?:G.FFZ<YNK@2LINV&T[ ,#Y.>E=G4$'^NN/\ ?_H* )EW% 6
M#8Y />EHHH **** "BBB@ HHHH **** "BBB@ J"T_U+?[[?SJ>H+3_4M_OM
M_.@">BBB@ HHHH **** "BBB@ HHHH **** "H+3_4M_OM_.IZ@M/]2W^^W\
MZ )Z*** "BBB@ HHHH **** "BBB@ HHHH 1ON'Z5%:?\>D7^Z*E;[A^E16G
M_'I%_NB@":BBB@ HHHH **** "BBB@ HHHH **** ,76)==W30V%A9RV[1D>
M9+<%&R1SP%/\ZH>&X_$-AI^G6$]C8_98HU1IEN6+;0.NW;U_&NGD_P!6_P!#
M3+7_ (]8O]P?RH EHHHH **** "BBB@ HHHH **** "BBB@ HKS/3[.7XDZ]
MKEUJ=_>Q:%IUZ^G6MA:W#0K*T>-\DC(06R3P,\"C[-<_#WQQH=I9:A>7'A_6
MI'M7M+N<R_9I@N4:-FR0#T(S^?& #TRBO.;J&?QU\0=7T:YOKNWT+0XX5DM[
M68Q&ZGD4MEF7!VJ.-N>O-=#X>\'1>&=2FDT[4]0.G2Q;?[/N9S-'&^00Z,Q+
M+QD$9.<^U '2T5Y=X?T@?$LZCKVNWE\VGF[EM].L+>Z>&*.*,[=YV$%G)!/)
M_P#K;UUH<WA?P#XE@BUB_NX19W$EK]JDWR6X\H_*'ZD C(STH [.BN?\"2R3
M?#_P[+*[22/IMNS.YR6)C7DGO6-\.+B>XNO&0FFDD$?B*Y1-[$[5 3 &>@]J
M .YHKR#P3X=NO%\.L/KNKWLNDV^K744%A!</$'/F$EI'4AF R %! &/>MKP^
M+KPE\2G\*"^NKO1[^P-[9+=2F5[>16VN@8\E2.?;\R0#T6BN'U[PEX>GOI]0
M\4:]>,DSDPQ7&IM;0P =D567IZG)JE\--2_XGGBGP_;ZPVK:9IDMO)8W+SB<
MA)4+%-X)W!2I'YT >BT5Y/IND:CXG^(?C&RN=:O+?1+:[A+VUM,T<DK&(87>
M#E4&#D+C)/M6CI=J_@SXGV>@V-Y=R:+JUC+*EK<SM-Y$T9&2C,20"IZ9Z_A0
M!Z/17G-U#/XZ^(.KZ-<WUW;Z%H<<*R6]K,8C=3R*6RS+@[5'&W/7FMS2/ ]O
MH<]Y%9:IJ1TNZMVA:PFN&E6-C_'&[$LIQD8SSG/:@#JJ*X;X7:A=OX>NM#U*
M9I=2T.[DL9G<Y:10<QOSV*D ?2F^ )Y]>UCQ)XHDGD:SN[S[)IZ%R4$$/R[U
M'3YFR?PH [NBL3QA<:G:>#M7N-&1GU&.U=K<*NX[L=0.Y'4#UKCO!GA[PKK=
MEI^LZ3KNISZG%Y<MS<#4Y&E9Q@LDL;$@ G((VC@\>M '9:OXC@TC7-$TN6"1
MY-6EDBC=2,(43<2:VJ\E\?\ A/3;KXC>$Y)'O0VI7<ZS[;R10-L/&S#?)T_A
MQ70^+-)@\,?"GQ#;Z9-=H%M99%DEN7D<,1V9B2.E '<T5G>'W:3PWI;NQ9VL
MXBS,<DG8.37(?#C4GC\):[>WDTLJVVJWS$NQ8A%;.!F@#T"N-\/ZI?7/Q/\
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M)/05N^'(IO"WQ.NO"L-[=7&CW6F#4+:.ZF:5K=UD\MD5FR=I'/)H ]$HHHH
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MC_?_ *"@">BBB@ HHHH **** "BBB@ HHHH **** "H+3_4M_OM_.IZ@M/\
M4M_OM_.@">BBB@ HHHH **** "BBB@ HHHH **** "H+3_4M_OM_.IZ@M/\
M4M_OM_.@">BBB@ HHHH **** "BBB@ HHHH **** $;[A^E16G_'I%_NBI6^
MX?I45I_QZ1?[HH FHHHH **** "BBB@ HHHH **** "BBB@!LG^K?Z&F6O\
MQZQ?[@_E3Y/]6_T-,M?^/6+_ '!_*@"6BBB@ HHHH **** "BBB@ HHHH **
M** /*]#URS^&VO:]HOB1GLK"]U&2_P!.OFC8PR+)@F/< <,I]?\ #-B34H?B
M+XXT&315EFT/1)7N[B_:-ECEFVX2./.-Q&22<8KTME5U*LH93U!&0:4  8'
MH \PDU6#X??$O7;O6@\&B:^L$T%\(V:.*:-2K1N0#@GJ/_UUU>@^-])\3ZK-
M::+]HN[>&(O)?K$5MPV0!&&.-S8)/'&!UKHV4,I5@"#P0>]"JJ*%50JCH ,
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MJAFZD#DT <'\-?\ D(>-_P#L8[C_ -!2BX_Y+U9?]B[)_P"CQ7?8 HP,Y[T
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M_P"@I4Z7*^>;O+O^B[+\7U"=2ZY8Z+^M_P"O0GHHHK8S"BBB@ HHHH ****
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MQ?"'AV7442&:X62)5@DDVE@T@4GUX!)_"M>35M/:)U35+1'*D*WG*=I]<9H
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MHR,"#^(H ?117FCR^*O$7Q'\3Z3I_BJ32++2DM/*CCL89MWFQECDN,]1Z]Z
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MBS1_$Z7']FW#F:V8+<6\T312Q$\C<C $?7I6U7GE_P#Z%\>-(>#Y3?Z/-%<
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MO^>4?_?9_P *-]U_SRC_ .^S_A0!/14&^Z_YY1_]]G_"C?=?\\H_^^S_ (4
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M[:C-YTJHK3O\D2\GJH);\: -;X=:YJ.J:/>V&MSB;6M)O)+.[D"A?,P<HX
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M/R!0V1S\V$';TKU:O-/BW=:;I4WA;6=6,<EG8ZB7DM6&3*"N-RCH2APV#[T
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M=CLOZOZA1116QF%%%% !1110 5!!_KKC_?\ Z"IZ@@_UUQ_O_P!!0!/1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,^-?$%MH&G6V[2_[
M5U"[G%O8V0 S+(1ZD$* !DGM735QWCW1]6N6T?7="@CNM2T6Y:=;21]HN(V4
MHZ!CP&P>": .6L_%.O?V9XAENO!FE3:AHUS$LME:XSY3)O8[CG+ 8Z#\#7I&
M@:I9:WH%CJ>G+ML[F%9(EVA=H/8@="#D'Z5Y#I?B/Q='K/BA].\!ZPE]K4T;
M0-=Q^7# 1$$)=R,'!&>.M>J>#M!/ACPAI>BM()'M( CNO0N>6Q[9)H W****
M "BBB@ J*ZNH+*TFN[F58K>!&DDD8X"*!DD^P J6H+RSMM0LIK.[A2:VF0I)
M&XR'4]0: .%_X6K MBNKR>&M<CT!B,:FT*[=I.!(4W;]GOCI6]X@\9V&A0Z<
M(H;C4KS4SBQM+(!WG&-Q89( 4 @DD]ZYKQKJRZA:O\._"L"3ZA<0"WN"@_<Z
M=;$;27/8[> O7] 8K/38].^-.B:8&+V^G>%=EL7Z[A+L)^NT"@#JO#GC"VU^
M]N].EL;S3-5LPK3V5XH#A6Z.I!(9>V0:Z.O/=4_=?'C0'BX:;1[B.;'= VY<
M_C7H5 !5.V_Y"5]]4_\ 0:N5GQ1L^I7NV5D^YTQ_=H T*Y/Q/KUQ;7/V&T<Q
ME0#(XZ\\@#TXKI?(D_Y^9/R'^%<1XDL7?5)YK?S+@*J^<P7.QL8P<>P%>5G-
M2K##?NG9M]-[?UOY'?ET(2K>_P!C-L]5O+%'BAG=(I"2ZJ>Y.21Z$^M>D6$=
MO'8PBU7;"4#)[@\Y/O7FECI]SJ,ZQ6\;,2>6QPON37I$%DUO;Q0K<R;8T"#@
M= ,>E<.0NK/FE.[71O\ &U_Q.G-?9QY8QT?6Q;HJ#R)/^?F3\A_A1Y$G_/S)
M^0_PKZ,\<GHJ#R)/^?F3\A_A1Y$G_/S)^0_PH GHJ#R)/^?F3\A_A1Y$G_/S
M)^0_PH GHJ#R)/\ GYD_(?X4>1)_S\R?D/\ "@">H(/]=<?[_P#04>1)_P _
M,GY#_"H887,LP$[C#]0!SP/:@"[14'D2?\_,GY#_  H\B3_GYD_(?X4 3T5!
MY$G_ #\R?D/\*/(D_P"?F3\A_A0!/14'D2?\_,GY#_"CR)/^?F3\A_A0!/14
M'D2?\_,GY#_"CR)/^?F3\A_A0!/14'D2?\_,GY#_  H\B3_GYD_(?X4 3T5!
MY$G_ #\R?D/\*/(D_P"?F3\A_A0!/4$'^NN/]_\ H*/(D_Y^9/R'^%0PPN99
M@)W&'Z@#G@>U %VBH/(D_P"?F3\A_A1Y$G_/S)^0_P * )Z*@\B3_GYD_(?X
M4>1)_P _,GY#_"@">BH/(D_Y^9/R'^%'D2?\_,GY#_"@">BH/(D_Y^9/R'^%
M'D2?\_,GY#_"@">BH/(D_P"?F3\A_A1Y$G_/S)^0_P * )Z*@\B3_GYD_(?X
M4>1)_P _,GY#_"@">H+3_4M_OM_.CR)/^?F3\A_A4-M"[1$B=U^=N !Z_2@"
M[14'D2?\_,GY#_"CR)/^?F3\A_A0!/14'D2?\_,GY#_"CR)/^?F3\A_A0!/1
M4'D2?\_,GY#_  H\B3_GYD_(?X4 3T5!Y$G_ #\R?D/\*/(D_P"?F3\A_A0!
M/14'D2?\_,GY#_"CR)/^?F3\A_A0!/14'D2?\_,GY#_"CR)/^?F3\A_A0!/4
M%I_J6_WV_G1Y$G_/S)^0_P *AMH7:(D3NOSMP /7Z4 7:*@\B3_GYD_(?X4>
M1)_S\R?D/\* )Z*@\B3_ )^9/R'^%'D2?\_,GY#_  H GHJ#R)/^?F3\A_A1
MY$G_ #\R?D/\* )Z*@\B3_GYD_(?X4>1)_S\R?D/\* )Z*@\B3_GYD_(?X4>
M1)_S\R?D/\* )Z*@\B3_ )^9/R'^%'D2?\_,GY#_  H F;[A^E16G_'I%_NB
MFM!)M/\ I,G3T'^%1VT+M;1D7$B@J. !Q^E %RBH/(D_Y^9/R'^%'D2?\_,G
MY#_"@">BH/(D_P"?F3\A_A1Y$G_/S)^0_P * )Z*@\B3_GYD_(?X4>1)_P _
M,GY#_"@">BH/(D_Y^9/R'^%'D2?\_,GY#_"@">BH/(D_Y^9/R'^%'D2?\_,G
MY#_"@">BH/(D_P"?F3\A_A1Y$G_/S)^0_P * )9/]6_T-,M?^/6+_<'\JC>"
M01M_I,AX/8?X4VWA<V\9%Q( 5'  X_2@"W14'D2?\_,GY#_"E6%U8$SNP'8@
M<_I0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7#_$2^U<RZ#H&D7[:;+K-VT,M\JY:)%0L0OHQQQ]*[
MBN'^)!T>[CT/1-4AN_-U*_6.RNK1PCVDP'RRAB1R,].^3P: -+Q3H-_J/AF*
M#3]>OM.OK$":*ZC<#S75",2_WE.<D?CVJ;P/KD_B3P3I.L7482XN8 TH P"P
M)!('H2,_C7+2_#/7]00V>K?$/5[K2G&V2V2%8GD3NK2 DD'OQ7H-A8VVF:?;
MV-G"L-M;QK'%&O15 P!0!8HHHH **** "L[7XM5GT&]AT26"'4Y(BEO+.2$1
MCQN. 3QU'!YQ6C10!Y/X8\+?$KPEI?V+3HO!;%V,D]Q,]TTL[GJ[MCDUT6N>
M&M?O+K0O$>GSZ=%XET^ Q7,;[_LUPK@;TS]X -DJ<?6NVHH XSP[X:UEO%=S
MXJ\32V?]H-;"SM;6R+-%;Q;MQ^9@"S$]\?\ UNSHHH *IVW_ "$K[ZI_Z#5R
MJ=M_R$K[ZI_Z#0 FIW;VUNJ0 -<S-Y<*GU/<^P'-26-FEC:K"A+'[SN>KL>I
M-5+3_3=7N+L\QV_^CP_7JY_/ _"M2N:E^\FZK]%Z=7\W^"1M4]R*@O5_UY?F
MSG_!O_(&G_Z_KG_T:U=!7/\ @W_D#3_]?US_ .C6KH*Z3$**** "BBB@ HHH
MH **** "H(/]=<?[_P#05/4$'^NN/]_^@H GHHHH **** "BBB@ HHHH ***
M* "BBB@ J"#_ %UQ_O\ ]!4]00?ZZX_W_P"@H GHHHH **** "BBB@ HHHH
M**** "BBB@ J"T_U+?[[?SJ>H+3_ %+?[[?SH GHHHH **** "BBB@ HHHH
M**** "BBB@ J"T_U+?[[?SJ>H+3_ %+?[[?SH GHHHH **** "BBB@ HHHH
M**** "BBB@!&^X?I45I_QZ1?[HJ5ON'Z5%:?\>D7^Z* )J*** "BBB@ HHHH
M **** "BBB@ HHHH ;)_JW^AIEK_ ,>L7^X/Y4^3_5O]#3+7_CUB_P!P?RH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 A(4$D@ <DFO(;WXB:YXETZ^NM+\ KK'A2,NDDMS.
MH-RBGYF6,]1P>@;IZ\5ZGJY(T6^(ZBWD_P#037F?PO\ '/A32OAMHMC?Z_I]
MM<Q1.)(99@&4EV/(_&@#0\)> /AQJ^FV'B72O#T)2Y02QB:220(0<$%&8KD$
M$=,9%>D 8&!TKQ[X1^-_#&C_  YL+#4=>L;6XBEG_<RS!653*Q''XY_&O6;&
M^M=2LHKRRGCN+:9=T<L9RK#U!H L4444 %%%% !1110 4444 %%%% !6!=?/
MK\,7K<H__?,;&M^L%AN\71C^Z&?_ ,< _K7/B?X=N[7YHUH_%?R?Y,WJ***Z
M#(**** "BBB@ HHHH **** "BBB@ J"#_77'^_\ T%3U!!_KKC_?_H* )Z**
M* "BBB@ HHHH **** "BBB@ HHHH *@@_P!=<?[_ /05/4$'^NN/]_\ H* )
MZ*** "BBB@ HHHH **** "BBB@ HHHH *@M/]2W^^W\ZGJ"T_P!2W^^W\Z )
MZ*** "BBB@ HHHH **** "BBB@ HHHH *@M/]2W^^W\ZGJ"T_P!2W^^W\Z )
MZ*** "BBB@ HHHH **** "BBB@ HHHH 1ON'Z5%:?\>D7^Z*E;[A^E16G_'I
M%_NB@":BBB@ HHHH **** "BBB@ HHHH **** &R?ZM_H:9:_P#'K%_N#^5/
MD_U;_0TRU_X]8O\ <'\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &NBR1LCJ&1@0RD9!![5S_
M /P@/@[_ *%71?\ P B_^)KHJ* .=_X0'P=_T*NB_P#@!%_\36Y:6=M86D=I
M9V\5O;Q#;'%$@54'H .!4U% !1110 4444 %%%% !7'>+/$FJV^OZ7X8\/);
M?VK?H\[SW2EH[:!.K%1@DD\#GKUKL:\^N@(?V@+&67A;CPZ\,.>[K/N('OM-
M %[P]XBUF'Q;<>%/$HLY+T6HO+2\M$9$N(L[6!4DX<'T/3]>SKSS5/W_ ,>=
M!2+E[?1YY9L=D9MHS^->AT 8GB'73I,21PJK7$@R-W11ZUR=MX@O(=3^W2[)
MG*[6! '''3'3H*U_&=C*TT-\JEHPGEN1_#R2,_G7)HC2.$12S,<  9)-?'YK
MB\5'%N*;25K+]?,^AP.'H2H*32;>YZM:7,=Y:17,1^21=PSV]JFK'TO1OL^F
M0132SK(%RRI*0 2<XX^M6_[-C_Y[W7_?YJ^LHRE*G%S5FTK^IX-114VH[7+M
M%4O[-C_Y[W7_ '^:C^S8_P#GO=?]_FK0@NT52_LV/_GO=?\ ?YJ/[-C_ .>]
MU_W^:@"[15+^S8_^>]U_W^:C^S8_^>]U_P!_FH NT52_LV/_ )[W7_?YJ/[-
MC_Y[W7_?YJ +M%4O[-C_ .>]U_W^:C^S8_\ GO=?]_FH NU!!_KKC_?_ *"H
M?[-C_P">]U_W^:@:7$"2)KD9Z_OCS0!=HJE_9L?_ #WNO^_S4?V;'_SWNO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6]C:2W5W-'!;PJ7DED8*J*.I)/05B6_CSPE=W,5M;^)-+EGF<1QQI=(6=B<
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MG2#5M8L;&61=Z)<3JA9<XR 3TS0!K45G:3KVD:]'))I.I6M\D1"NUO*'"D]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH X/XP7<]O\/+JWMY&C>^GALR
MZG!"NX#?F,C\:S?BGHNG^'OAY%JNDV4%K=:#/;S6;Q(%*XD5"N1U!#<CO72_
M$3P_=>)O!-]I]AC[<-D]L"0 TD;!@O/KC'XUR'B75=1^(VBVOA6V\.:Q8RW<
M\)U.6\M6BBMHT8.V'/#$E1C'6@#U=&#HK#H1FEHZ44 %%%% !1110 4444 %
M%%% !1110!PWQ?DNO^%:ZE;6=O<3SW310!((R[89QNX'^R#^=8MIK6E:)JFF
M0ZY\.TT*VN)DALM0=(),2?P;RG,;''<]?Q([/QG<>(K/0#=^&8(KF^@E21[:
M09,T0^\J^C=_P]:XKQ)J-Y\2K33] TWP_K-E&UW%/?76HVA@6VC0Y(!/WG/&
M * /5:*** "BBB@ HHHH **** "BBB@ J.<2M;RK ZI,4(1F&0&QP2/K4E%
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M8_\ ELJG.QO]DG'Y5N5R?Q$UW6=!\*R2^'],N[_4YW$,(MK9IO)R"3(5 /
MXSQDB@#F?']OIMUXB\+>'M!M($UZ"_BN@UM&%-G;)]\L1T4C "]_RJWI=O#K
MOQM\2S7\23C1;.UMK19%#+'YJF1F /?MGTK*\&:Y8>&T,4?@SQO/J5[(#>ZG
M=Z2=\SD_>9MW"C/3L/4\UKZD;OP;\1[_ ,0G3+Z^TC6+2*.X>Q@,SV\T60I9
M!SM*]_6@ \*1QZ+\6?%>B6<:Q6$]O!J"0(,+'(1M<J!TW'D_2O1:X+P397^I
M>+/$'C"_L+BPBOUBMK&VN4V2B&,<NZ]MQY ]J[V@ HHHH **** "BBB@ HHH
MH *P_%?AJ#Q9HZZ7=7$T-J9XY9EC_P"6RJ<[&_V2<?E6Y7)_$37=9T'PK)+X
M?TR[O]3G<0PBVMFF\G(),A4 \ #C/&2* .9\?V^FW7B+PMX>T&T@37H+^*Z#
M6T84V=LGWRQ'12, +W_*J6LF]NOB]K$Z^#)O$"VNGP6L"RB-(%!)D9M\ORYR
M<#&3U]*?X,URP\-H8H_!GC>?4KV0&]U.[TD[YG)^\S;N%&>G8>IYKHK_ ,5Z
M[X;\67T&KZ/?7VA3JC:?=:9:-,T9Q\R2A><YZ''_ -8 N^!-<T;5[>_AT_1E
MT:^LYA%?V!A2-XWQP3MX8$9P?8UUM<'X%TW4;CQ+XD\6ZA83:<-8>%+:SG&)
M5BB3:&<=F;T/(Q7>4 %%%% !1110 4444 %%%% !6)XF\+V/BRRMK+49)_LL
M-S'<M#$P"S%.B/D'*'N..U;=<YXRO?$&FZ=:W^@6@O?(N4:\M%4&2:W_ (A'
M_M=,"@#A1?:=JWQCT!=/TV30FTZ.X626[@%L;]"NU8XE_P"6@!Y]ATK4\!V=
MMKOBCQOK6H6\5S<#5I--C,R!]D,( "@'H#GGUJKJ]Y=?$37/#4&FZ%JME;:9
MJ,>H75]J%J;?RPF?W2YY9B>#C@8'X3VMW=?#[Q5XB6ZT;5+W2M6NO[0M;C3[
M4SXE90)(W"_=.0,9ZT 6?AA_Q+[[Q;X?B&++3=6;[*G:*.0;M@]@<_G7H=<3
M\.-(U"UM=8UK5K5K2]UN_>\^S/\ >ABZ(K?[6,D_6NVH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\34=-M;V-65+B%)55NH# '!_.K- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SG@WPK_PB5CJ-M]M^
MU_;-0FO=WE>7LWX^7&3G&.OZ5T=% '.>"O"O_"'Z')IOVW[7ONI;CS/*\O&\
MYQC)Z>N:Y#4O"VA>"_@]_8/B.XNK[38YOGO+6#8\+/(663&X[=I(&<GZ<XKU
M*F2PQ7$+PS1I)$XVLCJ"K#T(/6@#Y^^(%FU]X2BTYOB"WB>\N)8H]+L+58@7
M8L/GD\LEGPH89/&2.]>Q:'X:?2_$6L:Q/<K/)?K!%$H7'DQ1)@+GODDD_6K>
MF^%?#^CW!N-,T/3K.<Y_>06R(WY@9K7H YS3O"@L/'&M^)#>>8-4AAB^S>5C
MR_+7&=V?FS]!7/'PAI_@SP]XJ%U-->^%KM7G.E16^7M@?O[&W<COC QM!SD<
M^B4A (((R#U!H \"UU-/C^&\\,?Q+EU'2&M"NGZ2JPBX=R/W4;LOSL%8KE<#
M '/%>P^"K"?2_ VA6-RACN(+"%)4;JK!!D'Z'BI+;PCX;LK_ .W6N@:9#=[M
MWG1VB*X/J"!P:V: .5\5^#!XAO;#5K#4I=*UO3RWV:]BC$GRM]Y'0_>4\\9[
MGU-5-,\#7LGB*UU_Q1KAUF]LD9;.-+800VY;JP4$[F/J?Z#':T4 <YIOA7^S
M_'.M>)?MOF?VG##%]G\K'E^6N,[L\Y^@Q3/''A%O&FD6VE/J!M+,74<UT@BW
MF=%.?+SN&W)P<\]!Q7344 (JA%"J % P !P!7"2_#?\ XF?BZ>UU;R+3Q):-
M#+:_9MPBE*[?-#;AGJQ(P,[NO%=Y10!F>'=(_L#PWIND>?Y_V*V2#S=FW?M4
M#.,G&<=,FN1T3X66_AOQIK7B'1M1%LNH6DD$5J;;<MN[LK;P=PR RYVX'7&>
M*]!HH YWP1X3A\%^&(-'CN3=2*[RS7+)L,SL<EB,G'&!U/2J_BOP9_PD6L:#
MJ]MJ'V"_TBY\U)?)\P2(<;HR-R\' YSZ\<UU5% '%?$#X>IXY2Q:/4WTVYM?
M,C::.+>9(9%VO&1D=>.><<\<UV%K;0V5I#:6Z".""-8XT'1548 _(5+10!Y=
MIOPQ\5:$+N+1?B"UC:W-S)<F$:1')AFZ\LY/0 ?A70:%X:\8:=J\5SJOCMM5
MLU#![0Z7%"')! .Y6R,'!]\5V-% ')^%O!/]A:SJNN:CJ']J:SJ+_/=&'RQ'
M$,8C1=S848]><#TIOB+P/_:OBG2O$NF:C_9FK6)V22B#S5N8>\;KN7WYSW^F
M.NHH \PE^&/B1/%VJ^(M.\=?8[K4'.2=)CE,<8/RQAF<\ 8'&,X&:ZCPQH7B
M72;J>37/%S:W$Z!8XCI\=OY;9^]E2<\<8KIZ* "N9M/"(M_B'?\ BU[[S6N;
M)+..W\K'E*""3NSSDKGH*Z:B@#%\5>&;'Q=H$^D7YD6.0ADEC.'B<'*LI]17
M*7'P\\0:Y!!IWBCQB^HZ-$ZL]M#9+ ]SM.0)'#$XR.<=>O7FO1:* &HB11K'
M&H5% 55 P !VIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R=4T7^T]7T>\
M>XVPZ;,\_D;,^9(8V13G/&T,QZ'KVID^@+/XL@USS\!+"6QD@V9\Q6=6!W9X
MQM/;^+M6S10!R.C>&?$.AV5MI5KXBMCI5KA(?,T_-P(@>$+^9M.!QNV?A5+Q
MCIJ^*?%>BZ-!-(C6@DN=0>/^&VD4QF,GL9.0.^%8]A7=T4 87B#PZ=6MM/\
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M\DDDG ]*WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaOLecPtxJFz+Zkhv2p3fdkqLyoqT7qfxSco1BZWsf0J -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:avxl="http://anavex.com/20211231" elementFormDefault="qualified" targetNamespace="http://anavex.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Description of Business and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000010 - Disclosure - Accrued liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
	  <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000014 - Disclosure - Accrued liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" id="DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
	  <link:definition>00000018 - Disclosure - Accrued liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="avxl_ParkinsonMember" name="ParkinsonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesValue" name="CommitmentSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" name="SharesIssuedPursuantToExerciseOfStockOptionsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalSiteCostsAndPatientVisits" name="ClinicalSiteCostsAndPatientVisits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromSaleOfCommonStock" name="GrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20211231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20211231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20211231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20211231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20211231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER&apos;S EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20211231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20211231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20211231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20211231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20211231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER&apos;S EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ParkinsonMember" xlink:label="avxl_ParkinsonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ParkinsonMember" xlink:to="avxl_ParkinsonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ParkinsonMember_lbl" xml:lang="en-US">Parkinson [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">(September 30, 2021 - 75,918,465)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued under 2019 purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares ,shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesValue" xlink:label="avxl_CommitmentSharesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesValue" xlink:to="avxl_CommitmentSharesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesValue_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options ,shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) increase in cash and cash equivalents during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share-based Payment Arrangement, Option, Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalSiteCostsAndPatientVisits" xlink:to="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalSiteCostsAndPatientVisits_lbl" xml:lang="en-US">Clinical site costs and patient visits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">&#160;Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Share issued for aggregate, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromSaleOfCommonStock" xlink:to="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceed from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Additional common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl" xml:lang="en-US">Share Purchase Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_lbl" xml:lang="en-US">Share Purchase Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Remaining stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20211231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20211231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20211231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20211231.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20211231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20211231.xsd#DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20211231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20211231.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20211231.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20211231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER&apos;S EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Description of Business and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ParkinsonMember" xlink:label="loc_avxlParkinsonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlParkinsonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ClinicalSiteCostsAndPatientVisits" xlink:label="loc_avxlClinicalSiteCostsAndPatientVisits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlClinicalSiteCostsAndPatientVisits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20211231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903583363688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,174,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582182456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 151,146,355<span></span>
</td>
<td class="nump">$ 152,107,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">5,372,153<span></span>
</td>
<td class="nump">9,136,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">377,860<span></span>
</td>
<td class="nump">371,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">156,896,368<span></span>
</td>
<td class="nump">161,616,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,634,791<span></span>
</td>
<td class="nump">4,739,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities (Note 4)</a></td>
<td class="nump">5,450,040<span></span>
</td>
<td class="nump">5,614,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total liabilities</a></td>
<td class="nump">10,528,662<span></span>
</td>
<td class="nump">10,798,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">(September 30, 2021 - 75,918,465)</a></td>
<td class="nump">76,156<span></span>
</td>
<td class="nump">75,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">354,759,781<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(208,468,231)<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">146,367,706<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 156,896,368<span></span>
</td>
<td class="nump">$ 161,616,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903583345928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">76,155,187<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">76,155,187<span></span>
</td>
<td class="nump">75,918,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582258856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 3,066,951<span></span>
</td>
<td class="nump">$ 1,470,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,656,439<span></span>
</td>
<td class="nump">7,925,519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(11,723,390)<span></span>
</td>
<td class="num">(9,396,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">810,730<span></span>
</td>
<td class="nump">1,269,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">4,910<span></span>
</td>
<td class="num">(1,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain, net</a></td>
<td class="nump">55,363<span></span>
</td>
<td class="nump">332,634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">871,003<span></span>
</td>
<td class="nump">1,600,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(10,852,387)<span></span>
</td>
<td class="num">(7,795,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(29,980)<span></span>
</td>
<td class="num">(59,281)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (10,882,367)<span></span>
</td>
<td class="num">$ (7,855,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">75,997,738<span></span>
</td>
<td class="nump">64,295,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903584381032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">$ 186,851,752<span></span>
</td>
<td class="num">$ (159,677,230)<span></span>
</td>
<td class="nump">$ 27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued under 2019 purchase agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="nump">17,458,056<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,461,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares ,shares</a></td>
<td class="nump">3,346,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">56,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of share issuance costs</a></td>
<td class="nump">$ 1,515<span></span>
</td>
<td class="nump">8,517,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,518,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="nump">1,514,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">939,314<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">939,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,855,065)<span></span>
</td>
<td class="num">(7,855,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 66,964<span></span>
</td>
<td class="nump">213,766,108<span></span>
</td>
<td class="num">(167,532,295)<span></span>
</td>
<td class="nump">46,300,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Dec. 31, 2020</a></td>
<td class="nump">66,962,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">348,328,048<span></span>
</td>
<td class="num">(197,585,864)<span></span>
</td>
<td class="nump">150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">373,360<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">373,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options ,shares</a></td>
<td class="nump">137,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of share issuance costs</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">2,149,602<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,149,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="nump">99,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,908,771<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,908,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,882,367)<span></span>
</td>
<td class="num">(10,882,367)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 76,156<span></span>
</td>
<td class="nump">$ 354,759,781<span></span>
</td>
<td class="num">$ (208,468,231)<span></span>
</td>
<td class="nump">$ 146,367,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Dec. 31, 2021</a></td>
<td class="nump">76,155,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903584461848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,882,367)<span></span>
</td>
<td class="num">$ (7,855,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,908,771<span></span>
</td>
<td class="nump">939,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">3,764,678<span></span>
</td>
<td class="num">(1,728,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(22,311)<span></span>
</td>
<td class="nump">44,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(104,992)<span></span>
</td>
<td class="nump">227,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(164,734)<span></span>
</td>
<td class="nump">499,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,500,955)<span></span>
</td>
<td class="num">(7,871,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows provided by financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">2,312,785<span></span>
</td>
<td class="nump">26,243,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(146,717)<span></span>
</td>
<td class="num">(263,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">373,497<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,539,565<span></span>
</td>
<td class="nump">25,979,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents during the period</a></td>
<td class="num">(961,390)<span></span>
</td>
<td class="nump">18,108,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">152,107,745<span></span>
</td>
<td class="nump">29,249,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">151,146,355<span></span>
</td>
<td class="nump">47,357,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903581385224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zG4NB93uNQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1&#160;&#160;&#160;&#160;&#160;&#160; 	<span style="text-decoration: underline"><span id="xdx_827_zzJEo3RgaLhh">Description of Business and Basis of Presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Description of
Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221;
or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics
by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed
to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; text-indent: 2pt">Basis of Presentation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These accompanying unaudited interim condensed
consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management
are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2021 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes
thereto included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2021 filed with the SEC on November
24, 2021. The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Operating results for the three months
ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Liquidity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company&#8217;s potential drug
compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful
or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience
negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>






















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current working
capital position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date
that these interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing
and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated
and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors
including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and
development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending
levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to the Sales
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Coronavirus Disease 2019 (COVID-19)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The recent global outbreak of COVID-19
has not had a material impact on the Company&#8217;s result of operations or financial condition as of December 31, 2021. However, the
pandemic continues to rapidly evolve as of the date these consolidated financial statements are issued and has created a dynamic and uncertain
situation in the global economy. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s
financial condition and future results of operations. Management is actively monitoring the global situation on its business, including
on its clinical trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses
to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations or financial
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Use
of Estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial
statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting
period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and
loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other
factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other
sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To
the extent there are material differences between the estimates and the actual results, future results of operations will be
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>






















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Principles of Consolidation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited. (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Fair
Value Measurements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value hierarchy under GAAP is
based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure
fair value which are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 1 - 	quoted
prices (unadjusted) in active markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 2 - observable
inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value
drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">Level 3 - 	assets
and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair
value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of cash and cash equivalents
and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At December 31, 2021 and September 30,
2021, the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common share is
computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during
the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum
of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of
options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes
of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation
of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of December 31, 2021, loss per share
excludes <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_pdd" title="Loss per share for potentially dilutive common shares">11,403,769</span> (September 30, 2021 &#8211; <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zWR0O7F3Y0k6" title="Loss per share for potentially dilutive common shares">11,540,903</span>) potentially dilutive common shares related to outstanding options and warrants,
as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>


















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582098664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_807_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zLlEni6ponre" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&#160;&#160;&#160;&#160;&#160;&#160;	<span style="text-decoration: underline"><span id="xdx_82D_zYSEBSrYZt01">Recent Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUO8BYw2NYma" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span id="xdx_863_zD5cBxvCJu8h">Recently Adopted
Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">Effective October
1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations, financial
condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903581431384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_804_ecustom--OtherIncomeDisclosureTextBlock_zluVmor3G4sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 3	&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_828_zaV3cL0MM5V5">Other Income</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Grant Income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the year
ended September 30, 2021, the Company received $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_z1AsLRT9ojul" title="Research and development incentive income">497,931</span> of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s
Research. The grant will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to
Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">The grant income
is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2021 and 2020, the Company did not recognize any of this grant on its statements of operations. At
December 31, 2021, an amount of $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_ztn8klf9Fue2" title="Grant income">443,831</span> (September 30, 2021: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_zM2aXTHpLf33" title="Grant income">443,831</span>) of this grant is recorded as deferred grant income, representing
the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of
operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research and development
incentive income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research and development
incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the &#8220;R&amp;D
Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the three
months ended December 31, 2021, the Company recorded research and development incentive income of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zxIM8dcfeFPh" title="Research and development incentive income">810,730</span> (AUD <span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20211231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">1,116,362</span>) (2020: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zetSwaPz1gl6" title="Research and development incentive income">1,269,316</span>
(AUD <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_zFB0I0xBKZJ5" title="Research and development incentive income">1,735,962</span>)) in respect of the R&amp;D Incentive Credit for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582088328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued liabilities</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zti2obruejZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 4	 &#160;&#160;&#160;&#160;	 <span style="text-decoration: underline"><span id="xdx_824_zVYsMgXVBcM7">Accrued liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consists of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zuDqTtFK1Pe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_zmtjbytSdBZh" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20211231_zompnbTVj6ec" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210930_z9MpFvF0PSd9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_407_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzxk9_zZoRKfFvKak2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,689,740</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,035,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzxk9_zk8vnRD0lay6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,205,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,201,903</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCzxk9_zpVFxt6N2Yv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">649,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzxk9_zGYcs2kVpfy" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,195,690</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,727,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzxk9_zgWCmW0IOPH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 2.5pt">&#160;Total accrued liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,450,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,614,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582129816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_800_ecustom--EquityOfferingTextBlock_zl0TxZ1GVku8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 5&#160;&#160;&#160;&#160;&#160;&#160;&#160;	<span style="text-decoration: underline"><span id="xdx_82F_zl20FE9SSJ0j">Equity Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common shares are voting and are entitled
to dividends as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Preferred Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company&#8217;s Board of Directors
(the &#8220;Board&#8221;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with
Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer
and sell shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Upon delivery of a placement notice based
on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares
by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,
subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.
The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has agreed to pay the Sales
Agents commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement.
The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended
December 31, 2021, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zk8q2lcWl834" title="Share issued for offering, shares">99,588</span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_907_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFaMQJiBgp7d" title="Gross proceeds from sale of common stock">2,312,785</span> (net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering">2,149,701</span> after
deducting offering expenses) (December 31, 2020: <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares">1,514,829</span> shares were sold for gross proceeds of $<span id="xdx_90B_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock">8,782,017</span> (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering">8,518,557</span>)).
At December 31, 2021, an amount of $<span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20211231_zUptSGynmtw7" title="Sales of agreement amount">161,079,765</span> (September 30, 2021: $<span id="xdx_903_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20210930_zFdVdAaChNf8" title="Sales of agreement amount">163,392,550</span>) was registered pursuant to an effective registration
statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>






















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Purchase Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 7, 2019, the Company entered into
a $<span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdbSU8YLjkL7" title="Total number of shares obligated to purchase">50,000,000</span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020, pursuant to
which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXVcp3FcTGi8" title="Proceeds from Issuance or Sale of Equity">50,000,000</span> in value
of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In consideration for entering into the
2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September
30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTkAiWogLmT9" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At December 31, 2021 and September 30,
2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the three months ended December 31, 2020, the
Company issued to Lincoln Park an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zhtwFvurfetj" title="Share issued for aggregate, shares">3,402,930</span> shares of common stock including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgRJbbanxDAd" title="Additional common shares">3,346,288</span> shares of common stock for an aggregate
purchase price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues1_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXzMRXpmVMs7" title="Number of shares issued for aggregate purchase price, value">17,461,402</span> and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zWVTLdRcoidk" title="Number of shares issued for commitment">56,642</span> commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903581479752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zYuJPyeLiJ4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6 &#160;&#160;&#160;&#160;&#160;&#160;	<span style="text-decoration: underline"><span id="xdx_82D_z4z315gt58wk">Commitments and Contingencies</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">a)</span></td><td><span style="font-size: 10pt; font-style: normal">Leases </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">During the
three months ended December 31, 2021, the Company incurred office lease expense of $<span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_pp0p0" title="Operating Leases, Rent Expense">4,845</span> (2020: $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Operating Leases, Rent Expense">68,387</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-size: 11pt">b)</span></td><td><span style="font-size: 10pt">Employee 401(k) Benefit Plan</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The Company
has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2021, the Company made $<span id="xdx_906_eus-gaap--PensionContributions_c20211001__20211231_pp0p0" title="Contribution amount">22,682</span> (2020: $<span id="xdx_904_eus-gaap--PensionContributions_c20201001__20201231_pp0p0" title="Contribution amount">16,556</span>) in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">c)</span></td><td><span style="font-size: 10pt; font-style: normal">Litigation</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and
there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any
such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not
believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"><span style="font-weight: normal">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"/>













<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font-size: 11pt; font-style: normal">d)</span></td><td><span style="font-size: 10pt; font-style: normal">Share Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">A summary of the status of the Company&#8217;s
outstanding share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zR8tbH2IjLJ2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zptmiuf4vbz6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; width: 40%; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zshCiUTvTg09" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning">500,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zffZoKhRxUwl" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">3.88</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmK5xj1o0nY4" style="text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zX3ZX4j3Gj39" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zcP3u5JeiUB4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIzF2WN4Xq0j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">4.19</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zjVAp4R6SIv8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning">210,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgxE64p4zeF" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">5.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCrj4gWNDxOj" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zItBURLrGIr4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, December 31, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_znYsGskHwVf4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zMbEm7RyKi56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zz9Jlv3q2xpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt">At December 31, 2021,
the Company had share purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z9VRBT14uQY9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B3_zMK5DP9P8Oyj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 44%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zhabp6Kbtqb8" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zVTvXlSl7sZf" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_8A3_zlPXKFpFjCu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 14.05pt"><span style="font-size: 11pt; font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock&#8211;based Compensation Plan</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On September 18, 2015, the Company&#8217;s
Board approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The maximum number of our common shares reserved
for issue under the plan was <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization. At
December 31, 2021, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">146,371</span> (September 30, 2021: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlDk8QefFfQ7" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant">146,371</span>) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>






















<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">On January 15, 2019, the Board approved the
2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to
directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zytI0TLx1wEg" title="Additional shares of common stock available for issuance">6,000,000</span> additional shares
of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding
under the 2015 Plan or the Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under
the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The 2019 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At December 31,
2021, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zJ9yDVMkuGZb" title="Remaining stock options">406,332</span> (September 30, 2021: <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zrTcr8iXNUif">456,332</span>) options remain available for issue under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">A summary of the status of Company&#8217;s
outstanding stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zjNc9x8Nj2I3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zNxMyvqlO6Ve" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Grant</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Date Fair</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2020</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z76JMhWmbfP5" style="width: 12%; text-align: right" title="Options Outstanding at beginning">10,076,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgbgc8rWrId" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjyL7CjeODZ5" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">14,982,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zg8kDm2nkKgc" style="text-align: right" title="Options Granted">2,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbHgCahb0H3f" style="text-align: right" title="Weighted Average Exercise Price Granted">12.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzhsFA8zlgd1" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">9.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zydkA4JIAeo7" style="text-align: right" title="Options Forfeited">(55,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFgaxSlKcDB9" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbYrcSCgB0E3" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMmqYd7ujKbe" style="border-bottom: Black 1pt solid; text-align: right">(1,421,529</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1sAZmZBOP83" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkvDLFAjsqed" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVNyTicjux19" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">24,446,305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9airy7jroe9" style="text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zs30VwwFlObh" style="text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zN2XW8aEfxB4" style="text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Options Granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z7RVt3mDlfWi" style="text-align: right" title="Weighted Average Exercise Price Granted">19.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">15.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znomZGu57e8h" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(137,134</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zobnKnvMNfTe" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">2,276,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbh6nwP4tra6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">11,243,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKhbYnfHQZO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">5.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT04pNiDM8Gc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">132,001,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">8,294,684</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z501g5fLl7Cl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">3.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">112,870,598</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>




<p id="xdx_8A8_zkiH39LqkZfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>






















<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">The following summarizes information about
stock options at December 31, 2021 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1xG2dOoOy0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8BF_zoyRD3plMNz7" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zEhZCdW60Pq5" style="width: 11%; text-align: right" title="Number of outstanding options">4,172,215</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zJYLigHP4Aj8" title="Weighted average remaining contractual life (in years)">5.94</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">4,049,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,117,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIwNJcbuoUP3" title="Weighted average remaining contractual life (in years)">6.08</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">1,837,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">3,397,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zF12E5ZYZwef" title="Weighted average remaining contractual life (in years)">6.20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">2,347,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">230,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z2LqBMyyzMi3" title="Weighted average remaining contractual life (in years)">9.27</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">12.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">39,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">12.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">17.03</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,327,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zb09MQm3Cecf" title="Weighted average remaining contractual life (in years)">9.58</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price">19.35</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">21,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price">24.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">11,243,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">8,294,684</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zVlENWz2IvMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">The weighted average grant date fair value
of options vested during the three months ended December 31, 2021 was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_pdd" title="weighted average grant date fair value of options vested">2.85</span> (2020: $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20201231_pdd" title="weighted average grant date fair value of options vested">2.40</span>). At December 31, 2021, the weighted average
contractual life of options outstanding was <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zqOKm3mA3ZXk" title="Weighted average contractual life of options outstanding">6.54</span> years (September 30, 2021: <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zdoQ37djnXh9" title="Weighted average contractual life of options outstanding">6.79</span> years) and for options exercisable was <span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zYdMQr25P4i4" title="Options exercisable">5.31</span> years (September
30, 2021: <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_z1ZRdvmlBgg2" title="Options exercisable">5.51</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the
options that were in-the-money at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">During the three months ended December 31,
2021, the Company recognized stock-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation">3,908,771</span> (2020: $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" title="Share based compensation">939,314</span>) in connection with the issuance and vesting
	of stock options and warrants in exchange for services. These amounts have been included in general and 	administrative expenses
and research and development expenses on the Company&#8217;s statement of 	operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYZ4T48fmzl7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B7_zVT9ZTgfIqRg" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,671,726</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">422,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation">2,237,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation">516,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="text-align: right" title="Total share based compensation">3,908,771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="text-align: right" title="Total share based compensation">939,314</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zfF44lwTQFWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">An amount of approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20211231_zcbNuMzbgoN9" title="Remaining stock based compensation">18,170,000</span> in
stock-based compensation is expected to be recorded over the remaining term 	of such options through fiscal 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>






















<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 14.05pt"><span style="font-style: normal">e)</span></td><td style="text-align: justify"><span style="font-style: normal">Stock-based Compensation Plan &#8211; (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2cm; text-align: justify; text-indent: 0pt">The fair value of each option
award granted during the three months ended December 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwPsLhoK7iT" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BA_zUq8JrD5JSwd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_zlmP78wcUCDa" title="Risk-free interest rate">1.37</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20201231_zoDBii2fv6h3" title="Risk-free interest rate">0.62</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znXlzJntB7E2" title="Expected life of options (years)">6.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zD7Q4Botjoo7" title="Expected life of options (years)">5.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_z2SwyH0RMdxb" title="Annualized volatility">96.79</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20201231_zgS3NgWIFXeb" title="Annualized volatility">96.16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_znmFgHEvKVwe" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20201231_zRiN97It2KCb" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zhA8jAC66Gv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">The fair value of stock compensation charges
recognized during the three months ended December 31, 2021 and 2020 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903581432664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUO8BYw2NYma" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span id="xdx_863_zD5cBxvCJu8h">Recently Adopted
Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">Effective October
1, 2021, the Company adopted ASU 2019-12, &#8220;Simplifying the Accounting for Income Taxes (ASC 740)&#8221;, which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. There was no material impact on the Company&#8217;s operations, financial
condition, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903585673384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zuDqTtFK1Pe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_zmtjbytSdBZh" style="display: none">Schedule of Accrued Liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20211231_zompnbTVj6ec" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210930_z9MpFvF0PSd9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">December 31,</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">September 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td></tr>
  <tr id="xdx_407_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzxk9_zZoRKfFvKak2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Clinical site costs and patient visits</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,689,740</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,035,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzxk9_zk8vnRD0lay6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,205,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,201,903</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCzxk9_zpVFxt6N2Yv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">649,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzxk9_zGYcs2kVpfy" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,195,690</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,727,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzxk9_zgWCmW0IOPH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 2.5pt">&#160;Total accrued liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,450,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,614,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903580483688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zR8tbH2IjLJ2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zptmiuf4vbz6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; width: 40%; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2020</span></td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zshCiUTvTg09" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning">500,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 8%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zffZoKhRxUwl" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">3.88</td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmK5xj1o0nY4" style="text-align: right" title="Share Purchase Warrants Granted">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zX3ZX4j3Gj39" style="text-align: right" title="Weighted Average Exercise Price, Granted">12.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zcP3u5JeiUB4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised">(350,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIzF2WN4Xq0j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">4.19</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, September 30, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zjVAp4R6SIv8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning">210,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgxE64p4zeF" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">5.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCrj4gWNDxOj" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zItBURLrGIr4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Balance, December 31, 2021</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_znYsGskHwVf4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zMbEm7RyKi56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z9VRBT14uQY9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B3_zMK5DP9P8Oyj" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 44%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zhabp6Kbtqb8" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zVTvXlSl7sZf" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zjNc9x8Nj2I3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zNxMyvqlO6Ve" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Average Grant</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Date Fair</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Value ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2020</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z76JMhWmbfP5" style="width: 12%; text-align: right" title="Options Outstanding at beginning">10,076,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgbgc8rWrId" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjyL7CjeODZ5" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">14,982,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zg8kDm2nkKgc" style="text-align: right" title="Options Granted">2,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbHgCahb0H3f" style="text-align: right" title="Weighted Average Exercise Price Granted">12.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzhsFA8zlgd1" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">9.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zydkA4JIAeo7" style="text-align: right" title="Options Forfeited">(55,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFgaxSlKcDB9" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbYrcSCgB0E3" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMmqYd7ujKbe" style="border-bottom: Black 1pt solid; text-align: right">(1,421,529</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1sAZmZBOP83" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.89</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkvDLFAjsqed" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.43</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVNyTicjux19" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">24,446,305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Outstanding, September 30, 2021</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9airy7jroe9" style="text-align: right" title="Options Outstanding at beginning">11,330,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zs30VwwFlObh" style="text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">5.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zN2XW8aEfxB4" style="text-align: right" title="Aggregate intrinsic value Outstanding at beginning">140,132,451</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Options Granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z7RVt3mDlfWi" style="text-align: right" title="Weighted Average Exercise Price Granted">19.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">15.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znomZGu57e8h" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(137,134</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">2.72</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised">2.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zobnKnvMNfTe" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised">2,276,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Outstanding, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbh6nwP4tra6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">11,243,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKhbYnfHQZO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">5.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT04pNiDM8Gc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">132,001,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">8,294,684</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z501g5fLl7Cl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">3.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">112,870,598</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1xG2dOoOy0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8BF_zoyRD3plMNz7" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">life (in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">vested options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">2.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zEhZCdW60Pq5" style="width: 11%; text-align: right" title="Number of outstanding options">4,172,215</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zJYLigHP4Aj8" title="Weighted average remaining contractual life (in years)">5.94</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">4,049,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">4.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,117,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIwNJcbuoUP3" title="Weighted average remaining contractual life (in years)">6.08</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">1,837,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">8.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">3,397,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zF12E5ZYZwef" title="Weighted average remaining contractual life (in years)">6.20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">2,347,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">230,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z2LqBMyyzMi3" title="Weighted average remaining contractual life (in years)">9.27</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">12.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">39,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">12.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">17.03</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">24.58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,327,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zb09MQm3Cecf" title="Weighted average remaining contractual life (in years)">9.58</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price">19.35</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">21,250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price">24.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">11,243,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">8,294,684</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYZ4T48fmzl7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B7_zVT9ZTgfIqRg" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">1,671,726</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">422,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation">2,237,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation">516,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="text-align: right" title="Total share based compensation">3,908,771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="text-align: right" title="Total share based compensation">939,314</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwPsLhoK7iT" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BA_zUq8JrD5JSwd" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_zlmP78wcUCDa" title="Risk-free interest rate">1.37</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20201231_zoDBii2fv6h3" title="Risk-free interest rate">0.62</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znXlzJntB7E2" title="Expected life of options (years)">6.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zD7Q4Botjoo7" title="Expected life of options (years)">5.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_z2SwyH0RMdxb" title="Annualized volatility">96.79</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20201231_zgS3NgWIFXeb" title="Annualized volatility">96.16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_znmFgHEvKVwe" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20201231_zRiN97It2KCb" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903585676728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">11,403,769<span></span>
</td>
<td class="nump">11,540,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903583309864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 810,730<span></span>
</td>
<td class="nump">$ 1,269,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">443,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,116,362<span></span>
</td>
<td class="nump">$ 1,735,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember', window );">Parkinson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_ParkinsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582340408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ClinicalSiteCostsAndPatientVisits', window );">Clinical site costs and patient visits</a></td>
<td class="nump">$ 1,689,740<span></span>
</td>
<td class="nump">$ 2,035,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,205,186<span></span>
</td>
<td class="nump">1,201,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">359,424<span></span>
</td>
<td class="nump">649,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">2,195,690<span></span>
</td>
<td class="nump">1,727,422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">&#160;Total accrued liabilities</a></td>
<td class="nump">$ 5,450,040<span></span>
</td>
<td class="nump">$ 5,614,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ClinicalSiteCostsAndPatientVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ClinicalSiteCostsAndPatientVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903584261720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,079,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,392,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for aggregate, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,588<span></span>
</td>
<td class="nump">1,514,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,312,785<span></span>
</td>
<td class="nump">$ 8,782,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceed from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,149,701<span></span>
</td>
<td class="nump">$ 8,518,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for aggregate, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Additional common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,346,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,461,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues1', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903580534680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning</a></td>
<td class="nump">$ 5.69<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised', window );">Share Purchase Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited', window );">Share Purchase Warrants Forfeited</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 5.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903583296408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903580556840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">11,330,903<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 140,132,451<span></span>
</td>
<td class="nump">$ 14,982,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">2,732,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 19.64<span></span>
</td>
<td class="nump">$ 12.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 15.52<span></span>
</td>
<td class="nump">$ 9.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(137,134)<span></span>
</td>
<td class="num">(1,421,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised</a></td>
<td class="nump">$ 2,276,948<span></span>
</td>
<td class="nump">$ 24,446,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">11,243,769<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 132,001,363<span></span>
</td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">8,294,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 112,870,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903578165784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
<td class="text">6 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">11,243,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">8,294,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">4,172,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">4,049,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">1,837,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,397,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,347,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 12.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">39,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 12.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">17.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 24.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">9 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 19.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">21,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 24.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903584243816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 3,908,771<span></span>
</td>
<td class="nump">$ 939,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,671,726<span></span>
</td>
<td class="nump">422,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,237,046<span></span>
</td>
<td class="nump">$ 516,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582585640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">96.79%<span></span>
</td>
<td class="nump">96.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139903582191880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 4,845<span></span>
</td>
<td class="nump">$ 68,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 22,682<span></span>
</td>
<td class="nump">$ 16,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">weighted average grant date fair value of options vested</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 3,908,771<span></span>
</td>
<td class="nump">$ 939,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 18,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Remaining stock options</a></td>
<td class="nump">$ 406,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>e3475_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20211231"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-10-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_ParkinsonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-01to2021-12-31">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-01to2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-10-01to2021-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-10-01to2021-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-10-01to2021-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-01to2021-12-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-10-01to2021-12-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-10-01to2021-12-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-01to2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-10-01to2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-10-01to2021-12-31">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-10-01to2021-12-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-01to2021-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-01to2021-12-31">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-01to2021-12-31">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-10-01to2021-12-31">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-01to2021-12-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-01to2021-12-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2021-10-01to2021-12-31">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-01to2021-12-31">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-01to2021-12-31">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-01to2021-12-31">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-10-01to2021-12-31">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-10-01to2021-12-31">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-10-01to2021-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-10-01to2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-10-01to2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-10-01to2021-12-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-10-01to2021-12-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-01to2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-10-01to2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-02-08" decimals="INF" unitRef="Shares">76174887</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">151146355</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5372153</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9136831</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">377860</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">371914</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">156896368</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4634791</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4739781</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5450040</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10528662</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10798386</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">76155187</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">76155187</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">75918465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">76156</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">75920</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">354759781</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">348328048</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-208468231</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-197585864</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">146367706</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">156896368</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">161616490</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">3066951</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1470656</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">8656439</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">7925519</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">11723390</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">9396175</us-gaap:OperatingExpenses>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">810730</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1269316</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">4910</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-1559</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">55363</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">332634</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">871003</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1600391</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-10852387</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-7795784</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">29980</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">59281</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">75997738</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Shares">64295143</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">137134</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">137</avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">373360</avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">373497</avxl:SharesIssuedPursuantToExerciseOfStockOptionsValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">99588</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">99</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2149602</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">2149701</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3908771</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">76155187</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">76156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">354759781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-208468231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">146367706</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3346288</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3346</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17458056</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">17461402</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">56642</avxl:CommitmentSharesShares>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">56</avxl:CommitmentSharesValue>
    <avxl:CommitmentSharesValue
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-56</avxl:CommitmentSharesValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1514829</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1515</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8517042</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">8518557</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">66962957</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">66964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">213766108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-167532295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">46300777</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-10882367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-3764678</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1728467</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">22311</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-44999</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-104992</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">227894</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-164734</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">499947</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-3500955</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-7871378</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">2312785</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">26243419</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">146717</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">263460</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">373497</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">2539565</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">25979959</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">-961390</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">18108581</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">151146355</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">47357599</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zG4NB93uNQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;Note 1&#160;&#160;&#160;&#160;&#160;&#160; 	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_827_zzJEo3RgaLhh"&gt;Description of Business and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Description of
Business&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d;
or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics
by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases. The Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed
to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system diseases, including rare diseases,
such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein
2 (&#x201c;MECP2&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify; text-indent: 2pt"&gt;Basis of Presentation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These unaudited interim condensed consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These accompanying unaudited interim condensed
consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management
are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2021 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes
thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2021 filed with the SEC on November
24, 2021. The Company follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Operating results for the three months
ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Liquidity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;All of the Company&#x2019;s potential drug
compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful
or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience
negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;






















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Management believes that the current working
capital position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date
that these interim condensed consolidated financial statements are issued. The process of drug development can be costly, and the timing
and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated
and may be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors
including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and
development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending
levels based on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Other than our rights related to the Sales
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Coronavirus Disease 2019 (COVID-19)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The recent global outbreak of COVID-19
has not had a material impact on the Company&#x2019;s result of operations or financial condition as of December 31, 2021. However, the
pandemic continues to rapidly evolve as of the date these consolidated financial statements are issued and has created a dynamic and uncertain
situation in the global economy. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s
financial condition and future results of operations. Management is actively monitoring the global situation on its business, including
on its clinical trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses
to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results of operations or financial
condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The preparation of financial
statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting
period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs,
incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and
loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other
factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other
sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To
the extent there are material differences between the estimates and the actual results, future results of operations will be
affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;






















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Principles of Consolidation&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The fair value hierarchy under GAAP is
based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure
fair value which are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 1 - 	quoted
prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 2 - observable
inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value
drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;Level 3 - 	assets
and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair
value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The book value of cash and cash equivalents
and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;At December 31, 2021 and September 30,
2021, the Company did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;Basic
and Diluted Loss per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Basic income/(loss) per common share is
computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during
the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum
of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of
options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes
of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation
of diluted net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;As of December 31, 2021, loss per share
excludes &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20211231_pdd" title="Loss per share for potentially dilutive common shares"&gt;11,403,769&lt;/span&gt; (September 30, 2021 &#x2013; &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930_zWR0O7F3Y0k6" title="Loss per share for potentially dilutive common shares"&gt;11,540,903&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants,
as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;


















</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">11403769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-012021-09-30"
      decimals="INF"
      unitRef="Shares">11540903</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_807_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zLlEni6ponre" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Note 2&#160;&#160;&#160;&#160;&#160;&#160;	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82D_zYSEBSrYZt01"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUO8BYw2NYma" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zD5cBxvCJu8h"&gt;Recently Adopted
Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;Effective October
1, 2021, the Company adopted ASU 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s operations, financial
condition, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUO8BYw2NYma" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zD5cBxvCJu8h"&gt;Recently Adopted
Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;Effective October
1, 2021, the Company adopted ASU 2019-12, &#x201c;Simplifying the Accounting for Income Taxes (ASC 740)&#x201d;, which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. There was no material impact on the Company&#x2019;s operations, financial
condition, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_804_ecustom--OtherIncomeDisclosureTextBlock_zluVmor3G4sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Note 3	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_828_zaV3cL0MM5V5"&gt;Other Income&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;Grant Income&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;During the year
ended September 30, 2021, the Company received $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_z1AsLRT9ojul" title="Research and development incentive income"&gt;497,931&lt;/span&gt; of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s
Research. The grant will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to
Parkinson&#x2019;s disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;The grant income
is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During
the three months ended December 31, 2021 and 2020, the Company did not recognize any of this grant on its statements of operations. At
December 31, 2021, an amount of $&lt;span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20211001__20211231_ztn8klf9Fue2" title="Grant income"&gt;443,831&lt;/span&gt; (September 30, 2021: $&lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_zM2aXTHpLf33" title="Grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded as deferred grant income, representing
the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of
operations as the relating expenditures are incurred to offset the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;Research and development
incentive income&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the receipt by Anavex Australia, of the Australian research and development incentive credit, (the &#x201c;R&amp;amp;D
Incentive Credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;During the three
months ended December 31, 2021, the Company recorded research and development incentive income of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20211001__20211231_zxIM8dcfeFPh" title="Research and development incentive income"&gt;810,730&lt;/span&gt; (AUD &lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20211231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;1,116,362&lt;/span&gt;) (2020: $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zetSwaPz1gl6" title="Research and development incentive income"&gt;1,269,316&lt;/span&gt;
(AUD &lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_zFB0I0xBKZJ5" title="Research and development incentive income"&gt;1,735,962&lt;/span&gt;)) in respect of the R&amp;amp;D Incentive Credit for eligible research and development expenses incurred during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012021-12-31_custom_ParkinsonMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">443831</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-012021-09-30"
      decimals="0"
      unitRef="USD">443831</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">810730</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012021-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1116362</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1269316</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012020-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1735962</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zti2obruejZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Note 4	 &#160;&#160;&#160;&#160;	 &lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_824_zVYsMgXVBcM7"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consists of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zuDqTtFK1Pe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zmtjbytSdBZh" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20211231_zompnbTVj6ec" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20210930_z9MpFvF0PSd9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzxk9_zZoRKfFvKak2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Clinical site costs and patient visits&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,689,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,035,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzxk9_zk8vnRD0lay6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,205,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCzxk9_zpVFxt6N2Yv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;649,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzxk9_zGYcs2kVpfy" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,195,690&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,727,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzxk9_zgWCmW0IOPH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); padding-bottom: 2.5pt"&gt;&#160;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,450,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,614,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zuDqTtFK1Pe4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zmtjbytSdBZh" style="display: none"&gt;Schedule of Accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20211231_zompnbTVj6ec" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20210930_z9MpFvF0PSd9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;September 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ClinicalSiteCostsAndPatientVisits_iI_pp0p0_maALCzxk9_zZoRKfFvKak2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Clinical site costs and patient visits&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,689,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,035,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzxk9_zk8vnRD0lay6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,205,186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,201,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_pp0p0_maALCzxk9_zpVFxt6N2Yv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;649,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzxk9_zGYcs2kVpfy" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,195,690&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,727,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzxk9_zgWCmW0IOPH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); padding-bottom: 2.5pt"&gt;&#160;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,450,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,614,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1689740</avxl:ClinicalSiteCostsAndPatientVisits>
    <avxl:ClinicalSiteCostsAndPatientVisits contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2035800</avxl:ClinicalSiteCostsAndPatientVisits>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1205186</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1201903</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">359424</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">649649</avxl:FixedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2195690</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1727422</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5450040</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">5614774</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:EquityOfferingTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_800_ecustom--EquityOfferingTextBlock_zl0TxZ1GVku8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Note 5&#160;&#160;&#160;&#160;&#160;&#160;&#160;	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82F_zl20FE9SSJ0j"&gt;Equity Offerings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Common Stock&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Common shares are voting and are entitled
to dividends as declared at the discretion of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Preferred Stock&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company&#x2019;s Board of Directors
(the &#x201c;Board&#x201d;) has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges,
restrictions and the number of shares constituting any series of the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Sales Agreement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with
Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer
and sell shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Upon delivery of a placement notice based
on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares
by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions,
subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement.
The Company or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;The Company has agreed to pay the Sales
Agents commissions for their services of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement.
The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During the three months ended
December 31, 2021, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zk8q2lcWl834" title="Share issued for offering, shares"&gt;99,588&lt;/span&gt; shares were sold pursuant to the Offering for gross proceeds of $&lt;span id="xdx_907_ecustom--GrossProceedsFromSaleOfCommonStock_pp0p0_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zFaMQJiBgp7d" title="Gross proceeds from sale of common stock"&gt;2,312,785&lt;/span&gt; (net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20211001__20211231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"&gt;2,149,701&lt;/span&gt; after
deducting offering expenses) (December 31, 2020: &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"&gt;1,514,829&lt;/span&gt; shares were sold for gross proceeds of $&lt;span id="xdx_90B_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"&gt;8,782,017&lt;/span&gt; (net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"&gt;8,518,557&lt;/span&gt;)).
At December 31, 2021, an amount of $&lt;span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20211231_zUptSGynmtw7" title="Sales of agreement amount"&gt;161,079,765&lt;/span&gt; (September 30, 2021: $&lt;span id="xdx_903_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20210930_zFdVdAaChNf8" title="Sales of agreement amount"&gt;163,392,550&lt;/span&gt;) was registered pursuant to an effective registration
statement and remained available to be sold under the Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;






















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;2019 Purchase Agreement&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;On June 7, 2019, the Company entered into
a $&lt;span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdbSU8YLjkL7" title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln Park, as amended on July 1, 2020, pursuant to
which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXVcp3FcTGi8" title="Proceeds from Issuance or Sale of Equity"&gt;50,000,000&lt;/span&gt; in value
of its shares of common stock from time to time over a three-year period until July 1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;In consideration for entering into the
2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee during the year ended September
30, 2019 and agreed to issue up to &lt;span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTkAiWogLmT9" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion, the
$50,000,000 aggregate commitment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;At December 31, 2021 and September 30,
2021, no shares remained available for issuance under the 2019 Purchase Agreement. During the three months ended December 31, 2020, the
Company issued to Lincoln Park an aggregate of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zhtwFvurfetj" title="Share issued for aggregate, shares"&gt;3,402,930&lt;/span&gt; shares of common stock including &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgRJbbanxDAd" title="Additional common shares"&gt;3,346,288&lt;/span&gt; shares of common stock for an aggregate
purchase price of $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues1_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zXzMRXpmVMs7" title="Number of shares issued for aggregate purchase price, value"&gt;17,461,402&lt;/span&gt; and &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zWVTLdRcoidk" title="Number of shares issued for commitment"&gt;56,642&lt;/span&gt; commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">99588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">2312785</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-10-012021-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">2149701</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1514829</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">8782017</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">8518557</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">161079765</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">163392550</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3402930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3346288</us-gaap:StockIssuedDuringPeriodSharesOther>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">17461402</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <avxl:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">56642</avxl:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2021-10-01to2021-12-31">&lt;p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zYuJPyeLiJ4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Note 6 &#160;&#160;&#160;&#160;&#160;&#160;	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82D_z4z315gt58wk"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 11pt; font-style: normal"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt; font-style: normal"&gt;Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;During the
three months ended December 31, 2021, the Company incurred office lease expense of $&lt;span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_pp0p0" title="Operating Leases, Rent Expense"&gt;4,845&lt;/span&gt; (2020: $&lt;span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Operating Leases, Rent Expense"&gt;68,387&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 11pt"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;Employee 401(k) Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company
has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three months ended December 31, 2021, the Company made $&lt;span id="xdx_906_eus-gaap--PensionContributions_c20211001__20211231_pp0p0" title="Contribution amount"&gt;22,682&lt;/span&gt; (2020: $&lt;span id="xdx_904_eus-gaap--PensionContributions_c20201001__20201231_pp0p0" title="Contribution amount"&gt;16,556&lt;/span&gt;) in matching contributions under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 11pt; font-style: normal"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt; font-style: normal"&gt;Litigation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and
there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any
such matter will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not
believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"/&gt;













&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 11pt; font-style: normal"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt; font-style: normal"&gt;Share Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;A summary of the status of the Company&#x2019;s
outstanding share purchase warrants is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zR8tbH2IjLJ2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zptmiuf4vbz6" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Price ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; width: 40%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zshCiUTvTg09" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zffZoKhRxUwl" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmK5xj1o0nY4" style="text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zX3ZX4j3Gj39" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zcP3u5JeiUB4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIzF2WN4Xq0j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zjVAp4R6SIv8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgxE64p4zeF" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCrj4gWNDxOj" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zItBURLrGIr4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_znYsGskHwVf4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zMbEm7RyKi56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zz9Jlv3q2xpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt"&gt;At December 31, 2021,
the Company had share purchase warrants outstanding as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -0.8pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z9VRBT14uQY9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zMK5DP9P8Oyj" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 44%"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zhabp6Kbtqb8" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zVTvXlSl7sZf" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A3_zlPXKFpFjCu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 14.05pt"&gt;&lt;span style="font-size: 11pt; font-style: normal"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Stock&#x2013;based Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s
Board approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted
stock awards to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The maximum number of our common shares reserved
for issue under the plan was &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization. At
December 31, 2021, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"&gt;146,371&lt;/span&gt; (September 30, 2021: &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlDk8QefFfQ7" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"&gt;146,371&lt;/span&gt;) options remain available for issue under the 2015 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;






















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 14.05pt"&gt;&lt;span style="font-style: normal"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Stock-based Compensation Plan &#x2013; (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;2019 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;On January 15, 2019, the Board approved the
2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to
directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zytI0TLx1wEg" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; additional shares
of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding
under the 2015 Plan or the Company&#x2019;s 2007 Stock Option Plan (the &#x201c;2007 Plan&#x201d;) will remain subject to and be paid under
the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for
issuance under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The 2019 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At December 31,
2021, &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zJ9yDVMkuGZb" title="Remaining stock options"&gt;406,332&lt;/span&gt; (September 30, 2021: &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zrTcr8iXNUif"&gt;456,332&lt;/span&gt;) options remain available for issue under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;A summary of the status of Company&#x2019;s
outstanding stock options is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zjNc9x8Nj2I3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zNxMyvqlO6Ve" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average Grant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Date Fair&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z76JMhWmbfP5" style="width: 12%; text-align: right" title="Options Outstanding at beginning"&gt;10,076,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgbgc8rWrId" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjyL7CjeODZ5" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;14,982,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zg8kDm2nkKgc" style="text-align: right" title="Options Granted"&gt;2,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbHgCahb0H3f" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzhsFA8zlgd1" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;9.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zydkA4JIAeo7" style="text-align: right" title="Options Forfeited"&gt;(55,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFgaxSlKcDB9" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbYrcSCgB0E3" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMmqYd7ujKbe" style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,421,529&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1sAZmZBOP83" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkvDLFAjsqed" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVNyTicjux19" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;24,446,305&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9airy7jroe9" style="text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zs30VwwFlObh" style="text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zN2XW8aEfxB4" style="text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Options Granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z7RVt3mDlfWi" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;19.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;15.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znomZGu57e8h" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(137,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zobnKnvMNfTe" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;2,276,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbh6nwP4tra6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;11,243,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKhbYnfHQZO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT04pNiDM8Gc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;132,001,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;8,294,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z501g5fLl7Cl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;3.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;112,870,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;




&lt;p id="xdx_8A8_zkiH39LqkZfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;






















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 14.05pt"&gt;&lt;span style="font-style: normal"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Stock-based Compensation Plan &#x2013; (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;The following summarizes information about
stock options at December 31, 2021 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1xG2dOoOy0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zoyRD3plMNz7" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;vested options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zEhZCdW60Pq5" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;4,172,215&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zJYLigHP4Aj8" title="Weighted average remaining contractual life (in years)"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;4,049,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,117,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIwNJcbuoUP3" title="Weighted average remaining contractual life (in years)"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;1,837,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;3,397,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zF12E5ZYZwef" title="Weighted average remaining contractual life (in years)"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,347,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;230,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z2LqBMyyzMi3" title="Weighted average remaining contractual life (in years)"&gt;9.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;12.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;39,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;12.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;17.03&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,327,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zb09MQm3Cecf" title="Weighted average remaining contractual life (in years)"&gt;9.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;19.35&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;21,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;24.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;11,243,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;8,294,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zVlENWz2IvMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;The weighted average grant date fair value
of options vested during the three months ended December 31, 2021 was $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231_pdd" title="weighted average grant date fair value of options vested"&gt;2.85&lt;/span&gt; (2020: $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20201231_pdd" title="weighted average grant date fair value of options vested"&gt;2.40&lt;/span&gt;). At December 31, 2021, the weighted average
contractual life of options outstanding was &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zqOKm3mA3ZXk" title="Weighted average contractual life of options outstanding"&gt;6.54&lt;/span&gt; years (September 30, 2021: &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zdoQ37djnXh9" title="Weighted average contractual life of options outstanding"&gt;6.79&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231_zYdMQr25P4i4" title="Options exercisable"&gt;5.31&lt;/span&gt; years (September
30, 2021: &lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_z1ZRdvmlBgg2" title="Options exercisable"&gt;5.51&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The aggregate intrinsic value is calculated
as the difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the
options that were in-the-money at December 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;During the three months ended December 31,
2021, the Company recognized stock-based compensation expense of $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" title="Share based compensation"&gt;3,908,771&lt;/span&gt; (2020: $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" title="Share based compensation"&gt;939,314&lt;/span&gt;) in connection with the issuance and vesting
	of stock options and warrants in exchange for services. These amounts have been included in general and 	administrative expenses
and research and development expenses on the Company&#x2019;s statement of 	operations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYZ4T48fmzl7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B7_zVT9ZTgfIqRg" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,671,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;422,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation"&gt;2,237,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation"&gt;516,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="text-align: right" title="Total share based compensation"&gt;3,908,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="text-align: right" title="Total share based compensation"&gt;939,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zfF44lwTQFWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20211231_zcbNuMzbgoN9" title="Remaining stock based compensation"&gt;18,170,000&lt;/span&gt; in
stock-based compensation is expected to be recorded over the remaining term 	of such options through fiscal 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;






















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: black"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 14.05pt"&gt;&lt;span style="font-style: normal"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Stock-based Compensation Plan &#x2013; (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; text-indent: -18pt; color: black"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2cm; text-align: justify; text-indent: 0pt"&gt;The fair value of each option
award granted during the three months ended December 31, 2021 and 2020 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwPsLhoK7iT" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BA_zUq8JrD5JSwd" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_zlmP78wcUCDa" title="Risk-free interest rate"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20201231_zoDBii2fv6h3" title="Risk-free interest rate"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znXlzJntB7E2" title="Expected life of options (years)"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zD7Q4Botjoo7" title="Expected life of options (years)"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_z2SwyH0RMdxb" title="Annualized volatility"&gt;96.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20201231_zgS3NgWIFXeb" title="Annualized volatility"&gt;96.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_znmFgHEvKVwe" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20201231_zRiN97It2KCb" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zhA8jAC66Gv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;The fair value of stock compensation charges
recognized during the three months ended December 31, 2021 and 2020 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">4845</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">68387</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PensionContributions
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">22682</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">16556</us-gaap:PensionContributions>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zR8tbH2IjLJ2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zptmiuf4vbz6" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average Exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Price ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; width: 40%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zshCiUTvTg09" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zffZoKhRxUwl" style="border-bottom: Black 1pt solid; width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;3.88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmK5xj1o0nY4" style="text-align: right" title="Share Purchase Warrants Granted"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zX3ZX4j3Gj39" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zcP3u5JeiUB4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Exercised"&gt;(350,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zIzF2WN4Xq0j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zjVAp4R6SIv8" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;210,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgxE64p4zeF" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;5.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCrj4gWNDxOj" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zItBURLrGIr4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_znYsGskHwVf4" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zMbEm7RyKi56" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">60000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">-350000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice
      contextRef="From2020-10-012021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.69</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited
      contextRef="From2021-10-012021-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">-50000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice
      contextRef="From2021-10-012021-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">12.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z9VRBT14uQY9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zMK5DP9P8Oyj" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 18%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 44%"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zhabp6Kbtqb8" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20211231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zVTvXlSl7sZf" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20211231_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-12-31_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-12-31_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2019Member"
      decimals="0"
      unitRef="USD">406332</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2019Member"
      decimals="0"
      unitRef="USD">456332</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zjNc9x8Nj2I3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zNxMyvqlO6Ve" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Average Grant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Date Fair&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z76JMhWmbfP5" style="width: 12%; text-align: right" title="Options Outstanding at beginning"&gt;10,076,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgbgc8rWrId" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjyL7CjeODZ5" style="width: 12%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;14,982,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zg8kDm2nkKgc" style="text-align: right" title="Options Granted"&gt;2,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbHgCahb0H3f" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;12.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zzhsFA8zlgd1" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;9.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zydkA4JIAeo7" style="text-align: right" title="Options Forfeited"&gt;(55,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFgaxSlKcDB9" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbYrcSCgB0E3" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMmqYd7ujKbe" style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,421,529&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z1sAZmZBOP83" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.89&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkvDLFAjsqed" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.43&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVNyTicjux19" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;24,446,305&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9airy7jroe9" style="text-align: right" title="Options Outstanding at beginning"&gt;11,330,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zs30VwwFlObh" style="text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zN2XW8aEfxB4" style="text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;140,132,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Options Granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z7RVt3mDlfWi" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;19.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;15.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_znomZGu57e8h" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(137,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;2.72&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;2.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zobnKnvMNfTe" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;2,276,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbh6nwP4tra6" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;11,243,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKhbYnfHQZO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20211001__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT04pNiDM8Gc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;132,001,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;8,294,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z501g5fLl7Cl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;3.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;112,870,598&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;




</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2732000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">12.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">9.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">55834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.43</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1421529</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.43</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-10-012021-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">24446305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">19.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">15.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">137134</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.12</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-10-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">2276948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">11243769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">132001363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">8294684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">112870598</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1xG2dOoOy0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zoyRD3plMNz7" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;vested options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;2.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zEhZCdW60Pq5" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;4,172,215&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zJYLigHP4Aj8" title="Weighted average remaining contractual life (in years)"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;4,049,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;4.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,117,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIwNJcbuoUP3" title="Weighted average remaining contractual life (in years)"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;1,837,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;8.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;3,397,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zF12E5ZYZwef" title="Weighted average remaining contractual life (in years)"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,347,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;230,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z2LqBMyyzMi3" title="Weighted average remaining contractual life (in years)"&gt;9.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;12.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;39,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;12.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;17.03&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;24.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,327,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zb09MQm3Cecf" title="Weighted average remaining contractual life (in years)"&gt;9.58&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;19.35&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;21,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;24.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;11,243,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;8,294,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">4172215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">4049714</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2117500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">1837500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3397054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">2347054</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">P9Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">12.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">39166</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">12.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">17.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1327000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">P9Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">19.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">21250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">24.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11243769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">8294684</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2021-12-31">P6Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P6Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-10-01to2021-12-31">P5Y3M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-10-012021-09-30">P5Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zYZ4T48fmzl7" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B7_zVT9ZTgfIqRg" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;1,671,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;422,823&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation"&gt;2,237,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total share based compensation"&gt;516,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20211231_pp0p0" style="text-align: right" title="Total share based compensation"&gt;3,908,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="text-align: right" title="Total share based compensation"&gt;939,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1671726</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">422823</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2237046</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">516491</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-01to2021-12-31"
      decimals="0"
      unitRef="USD">3908771</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">18170000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-10-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwPsLhoK7iT" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BA_zUq8JrD5JSwd" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231_zlmP78wcUCDa" title="Risk-free interest rate"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20201231_zoDBii2fv6h3" title="Risk-free interest rate"&gt;0.62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231_znXlzJntB7E2" title="Expected life of options (years)"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zD7Q4Botjoo7" title="Expected life of options (years)"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231_z2SwyH0RMdxb" title="Annualized volatility"&gt;96.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20201231_zgS3NgWIFXeb" title="Annualized volatility"&gt;96.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20211231_znmFgHEvKVwe" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20201231_zRiN97It2KCb" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-01to2021-12-31">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-012020-12-31">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.9679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.9616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MSD(N]0-P?RV$.I[H%Y2;S^/_ %!+ P04    " #1@TE4;88:$6<$  "&#@
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M ]<!:G[%F'SKZ&NA_A<0_@=02P,$%     @ T8-)5) 95LM-!   V@T  !@
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M_Y=8GZAL6;YX?\R4RI+R<"$%S#5M +\_99G:G.AW^=M_AX;_ E!+ P04
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MS!(D-F8PYK"[4CLJ!QCRNL7E8BBO#D$]A@'Q7 \/=<M>3+ _/LD-.L0!-@/
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M[A/5;9I.,;)UTUU(@[O"B34N9U#6 >T;B<_GH-@ _;J?_P%02P,$%     @
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M(+]6[@E)H*EQ^,J,HZ?F/GIUZK.[M:1DAB1;JI1M12ORH/&M451M;+>@+ =
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M\SSVLSP::4WLSY)X8#99QN9!$A]PD\S/DQ3<) G"E,5!FNR3G\A/$9TLGF-
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M&KU2R27R1+H2>.K*^BUZ-QVWN$'FH?>,A<$\IIUT,)^RU(]FP _X7!;,"?$
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M=9D&X/U2P4AW0PN,'UK/_P=02P,$%     @ T8-)5(S-JDDB P  F@8  !D
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M8<4?#Z00P/N%M?XP"0+'S]'T)U!+ P04    " #1@TE4)5U)IZ\"  "W!0
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M</A5WI;*'!U/6]1%$M.LQSWK<,4+N#Y<(M+2P,<Z5_ES^2G:.!HJ!D//Q%[
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M]/&,/5^IA0U?LNMMXXB4K75:]F!4(+GJ_NRYS\,! 'F. ](>D/X/N#H!R'I
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MM4^)>,Z9U$WHZ1Z*.8BVA&#O]6+UWN,$<.,FQV]W!A7W7FWWN_VCVG8;K:8
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MKNO-I,$>ZH8KO.5 V0#<7TAI]A/;2-M[,_\'4$L#!!0    ( -&#252')5_
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MK(B$!<]N:*+2F3-U4 )KLLW4%2\_0^W0V/#%/)/VC<IJ[>3$0?%6*LYJL%;
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M1W'3BN7JR((&6#"X5:-O!?A8K.C*XK\8]X=H)("K)J:>'?0R.U=H-.(U31V
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M+W=O<FMS:&5E=',O<VAE970R-"YX;6RU5EUOVC 4_2M6M(=6VIK$"0E4$*G
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MM]!:F5O6E&B2#:78(&FC#9MM.&\<VJR&<KN-=UJ:66IP.IL(QJ@V^Z(5(KQ
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M^>BT752*6FV[F'9![.,$%8,')TVS7S_ CI=5#ONXL0'S/IP7CCF3@U2/>@>
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M'W7#U'=J6><C\X)6[(D58)+]4L[YY=$@BGK#_V=9$WUX=O%5H+:N'FB2R[W
MYE[I1KN2,W<W[8OQA2E%3>7XA6GJV!U56V;2DD-ID-$@,RFDFMK0=%#6[GK=
M2#27M6ON3#D%92>8[Z64>.K8!;H"/?L)4$L#!!0    ( -&#2523KWZR;00
M (0/   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;,U72V_;.!#^*P-C
M#RV01J)>E@/'@&-W=P,T;9"@VT.Q!UJB;2&2Z"4I._GW.Z046;9E)D OS2&6
MJ'E\W\QPAASON'B2:\84/!=Y*:\':Z4V5XXCDS4KJ+SD&U;BER47!57X*E:.
MW A&4Z-4Y([GNI%3T*P<3,9F[5Y,QKQ2>5:R>P&R*@HJ7FY8SG?7 S)X77C(
M5FNE%YS)>$-7[)&I[YM[@6].:R7-"E;*C)<@V/)Z,"57<Q)K!2/Q3\9VLO,,
MFLJ"\R?]<IM>#UR-B.4L4=H$Q9\MF[$\UY80QW^-T4'K4RMVGU^M_VG((YD%
ME6S&\Q]9JM;7@W@ *5O2*E</?/<W:PB%VE["<VG^PZZ1=0>05%+QHE%&!$56
MUK_TN0E$1\$+SRAXC8)WI$"",PI^H^"_UT/0* 0F,C45$X<Y570R%GP'0DNC
M-?U@@FFTD7Y6ZKP_*H%?,]13DQDOBDQA(I4$6J8PXZ7*RA4KDXQ)^#!GBF:Y
MA*]4"*HS]!$^P??'.7SXX^/840A FW&2QME-[<P[X\R'.S2_EO"Y3%G:HS^W
MZQ//8L!!YBU][Y7^C6>U.&?))?CD CS7(SV 9N]7=_OXV-4?V0;5W3[O!VS\
M-IF^L>>?L[>F@GW2VT GLL#>(*G975/,'B95IQD6+]"5NZ<O9GFZHR*%GU_0
M)-PJ5LA_+8""%E!@  5G 'W;,%TVY0J^,/0F+^!!^_K\K*&QO@*J[47&GNY9
MVTD0!^'8V7:3<BH4Q7X\;*4.L(8MUM"*55>^R!95W8X*7I6J#V!XXMOSHM@[
M0G@J1:(PC/H11BW"R(IP9YH8YHQN,:PK!BO,JH*4*@9+F@G8TKQBP)? -YJ%
MA"V3JG>CW=2>XBZ-R_@XSGU"03^'8<MA:.7PXYA#HL..W;^B.>39\@ ^SBFI
ML"MA ?5QL'N*X(51(2&"HNX9),!0O<B^;?H^2R.KI8-PQ&TXXC<V2,V4/3.1
M9)(N\MY=83<2-OC\5WP>.<OT?9;:F/EO$1VU1$=6RZ;E0-URDDYKZF,[.MD\
M_LB-AT-R5)ZG<B-_Y),S%4K<_4ATK5@?F#XPZ:Z%XS=Y>B?JQNC!GH_)T,6_
M,X Z,YI8 7DN">%;46)WDG!;)MA#<13#?4Y+^'G'B@43MFY-O+TC[_<8(&0_
MTHAOY7Y'G[.B*J"L-$W='3 16)T@-0:)9T_)Q!9QX!D8EI6JL,PR*2N*8>I-
M4^TN[ X/-W3#T#^3I?VL(_9A]\O!NX"O+<G'FMUTB\<OW14,O;]TO^\E%9R0
M(D'D'^^8^=MRA]SWLY/8AR=6Z.A7*G0_ DGTFU3H?J(1^WB8IFFF(>  :VJR
M4Z2F@="#+%JK<]A3G:ZEA^P'#;&W]N.FULS87A#QZ2',C7S?.ZZF'KGP0*[&
MZG2N)P43*W/-DQ@B/&+51_5VM;U*3LT%ZFC]AES-Z@OAWDQ]/[VC8I7A',W9
M$DVZET.,H*BO?/6+XAMS"5IPA5<J\[C&:S(36@"_+SE7KR_:07OQGOP/4$L#
M!!0    ( -&#253[B)C8$ ,  # 1   -    >&PO<W1Y;&5S+GAM;-U8;6O;
M,!#^*\8=HX51Q_'JQ6L2V *%P38*[8=]*THL.P)9\F2Y2_KKIY,<YZ6ZTO7#
MELXAM72/[KE'=^?*9-SH-:<W2TIUL*JX:";A4NOZ8Q0UBR6M2',N:RH,4DA5
M$6VFJHR:6E&2-^!4\6@X&*1119@(IV/15E>5;H*%;(6>A$EO"MSM2SX)X_1]
M&#BZF<SI)+P[??NSE?KR3>#N)^].3@9W9Y>']E,+G(61E_3B&:3G@P%.#"!&
MGCZ/_"EN2QUU"9J."RGV\P0&$YM4-+@G?!+."&=SQ<"K(!7C:V<>@F$AN52!
M-@4R8F*P- \.CMT,:M?Q5$Q(96.[".[OO%M^ &QF()!QW@L<ALXP'==$:ZK$
ME9G8Q=;X" JZ\>VZ-@I+1=;Q\"+<.MB;"3*7*J>J#Q.'&]-TS&D!<A0KEW#7
MLHX U%I69I S4DI!K(:-1S<PM O*^0TT]H]BCWM5[%1U #45_= (ZH:.QDV
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ T8-)5*?2EJ+N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MT8-)5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #1@TE4V-'Z"ED%  "(%@  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MT8-)5&V&&A%G!   A@X  !@              ("!G T  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -&#251S'>"TN@(  !$(   8
M          " @3D2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #1@TE4D!E6RTT$  #:#0  &               @($I%0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ T8-)5-HHN5:Z!0  *1H
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M965T.2YX;6Q02P$"% ,4    " #1@TE4(MA ],<"  #Z!0  &0
M    @($%.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M -&#250%88UYG08  '4/   9              " @0,^  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ T8-)5'%()P&%"P  =!T  !D
M             ("!UT0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #1@TE4C,VJ22(#  ":!@  &0              @(&34   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -&#250E74FGKP(
M +<%   9              " @>Q3  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ T8-)5#GN\&D*!@  ?A   !D              ("!
MTE8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #1@TE4
M4F%.N'8"  "D!0  &0              @($370  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( -&#251/=J"*]0(  % )   9
M      " @<!?  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ T8-)5*WG?F&_ @  0P<  !D              ("![&(  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #1@TE4AR5?P!4$  #\#0
M&0              @('B90  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( -&#253$TC<@/P,  #0+   9              " @2YJ  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ T8-)5)-R[(J_
M @  X@@  !D              ("!I&T  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #1@TE46\RL:'@$  #6$0  &0
M@(&:<   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -&#
M251V9]3XQ@4  %$A   9              " @4EU  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ T8-)5"(WID'& @  &0@  !D
M         ("!1GL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #1@TE4)0M&-J0"  "L!P  &0              @(%#?@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -&#2523KWZR;00  (0/
M   9              " @1Z!  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ T8-)5/N(F-@0 P  ,!$   T              ( !PH4
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #1@TE4EXJ[',     3 @  "P
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52P4&     "( (@ E"0  ]8\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>63</ContextCount>
  <ElementCount>253</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Description of Business and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e3475_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e3475_10q.htm">e3475_10q.htm</File>
    <File>avxl-20211231.xsd</File>
    <File>avxl-20211231_cal.xml</File>
    <File>avxl-20211231_def.xml</File>
    <File>avxl-20211231_lab.xml</File>
    <File>avxl-20211231_pre.xml</File>
    <File>e3475_ex31-1.htm</File>
    <File>e3475_ex31-2.htm</File>
    <File>e3475_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="280">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>44
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e3475_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 63,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e3475_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 265,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20211231": 5,
    "http://fasb.org/us-gaap/2021-01-31": 16,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 26
   },
   "keyCustom": 27,
   "keyStandard": 226,
   "memberCustom": 15,
   "memberStandard": 7,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Accrued liabilities",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Recent Accounting Pronouncements (Policies)",
     "role": "http://anavex.com/role/RecentAccountingPronouncementsPolicies",
     "shortName": "Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Accrued liabilities (Tables)",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Description of Business and Basis of Presentation (Details Narrative)",
     "role": "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative",
     "shortName": "Description of Business and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Accrued liabilities (Details)",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ClinicalSiteCostsAndPatientVisits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Equity Offerings (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2020-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 1)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2020-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 3)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 4)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details 5)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "shortName": "Commitments and Contingencies (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement -  INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement -  INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "AsOf2020-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInIncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://anavex.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e3475_10q.htm",
      "contextRef": "From2021-10-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 22,
   "tag": {
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ClinicalSiteCostsAndPatientVisits": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical site costs and patient visits"
       }
      }
     },
     "localname": "ClinicalSiteCostsAndPatientVisits",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesShares",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_CommitmentSharesValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesValue",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20211231",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20211231",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_EquityOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingTextBlock",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ParkinsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parkinson [Member]"
       }
      }
     },
     "localname": "ParkinsonMember",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options ,shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsValue",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues1",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Total number of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20211231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r260",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r206"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r20"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities (Note 4)",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r152",
      "r153",
      "r154",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r122",
      "r148",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r45",
      "r70",
      "r72",
      "r75",
      "r80",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r172",
      "r176",
      "r185",
      "r204",
      "r206",
      "r225",
      "r233"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r18",
      "r44"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r193"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "(Decrease) increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r87",
      "r228",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r47",
      "r48",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r206"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "(September 30, 2021 - 75,918,465)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r46",
      "r162",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r53",
      "r60",
      "r62",
      "r69",
      "r81",
      "r109",
      "r110",
      "r152",
      "r153",
      "r154",
      "r163",
      "r164",
      "r182",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r241",
      "r242",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r70",
      "r71",
      "r73",
      "r74",
      "r76",
      "r224",
      "r229",
      "r232",
      "r239"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r25",
      "r227",
      "r237"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in non-cash working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r45",
      "r80",
      "r185",
      "r206",
      "r226",
      "r235"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r45",
      "r80",
      "r97",
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r173",
      "r176",
      "r177",
      "r185",
      "r204",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r41",
      "r43"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r26",
      "r27",
      "r30",
      "r32",
      "r43",
      "r45",
      "r52",
      "r56",
      "r57",
      "r58",
      "r59",
      "r61",
      "r62",
      "r66",
      "r70",
      "r71",
      "r73",
      "r74",
      "r76",
      "r80",
      "r97",
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r183",
      "r185",
      "r230",
      "r238"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r50",
      "r51",
      "r54",
      "r55",
      "r63",
      "r64",
      "r65",
      "r78",
      "r79",
      "r82",
      "r83",
      "r111",
      "r112",
      "r113",
      "r114",
      "r155",
      "r165",
      "r166",
      "r167",
      "r181",
      "r186",
      "r187",
      "r188",
      "r200",
      "r209",
      "r210",
      "r211",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r20"
     ],
     "calculation": {
      "http://anavex.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r16",
      "r17"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceed from offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r151"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r26",
      "r27",
      "r30",
      "r38",
      "r45",
      "r52",
      "r61",
      "r62",
      "r70",
      "r71",
      "r73",
      "r74",
      "r76",
      "r80",
      "r97",
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r171",
      "r174",
      "r175",
      "r178",
      "r179",
      "r183",
      "r185",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r115",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r115",
      "r201",
      "r203",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r159",
      "r207",
      "r248"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r110",
      "r156",
      "r206",
      "r234",
      "r243",
      "r247"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r47",
      "r48",
      "r49",
      "r53",
      "r60",
      "r62",
      "r81",
      "r152",
      "r153",
      "r154",
      "r163",
      "r164",
      "r182",
      "r240",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r122",
      "r147",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r123",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r125",
      "r134",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r127",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r142",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance ending, shares",
        "periodStartLabel": "Balance beginning, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r24",
      "r28",
      "r29",
      "r30",
      "r47",
      "r48",
      "r49",
      "r53",
      "r60",
      "r62",
      "r69",
      "r81",
      "r109",
      "r110",
      "r152",
      "r153",
      "r154",
      "r163",
      "r164",
      "r182",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r240",
      "r241",
      "r242",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r69",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Share issued for aggregate, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of shares issue costs, shares",
        "verboseLabel": "Additional common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Purchase shares ,shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r109",
      "r110",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued under 2019 purchase agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of share issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Remaining stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r45",
      "r77",
      "r80",
      "r185",
      "r206"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r249": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r251": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r252": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r253": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r254": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r255": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r256": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r257": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r260": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r261": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r262": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r263": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r264": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r265": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r266": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r267": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r268": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001731122-22-000196-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-22-000196-xbrl.zip
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M_KMN]P%1O:/I@_9-8]0%@L-HW8Z+/FG.$)UBT:5#FQFW,V:9D+JV[QQB/^;
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M!:06*:^W+/Q[/#RV^[J:%93J%E0BI7DV5+3J 9<X=]>RXE+;@DN^&GZ%2^V
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M?\V[+-G<D3.[/.5T#C,^8>9(+4RFP[V-@NY"%9S@.3?9'!':M?%<4H)MSEC
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MK=8%-^P<N7];,6]M'6NI.S%GW SE.::7-91:%NP3 3BVA[!FZ;$V7E 7VSL
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MRSXR9Q"F\XD;= 7Q'.'E.<*>QX%$]\M84/RKPR-M/B6QFNG'>H;^;=:Z\A7
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MN7] ]QK.T+W#FE-T@<"WFTJJ;YS95:>UK!B3O)"]X#G[PSI?^N3_4$L#!!0
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MB?OGB0CC(P*2]1*E*^I\&:(!VUF2M.1 <44#3K]4J>3]L^7ND<0Q=WC!2?_
MHA)VS1@]X#9GNI*@6*.%I^6-T$"%"BSJG#]QJYV93I8%KLG[)% 'MHE#E3!8
M&K416C))J"&NYY%-M7#J/3SJ2+IFD 9JFSLM,5"L46/3\D6*(R$/@RCG26A%
MDTK.#TE:,-44*80 $J2)K(\>Y_S Q2\Y+J(LP+'$<\%^4T7E,<BZ)HD6;ILH
M'4%09-&ATQ)&*I2\$2K>2?,?!%,[RM0D_1"F U5-ETH,(%G:V/JHPN6]$47&
MPZPAU\\^>E%GA[D]8*MS78T<"++T@%,'+&V2Q>-L)..3\;?"/J\5?B5J$5?\
MT($K>='^#H(/&E"=FS4R,!R70U+06^N7IPI)SF]S:XO4%G/+ C7()A.:,H#8
MH 2F8<1&5ERN]\:*4S9*41Q?)B%Y_G?RHBU;1\XM+S0PF\1H"0%BAAJ9AAJ%
M,!+2B(E[(\<-C9:8OMQ%0<^TT15T2P\=T"8_VE* "**!IF%((8WN+D]]SRKW
M^/DR9(2-YI'T ^]ABE;>+6%Z8#=YHQ$&1!\S0@V+F!)J:ODF$[]<0%=IS5WB
M-%VSP?#E- WU%DN/EEMB616A22^C"B"2V>#44*VA>B!]6E#*WRT6"2">@C?6
MS<*05596_,]5E) C;1TH9=TRS "WR2N%(" VZ=%I.%1('I1_(*Z#KA-(Q#D>
M4-QC_\0YMB7.,6CB'&]#G/NO*2#B?!A0W _^B?/!EC@?0!/GPU;$88WO?<PY
MY8]7T/OTJ\KA6ROIA39=J$K2;,3@4::#K8\P7(';-US%-U6$L75-;VCZ%"6!
MWHS6B7LAC0:TDCDM67CT40/LXU!E))=ZOHE4&.N]G:44\S/:-$&JAQHI X\H
M36"]@XR4]DV+FS3+<?Q_HY5QD:X6]D(1)6 E41J2\.BB@M='&JF#F)*O17=!
M6WX HKRNUOKN[LJQ M;FRG'M(P@BJ!!UKQS+W14IY*.I.5<IP9J1H?G964,K
M0%7M7/L&HYF[@#JM+/HWD_'5H7D$F/CF,4WTS@5=$6</SVG 52_/M;Z#:'4-
MJ,X+0*GP6>-R'G?NGW.29.JAO/;-V4S?AE--[.4'$"W<1M.-R%I\]]"BO](H
M9[F?ILOE.BE.AE0^B!HY5RUMA%FVNE((! -,R-IL*&114]@#->[2. JB/$H6
M/['%*8VPJF0J(5>DT ,L&=&5 $$'+:PV%S:"J)3T0(0;2C@9"6L,<>&0\"C4
MXDU<1=E,PJZ(T0^X)(A>$@11>N%U'G"AY#"H:2"I(E\P]D^=RRQ;$SJ(0 H5
M3S32@M>0J2,/D5(ZD+W$DHJ^^75'@C6;+U^.CA_NHSQ6+3R[(L[F)PVX:G9J
M?0?!#PVH-A_$-Y3.T='QVX=O4*GE@0*?TWN*0_ZN^\OR(8TUD;"44JZ(8(!8
M<D$A H(.>EQM1GQ.42&*I*RO2%D-P(HBM;Z[(H$25MG\C8\@&EZ%J#,(--K;
MX_!__AP\\G=,-)<=U&*NIP$5R/944)<!00,#L,YBI1!%I:RORPZ;*6S1;Q0L
MO!D%BQZC8 '1*%C8&@4+KT9!F;4,4\+&J.N'.%I@3=!$H[1K8A@@MSFB$ 5%
M%ST^[=A1J:"-CH]HFR+LVF4R3^E28+A@?RA*JI%S%F_3!+,*N*D2 L$3$[).
MR$T9"*\FC+BT#VZLPR@GH01T$24X"2(<5Z$;5;OG_2K.&&,)OB)/CSP,'MF!
M[%!*JI4Q%BO%31A.']ONTHGC5Q+'_YZD7Y,[@K,T(:'<;U&=+IGEW7K=],!N
M.MYHA$%0R@:AQOV&*QU^X5JH5"MVR[RQZ9<T7B<YIN(..U6-4!HYM^S1P&RR
MIB4$B"UJ9!J65,)(2ON[%"ZC5U2&%Q_\E&%HS.*.KX@;0;=NBBME ?'&"%!W
M;[R(.;*QEZ66Q^N<.>%O741/Y SGN,"G+;-.W/4%3A/H]LU-E2P@&AD!:N]J
M5CH\7 TN>>4U; T]9>;7(C5XG[>DW >OZ4#LQJ^I1 !11(7+$,6&HE+6&Q_N
MECB.3]99E)!,/RFUI-SR00FQR8>&"" ^J'!I^"!$42GKC0_G2T(7;+K[D:9?
M\\<BAJRV?!IIM_PP0F[R1"D*B"\F?!K>E"I(ZI1A?_T1Z'D3 %U&@-275B'J
MF#I:L"W>=.0@D48'KL.8F 1\/^9SFJ/[%/V<$90_\A<=<^YD$M8CU\MT?+Z2
M$@3\PH6TUI,04Q6-3,+.7TS1 NZ\F]*1!$&F7GCZ-U0J#52J>&#.->,RK:_Q
M!)#+G"RU-RGZ55RQR!9\R:4^>1",L@39>7.;JS47WD(1<4W?497J ?GU9E]#
MR+&UK #8,I9K$B!XHH6E,Y7K[QOXB^>W?HBCX").L7X7IB'C.(I?%UXK@-]&
M ! +NJAT8?N$(!*2WCAP@I,O=+W*@Y<;F@:$<&^MK!JY^O;H++7=\F90D9J,
MLE(%Q+4A>#4LW"2!:FD<U&8OWQM^W!F=1YA+@R]WCYA5XO4ZS_B,RL#I=\R-
M2HZ/(BP*T#J0,&@ HI\%3-WAA-!$0O4 2654T_:X;LLVT0E)>/)R2^:$\CL-
M]^0Y/V&9?3&L/"QT7:_JK(O37N3U*H(@XE"TNB5@ANH)H ?N9U8D@7[CB2"1
MRKCOM,]Q]B#*N<X.%QBO!#O?D3C/RE\$20_?'QU^.!)$+7[^O?(_N9Y73BDW
MJ=SZ*-^4;]76,%47--VF,)RE0_2\DW0+L!W7QU*5.\YN?)!*;?1;J0^%G;,L
M(WG6P\.VD$O&J0'6N=64 ,,B):R.UYH0 L6%PH:THD1'UCTS-'"[!&D) N.)
M&IWN<1H,B3:G.'N<)2'_G_-_K*,G'/-)>I:?8DI?F('X"X[7[6L; W5=TFI0
M<>HTLU($0[LA:#LT9$J(6?\HX'^0C3H01G+[<$GN\3-A*^R ,'0/G8M#/;(N
M&6>$6V>84A ,HTSHV@QBLHPOW%&)TRC'SXA6*E!8=$/)"D?A^?.*)!EA?46<
M%32&:TU-6&FZ9-B HM3Y9J$&AGWV6!71$+@F(E(U$Y1,Q;E0 '&^E64R6A,^
M##&]Y>64(WF:X_BJU][277KDVK":^RK"#U',EH\D8ZP6VW"/:1P2FO%Y.W_I
M,=3MU5U29FBAZJ2RU04S- T$W D6N%$70U-62^"?_O(OQT?__#=A@XU\-W<4
MQMHM)DT*GEAIL:S42T-DWK %9DT1"*D*OY_L!K]P(]%L@.F$G<Z*1L"-65(I
M"89$1GB=#:U"&*VD-!SVT#4)N_U!7V:=O&,.F6&W:*06AL0D(T(%F;@\BFLS
MX-O/:4[0QV^ $.N,'SU1$LK%KYE4&EF7A#+"K9-)*0B&2"9TG6/#0A8MQ)N]
MD5 !PA[K\<CW0&0W GD>>GJ7?M8#CUP&QN",(.Z+$>7B$)SOW:;"#YHD 4.H
MV^8U:3C=5N^'WMA,UXN#&87Z,7;?=:@TQ%*NH8,.D9C;_@J$;(.W&J!L+@S;
M3MB##83!6P9WT+<(;F@Q*PNDIA-"I:3CO7,=U-9>>5L,#'_TV-K$.7I_\/Z]
M^'^T*I7DAM,!6]%1],1UT?]\_^W[]T=H12C*N#\@$%+5?!R-9\X=,=?SH ID
M>_*KRX AD@98FT5O[U@E$'YU!GUX?X!X<[')[9^_._AT]"\''__Z'93%VRP,
MA5L6CF]PQ!83IW@5,<.O5DK=0M9"T>D^@75!&AL&O5I@B&<-M;.%4"DB?LAW
M&"4HD+I .'A+<APE)#S'-.'N_+,@6"_7,7=M92M7_F"$IDIL%%URT+X@=0[V
M:X'AH#54Q396*8A"*0F$?%W#TMH"]6W2VYGRL/8?M/C4^P_[=-"G/-C<\CP4
MUE'T-D?0L&AGB;9W$VP_3I^;BQUY7VFVSA]3&OU!VH$=;)7\+3AU!="O/=L:
M8"90*Y@*[ZSF,C23-]!PI0B2=S>87E-Q&R04*Z4;0D6!K:I&K^R/AWT%TO-1
MIPF4ESUP>_E9;9, X67GYF?O8&C4\+178C,,&L3!<*T?H^K,($V@CWZU<@T<
M^JPT/;%NR*!GH0:1A0.'NR8;P8]U(E2W]3A72GL=XYJ0C>.;%(7(*@4^JW$M
M$AI0V:2/9F&GXI57FD@6-O)P&=8?Q4))LW2B\!6[7EFKKH_WG+1KI=U?6]-"
M[EY<ZXB"X949G^+R&I/>/"P"[U;_]8I0S#U+BNM0?1?\#?(N&=4+N\XIK3 8
M5O4A[,0B+.6KJVA Z/0C21BR>):$LW 9)1$O!;^\691+4_Q>+9?4LBQ"G6 ]
M*F!H9H>S3;9"2^SIXH8>$-+=DHRP&N67U,_($XG3%1]KS93KT7%['&H!OWD2
M:E  0S8;E&VJE3J":^%&"PC1.L.T[7#N>7*TFA3=$.>3)$Y"%GP?X;[O0$J'
M4GT"E4*=%C^G285-VH3E[7.SM66AYY)8UL6H$ZU7"<R(98M4'1E:7A=!;TOJ
M[>RZAI^>8T&HH^."3OP7S;A:A<F0P%LE'*+H@E##"\(99:_EG5*#H=K.A)QF
M13P44/>3Q(M2),L;_>8ST6]+Z,3=[DN803<W)M2RWJEF";"[-2'%V^/6-P<H
M(5 ,KHN4DFB1R"M8P8MX"80_6Y8F/^(HN4JS[(3,F<P]?M;4RJ 47')OBZ+5
MZ3A '0Q#AV-ND[9(@9EWP2/[G: %4X1$6*T),=3D &+8#3+H8/FR]<'4+"%J
MMAPD8LD2\#YRP5I.W@9<LY(5"Z0T*?I.+;3:^3,S6E,:1@FF+_R1DHQ5"2-#
MSNHO%I4B9P#C3O=$.;H_?9BTZKHG&)-D!ZN#35_0=A=EU@R*67[H022,5C1]
MBC(>+9G]LS1D<IX1D%Y;W!VO:J 8@4Y(0N;:ZQI]2D[/AJT*T#@=-FKXV&0R
M<=@*K>94C\>B+(SF@S+^'Q#>L8ZRZ9VZ^;$IX]3<4,%KF!AU 5BCG@J:=IP2
MD6_3Y8J21T83OFCG/P,A27D[J?3C.L%9%/"]BBA>LV[3LS5IK>V26 .+5*><
MI2J8Q=0PO"J&<@*#NYG=4ZSM*@,4";<@W[Z03D,V(24W,J4<$*[]2J+%(^\K
M3\Q@71#YA./UO.,OUC,2#D_&)1NW+62=GD/3 ,/7+8&W"5PF@[!,!R4B(?YR
M"U@W05/1:R6W&U^W30P*T?L+;$MW?4I.2<^0/:09,1FJ.Y5B7X;PRK/RWO!P
M0UO(RS-8][JG&IH28(9.)2S](U:_"3$H7JT5KJLH(6*?J:^4-4$O].@ 55*D
MDH)'DS8T U6XJ'@U.S/R9=)JWS)(Q+'3BF>+LR@-6<W1W#32&W!VQG&RB!)N
MPJ,'S#X$Y #4K2S;RS.>;\Q879/Q>S?&ECJ6=V-.)%O00\F?\H(,%.+P+B O
MD9VM*<-W(\HO[BE^)E_%%_T<8*7K/(B-;7$Z0U:?(J#)PQYM9SZI7P-$ZX0-
M?NCX_=$GM&(('W%&$%Y00@!Y#YM*>U. OIX;W^P9E@04QNH*9TO<MOY>\%<#
MNA,4HF3K/@RGLL_MQE5=&@#(:BZ>!5O5"4"GJQ%U#U_1P3B\U?@Z;Z)@2Y"J
M8*TF06>^S$:@E>^R4LH[/7JAZ6.3CS1J6;:^_*\-^E+26_LWH6H)(/\+DP$-
M;+T4&&L]H*%"/4H$&X*R-4[R^_3\F= @XF.6&-JN5\+K2#M(;)&(,P)M7<"*
M6X-3@$&[;6&;UP.K(B64IX@4:8GC&IX:2F5R +BJ']*V204D6S5#X? D]H^O
MQB%T"\*.96TY6-"*.W%;+)L*/0"K@6XQ;->K0LD[6X<BM=E@N<,Q^VE6;JP(
M!_GJ%%R(BEW"(,W /(IK7/1LP=*&(@":*@IBO5+="Z)VH>[,U$)6\A3:3G;A
M5T5"9F-SYV+A2F_:OE<(.S\,T0+NG(AT).'PSP1/R3GTP*6%AV\I#H1%-S2=
M1[G!^[LNX#94<!M8,QQP^14,*SJ0=,[>^W:4_<'#>>1Y8KR-84#9KO5S<5HY
MX!0;WG&P#U^"O@;0@M0="!,A!FT.+7U-KN>G.'N\B-.O?7'MS"I>7((,X)7.
M00IY,*.H!4B]PQ SV[@2$EKP0BBR"8##N^&7$4,2GKS\G/'WAJO01;,@CY[D
M4[**.Y)]$8!&2MSQ]:X1*Z1U+VR$E,'TBE&+T]FBYUUF+KK,FENI45*+CX6K
ME#W-F0.O +J=*RV\J]7PMK$-G;YB^/_6F7Q4F-^[9@017ICWZ2WA31;%I%&L
M^]22G3UCV/39NGU!T4TE-M]?G#9/,".BHX)VWWZLLN4;\+3,3.P:B9N\[%?^
M-T?4'D[94/R]SY7'+GLOX,;5'IS*YZL/P6[#,*92PL"=$?F_-6X6[Y+VAV^W
M3L!Q3)6!!6N%2+'4!C,P#8;<,<=$P*J,CQM)FAR*@>1K2K]P:ZQX9[;<S<C8
M "3? &6CCN4@XY74M0@O;)PFT9/A,I:UME\Z&XMDYK)2%5K@DV&P%1%0BB"4
M_$H@#X1"*Q4HQFZWA#>4\)>=S1'9^M7\$E-="#,CFSKPJ:C$JWA.CPM5H9X%
M%67XMB(8#\+"DQ4L'V=!D*Z9R7F#7P8-F!T]OXS4%,-,R982-#/4%K#B 6\A
MA592##+WZ)KUR\V;O4-JHJ/JG8&:PO22L*4'V-[4@E5PD O6WV,&0D/[_<Z=
M-TRA[GCOMJL-+A3:,-RJ[5'5CHKU!K5_[EY$"5NR373*,SAQ )S?LD(L^L/
ME,$,Y:,6QW#*LRHR0 \O:%XF#J\CL7H(" E%T-C+PF/T>EY[KU'OB-.GY]B1
MR:X8+?\FLQ(8TMHB[>P,E#[ Z9QOR(H'-2&YAC#S76SS7\^K_G?*O4!UU: 5
M=\JU'M -BFEDH:WZ>W"J_2UK;KM0^%3K)_6K'^6%$%U$-0L]7Z.9L1BZT4RI
M!'(T,R'M[C%)/<1K:[J+9,Y-U)TM%:BFYF[FY%XLK_2XM<NK/;$,>6GY_W/7
MWR<<\]GAEC#K-PK87,(_S)*P^4--4EX6:6^;G#\'\9I[J)X7+\;<LGGI?#XG
MVJ68:Q!.H_E[J>#&ZP!.$8"9?[P4NST<O"U5O^%/98B_^)Z+&"%$H'K^!]GD
MBT)Q"POECP1)[W%/7BY%!;6J9<9&1TI?&,+.??A!BC!C^@V#KMP54+7IP2:"
M&[=B7G.S KS?,@SX@$8E_.C3ICE=7L)8KU:Q<.#'<>GS?YG,4[H4&UM]]S%L
MM9U>S1A6I(;_G9TJF!EK&-[.:KVFO;F[@6H)3!4RB!O,. HO4BKNC[#>=L74
MXY^B)%JNES4?EU:Y!VN["RTTN$B;<$/6JMYYMQU>Y1 IO$+X@V 93T.,F)Q"
M,5K*9" ^%'9-%SB)_A!=XS1-LC2.0MG1DO"&U3'O2?R?U6X9CJO[47V'2R.E
M[?0%^S&KH_'J_1@)>^\L4Y2F\ZAY+>T#U$A==*EZ^MSVJ') FRS@W=7;J<;.
MHBR(TVQ-R3UYSD]B_5G5^-GL3>\S5-)H'5&1Q^OHD_J"M;OG&<D"&JW*WG>R
MSJ*$%"_.\<<Z,OYK/3\@';!PD..G/=(AGE7+.:4I/4TI)8&-L\2P))Q>#=NB
M<(UK7@/TP1!^"] :KTF^*5%>D^ \%JF@6C+PYI//Y.L&_ U-$_9G4,RO;*$O
M"U,YCPH99GU&;'&4]<TAXR3M]IAFO,IH'N#LGBZ8[C)B8=K=B%_;2')4ZTW-
M]"=:<V\F+1&D2Z[2-&.XC8*SE;45\&HQ;93V3B]KB!T[7]R8D*(3$:0&IM^$
MMM)P1A$[Z!5'S.)0+CG80YV2+.,Y=(E;9VSP%([O..ZS'XT:CMVZ^J"W/+MT
MXMZ''WN,'1>;0D-8?*4./$.O=?VG>QF#E5CTCMI/FWY5/#/?9_*-G8F'M<_(
M%:18'8V4 Y3!>-+2.;@:U&L4RD!^U_,YX=X$NL'95LF#<=A3 (6!J-'P/DH/
M@MF)N"BD424^$7&:H(Q6HE;4&4EZP%;4T,A!&8,L,$[-AK%<"*MW2<1J6MRG
M61"V?JX/ECWVX< TG#KP;5.\ANO,D 2\CU>[H-:_6"--S48J:),,/-.SAMS^
M!*I/R1-K+4^'S!H0>6F_AC82$0CE#)N4-VD<!2_ROSML86N2 ;)=;2RDY=:T
M,@TPU-T2N'K+.7Y!LS!=\8A5DVT^C^65&#R2<!WS9PX[*RSQA'T?IX<DX-0W
M<7#!&NZ)UMI@&#P8<L=)L4B GY27"^,K<#$S-L44JW]U?,3B*M#+0 9OD:(?
M2F]==#7'!R<'D/3;EL'4"XH+CERM>-*I>DS[*Z84<Y,EW3P.,-7[>5491?'*
M%V=_+1#47B<PTGW'M-R]I;=C<3<OZFV9D'=RCX'>1&L'5!Y]L*_?4KY-X_@B
MI0QW.'" MTS%SZ ^J(CJ@=PJ">_\W@VWB=DU!A<WTBN6P[J:WNK=G2FK7B%;
M&C/;)^R)_CM6A*9';)DJQ$ZR6U&T_>9ZCD321=CP(A )FO%985&\%B@S.$!E
M#N"ZT?ER%:<OA-P1^A0%1&,(Q@*,\#;F ?072?0'">5]8A%LQ;YWC9Z?GTXW
M4;6I^^+(F0'LHM.4T#3C+4A"*([%SBD.^8TNOEDO0E$W @%SSW=6/?+";$B>
M2)RN1#<OI<#UZ$WE%2/2C)L$[>?/98UFV7HI?]MZDMPE$]\3YNX5U#=Y;I\#
MP%XZ8K%,7?,KB1:/? \8/[$NNB \_':9F+B/.<<1E0\UBLT&S'JGM%(1YH"
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M.(@!#_&4C^7_D&9D2B>:46IC/^?UJS3+N G-K!>2!!')[GEQ-?6L$W;9%\V
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M,S1E5XNZ))$);)U#*CDP%#* :S.H+H/P,ETG4)SCV?B[3!/A97R*5Q'K"_(
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M2P(2/>D"F5NJ NIG0Q$K+!6AA]Z6*7S#3U;J!@G:) .F16\H6>$H-*Q:^G1
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ML,[I>LLP.D!%3JAQ^,O7^R*W^L]HDU]U/(Q^XWDBD:GK0WK%90[]8*"1 \
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M].53CWDJ?JXZB=RX[#@RE6"1SABM_W3%_F(_ES^Q_W!<[)?_#U!+ P04
M" #1@TE4LVU)?SDC   K:0( %0   &%V>&PM,C R,3$R,S%?<')E+GAM;.U=
M;7/;.)+^?E7W'W39JJNY#XYC.YG=9&=N2[;EC&L<RVLI,[?W)463D,P+16I
M2K;GUQ\ DA+? #8I0@W)FJJ);0DOW4\WWAK=C9_^\3SS>DM"0S?P?WYS\O;=
MFQ[Q[<!Q_>G/;[Z.COJCB^OK-[TPLGS'\@*?_/S&#][\X[___=]Z[+^?_N/H
MJ'?E$L_YU+L,[*-K?Q+\O7=KS<BGWF?B$VI% ?U[[S?+6_!/@BO7([1W$<SF
M'HD(^R+N^%/OP]N3$ZMW= 1H]S?B.P']>G^]:O<QBN;AI^/CIZ>GMWZPM)X"
M^CU\:P<S6(.CR(H6X:JU=\_ODO_BZC]YKO_]$__GP0I)C^'EAY^>0_?G-[S?
MI-NGL[<!G1Z?OGMW<OP_7VY&]B.964>NSW&SR9NT%F^EJM[)QX\?C\6W:=%2
MR><'ZJ5]G!VGY*Q:9M^ZBO(92D+W4RC(NPEL*Q)BK^VF)RW!_SI*BQWQCXY.
M3H_.3MX^A\Z;%'R!( T\<D\F/?Z326_5J^5;2_+,Q77,OSJ^")@Z,CI%I4=*
M)C^_L9;/'FO[].3D-&[Y+[E"T<N<J67H<JUZTSMNU>NU'Q'JSBX"WR%^2!SV
M2QAXKF-%Q#FW/([=Z)&0**RCK'%#6Z7^SJ+$CQY)Y-J6UQDKE:WJYHL/6S)C
M_8;#R7#.IQJFRQN)1]WBUO@93BX>+7]*PFM_% 7V]\? <]@\.?ACX48OG? '
MZF&;\KNPPL<K+WCJ3'RE!KO@YI*$-G7G7"N&D_-%Z/HD#/L^&PNAR_J\HR1D
MO0NMJ>.C15-=<'!/;-9LW[:#A1^Q)?Z.!C[[U8YAJR,:5KL+.H=L,J'7;!\R
M(W5$513M@@+&)5T0Y\:U'ES/C5Q2BXZ\1A?TQ&-S.)DP]?>GM<1(BG=!"=N]
MS=Q(B)PI+!N 7!78GA$ $:"J?BV_8_,%A-AFK>C1N;'UX+71O'P]S5*'$0EN
M8,LS]26)+-<+;RW*U_ME[7S30=,=SY!-.0!4U:/-26_-U;E04<-\VA1#8'7-
M(P\(*+R%[=![LCG!)]NE^'1SBD^W2_'9YA2?;9?B]YM3_'Z[%'_8G.(/VZ48
M/+^U:$K%P3RS*MZP#W)5R'-$V''.21OBO,"L0Y$;\:*)N>ZD=\1M>PM.-?LU
M+IF0D1+B!7:N;X_;P(*"N2FU)PI+5TCLM]-@>>P0]YA#],=[_NM1_*O BOWY
M3736?P@C:ME1VIIG/1!/]/&-E2D4.=X292DB8]9J-6'Y$D6ZLJ+K4[L74(=0
MAGG:ED7MG,#*)L*DQ/%<6(F.[$?76\EZ0H.9#*$$C4!":!8LUL7V$.TS&AQ.
MQY5G3:LA+10!8GJ" 6HE-YBH9C;8->#F2@(Q/D7%N((W!*C3<71/IBZGF9.S
M,IZIYPA)%2#X9YBSAI);1"GT?7]A>?=D'M :\/,E@9B_Q\2\BC=$J/^YL&A$
MJ/<"0;M4& CX!TS )1PB8CZFEA^Z'",(Z.720-1_1-V02'A$A'WT2#R/7[1;
M/DC;J\H#H?\K)O1R/@T!?[#DZSY;;N#X9ZH 1? W4T10XA91"G>$N@&_%:0
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M%A=@5#9I8^?.D\T!0A]XBNV#:@1^:+31-6(LOKX=[UH=A1&C.A%"XK_ZTGP
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M^U#/]4,]U_F5I>JI[BS2FOJ$ZN<.76EM 36I2IH6@'ZVHC47@'[6,@#][!"
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M*K]&_G?)-_P?/D^S3_X?4$L#!!0    ( -&#250>/<)'[?,  !+)!P -
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M$BR+%S<(*PC*&4.;2FL4V_ IP60N9_NHEC4DIIL+S+4Q"9'0\'&;91Y9F-/
MX]5OYPT-YK%L$/IX>M&F,4^L^7,TD]T1C/BQ1"::(<%JKUY/@&JJYY1YL7)M
ML3G^-AP5+DNUUD5&]5BT1J<#>&8.6^>,>Q#@Z#)K'B(="O!?,<C%@#+%L!72
M5L&I/>"<'ZQ_#\ZO:@<<EB:E0[A58PMY7BQD^6*QX#*T"]^T:;XJ1??W7-H%
M*1&@)2-*C;3,H6R.N"*MG21M(G2>6I'1R5Z(88!+GSC6&\,ZPHD<D^,3RY';
ME'WNKZ(DA&>+3A4+#!F3FMK^I;J+_,1A)<8C[L)X(B9%Y"<.4Y$8,JX,7*(:
ML,;=-_&;O])="/+F=)W@9>>)+/ 8D1_7.FZ43RZJ6".J<GW5J%XUZAQ3;QO;
MC9.#*/_!T_3!U'H'410.ZE"@&#WBAH,!GJE89"'> $<+PWX8'6H;"*[^[P$F
MYLA<ST0!_+]R$^R;@^.;\FV#.^> J<ZORE>5\_(%!Y+Z^O:RC,6ZP(SZ-/^)
M?S[*_FC4FO]$!+,<NR,;C,]L^3_+$\?EOLU@TS?;VT+I5.XO%AH_MTF?$S^P
MQ<X\4LS]=WIG #4F[$Y+:E^B $)NQSVQ&1IYD@+A"S!_+$0$*!S\]478*Q[0
ME%221ZHINF0.CB]E'?0>YF!ZQO:I:K6'M,P:S9PHZ[(VLE1FTWD1EXH!MI[M
M/G-+K*%FTT>N!X3= <7TS7CTG;]TL;0A6J5(@4P4!;('Q]\P-*7:,LW50V3"
M!YK[.])",[ M@<7)+3"RW33N6]5Z8!A>;UF93>V$%+&;C<)N#B^JZ+8)6H%B
M]L8TVD1!9,;"7/Q_XN/X5<J:!*9<%L#U3+&\:XJ=T\0O402/K/&Y>OM2ME;F
M98VMF+MIJ\RGS5DGA8/C"](%G4;% \U9CJ^[DD% P#;9F$A.!O8UA;=8CI+>
MQ8-CU')<36[;AKD$2;9$X[V(25<Z.+[3S<E5_KJLL6A=]<^01MHG-X90(]Y9
MM)BFP_E)F6R9W%88%0D;:Z* %>$[,K5T[P9X)8+HJF'Z</JV\)>*42:*X'2H
M.@'.[!!@2)^%NT.>B[Q<%/) ,5_3(\ISG9T3@*.U8SH/;_D/7 3BP-6M/O?4
MEFHG;?LO@=:MT.5;;OVO:?J+X%'7S\^NRHV[VVI]LY3.OR#6O.RZ9$+Y82'T
M-([7PN>)<\B6^?O.T_[R [4X/+DAOIR:H65H2F+3S$W"P#0&YZS).4Z?/5#:
MWPM$.5X.Y/GB8O-(DSRD.3$"/\[\QQ(OC;($Y:PGJ=S^>A&RBQX1EW7YD3QS
M%VH'S/.VBM+%XBJ&.?B0V%'Q4O#X;^]O=&YZ#5KMTU,.;+BMX$]4;]"+3I-C
M$*^+M[5A"%^$14+ZH;W]1;^[T^6AH@+=WZ=89#+]]L@Q;*KL_,2E[!LRM,JF
MW%+;LT96-M+&>N/6U39LM0VKH"F>FH9QD1K8WSN1-1FYH]XC)&D-L!"XLL7)
M-N<7R?M[*)-I7+=.!K;SN9"@J.8DL?@AGX,WA'#&F0(T^R$_8>>5TL'<O-V,
M(#5%46R.'W]8)XTO/S__?I ..&O8!]A&])&CB3(&:Y@[OVI4;\\O,=OMM'I5
MKY[B3_7KB_-3L/-.N9/R!5A^5:[^N5IMU#F?D%\A!2VR_$$@.VUA+02W7N9L
M_<GO/=4F(1=/'<Q1CO#^B+,[[E ,B)6HR%)$? ,;2T^_[!$F6\KYTOKCQ97B
M3Y,4C!*%42AEA*1A7!BC9%1=@7CS-E8H00,:](G@FIC7$G*:&PBB90XB7UUL
M"&Y^]H!PBWUU.SX=Q(3H$%JT=PWT+*J_&Q-]3!N\,E 3)?#KV6@!YV.>2 R9
M8IY9-XU23U+B1:ZA==B5Y<'A8=FRP*XIM_ >7-MNJB?-\9^GST_GXZ>'>X,<
M+*_'S&[KG21D>2E3Y*5<[OURQ(K"V12M&-3):)#MTF=I:*YI^A=GZ.\4@9NP
M@2 "(XS.;BH_S$)OE,^OP BK&C2^Q803WP&6DW=,L 83^(5 1;9Z95W!OS"'
MY%'6,-Q5MBNR:>+];!H< *:0SIM]N3+N&(/F^'=%+#ZHM[VKQB:EA$3YQ,VD
MFJX(-8=G8&G4:VKC#V2RR*@<LO_&UXU3"6IA;\Z">7#\GXBI16GQ"&[V2^@-
M18>L1[&H&GI1,?2Z;>1%1<%W3?&N?GIP+.9$7LSF^4PN%W)),7S1<;$6O@$\
MJL4FT9+TV"CRA=(A.C&K(E_B1:' %[)+(7\5$2+Y1 @VN.V3AOQ,K%OP'&#!
MX/I/B8R!]'QGDHN&7BZFK4^D)?0)@([5^9S4?%M^YDQO!3/R84FAL 9/)R$"
M0JF2QI;/\9D"\%TNLY#G5L!(6LHT.=RMM6-+O)C)\\6,N!!WJVS2$]\FO3')
M0%:5ZO, 0YT@GFBB6< $G-JRE\6[.]7X*=9ZVH:TO+CD[G76Q!&V*);SRIH@
MMT,-Q43\X61\X'G\NN;0L5@\!C^D(2PRA0)?S L+V3T>A>*C-&2\]<B;%"TW
M2+BU)%6F(/(E,;L:X5817N493Q5=TP8(*-L14)WZEQ-R]4WZ5?N=IDTA?<@M
MZ:4V#!NK5L42/73T9(0/ U0QAJ"L5G5$UA\X%A,S@J;C@( ^+8$#DB\NS:M1
MM%A=S- 1UR9E,G1+EDCK.2IYD<^+>3Y;6EX3.$2*+U(V',9,^V3N[PM757V:
MX$*56ZI&;^. ZJ,%F'JP0XEIL1M0@6CV=<:J?+L]L5H_,YL)8L:0'.$,XEL6
M-6(MW\*<F_LT<F6/MI%LVP7-XL"W#]OAT>_>6)<Z_<>Q7BIL_!ADN4"X;RG;
M2(OM@B:<,T2_H<DJC5HW\@A=_AG'F%P]-L?EN^Z%V,C?U)Y3/QM9QAMV8><&
M#/A-A*]F[)!$C,-0(J1A+&;Y?";+%TJ+PR_IAZYF4)DNWM:RWP!GF1)?**83
MMLH&-Z0Y),JLQ)[:DU*M/NQ^5:3S7^K&CZ1B;T]<":?Y5/V[*\,F7/;])K9J
M>I'F2!JE$VW.Y@1>R"YV'%Y-M'E9_*VU=7/@>,'V+2R.Y*P;<3XE'0++4%@P
M/7S;YJX[N>_]NWR]L8JA%5N5+AM8=D'GNJQ"-%W!+H@\P[FA)$Y%46<SL4Y)
M=F'C)$BUGFVP#JE6D3FEN9X="APG:(P2AYYNM8;-L::8G\]J[<]==14C?M73
MK>6CR-JL@[<30!Y7;\;F$ 4^)Q7Y?%[:":"5!=!FS!L@5:%4Y#/%?-H":&-)
MD;M8<H+!'L&?^FCT^ZI-K_=BNI9!.\P0O0T<BG' \^;XD9SG'L_;5[UL>UOC
M@),UT,!Q8!7<(4<=S/PVTF>[H%D<&IQWUD"#QOV*\+5X\OCTZ\LJS)):RG1]
M=Y20"%=LY_:7!RI:B:Q+QS:B<+N@V9P"ER(5>'EH]PQ3'1/E:!M1M%W0A,OE
M6C"QD7FV5- YUQ5 =S\5A;IYU1&_2MT-ZNY,)-E#6H1&K('U^YFPB=-B"_N#
M#A3%:Z[EO<0YW9*<WCVR]^+LI,4E)\4KM<M/NBA_;<ZT";AOX<V34@!J&4<E
M'"CP5@2!_@GQ5N:V>.(&TX08R";WB-S/_6>:ZE(DU6]D\]JD%^L5NG-NB$EA
MB\MRWJ2SK%9=<=+%+.>?= FJ1DV;.,N!(WJS"MLM">#J[.<'4/@@"&'!N@7<
M1TRV\Q/5&1&R-SS8X.]Q=FB1]J'Z?-A3%9"Y1QQPH*0^MTQ-$(J9@^/#0,OB
M#2O"5!:57751FS. XFO"\I1/'FBLMU -5@(= V/H0&F9Z6:DT>+IYM\-BY[P
MA53?\A"MK_<D877%%^P0.4?K38=ZG$4NJ?(JX=/-LE5NE>D6L%=L31=CPA=4
M<ZM#]_9T7)C4WQ+_[!7$1I:ZVXE-9A5V)VS2OG3G<V^1C1!]RC$M7<5Y2IM1
M>AG[@#8@#K$-(G3&;._@)>;R,=_2NIBM;%LL@T5-CI, "9L<YW*\&-KD.)YE
M0$?:QHVU7="$A]8*X3O BZOUY7IU?/%CU!Q?:+\SLJ%GM&^]ESD<FQ(9[V:K
M(G*',_W!3^(*DGB6?Y0@J2TE2.A<X]Z?/JF<B^>G?S(O)%'6M^P3ERCK@U3(
M\26QR&?S844QYDJ45YZ7.[U]TTB-H>)Z<:[%J\G%C8FSM7)4D"&EQ?G+JTCO
M0'DOA;5PE;4;657.=>>LT+?"H#S_7?ZLC$M9\6MC0[?E8N;->\O@\-X[?,VU
MV4I>]^Y<3)Y4ZB_DLGPA%^_NQJO9M"NC<KV*"-DBGY&*O)!=?--\E;U<\>WE
M6V++JDZ4JFSJV,"RW&X/^T,-PRBGI*.V53NXE[_]^%']7FCH96E3%=J6S6[U
MK0"03)?P5^:WOIO/VHL)GXR4L "F?P\.IWE<$M!P BY(-?=^QLYZ35FO:1%P
M2=D404"Q5.!SQ1Q?S"=6NN5]7/=Q-F.NJ3;.O13\ONU*J^>3FZMS;:P_78II
MWP):/@%_\57\OTI>S>?V69*GDH^/!2;S!;X@K)CEO4O(7X96:]:D%/@BN-^B
ML,':4;DE*H8PF60[UX)NZX.KL6I_OSC=D-W$:O0L<ZXQ<R\H9L60*"S_G16H
M%K'%KC95/%HD0]%-D>^55*U*JMWK9/C5NP/Y00[MSS7;G0M[>! .RU'T![*.
M)8_I/12+LXVHGGMN+Z;4>N\E@0K?8''ZK>7^JM9JN;^NM=I&=E<DB<*;J>WO
M)=)-;66PYO=4>Q&0)H*$,SK<]8"8,FV"N+_'+LSU!R;I :Q8!?S"L-82-RL#
M63-,SNX1^&."Z.S#A#V+(X!#):H''/P@<$EWK^3$0N%#,7X'.#&78 NX4E,4
M,\UQ_^SL<RXW/O^F=M9I 3?I^,M=U[CKF^HM[9C\ZIK!)1IAG[1,J[&V;H(@
MOH+^;J<(H^ "*Z0![-J-WJ*]UK#N3 E%C5Z\C5AR<$4 (<3U\QW!KG>=RMC!
MQE;YRK,@W]W^LFK9=!S[6>[R /+JTV]C%M!V0;,XJ'Q&=$"K!DY?6>FKNHHT
MQ@8>#M7Q+C:-,&=/!LWQ9RLK]&X'7[NC7(*!Y7DMB Z.'0"ICI8#($ZCX@WU
M&UI E: W7C.-/@NF"(>":!L)G&KS0C[/EW*+#ZG>:L^A50@@, *PG]:*:_'9
M@L#G8^0!K=EU*!\X$K>(;+:QT](I>22:,4##,%0,?+^SQ;-L]6S44U*-ZBX*
M7+L@4]F@3(#>'22%')O.H6[:XJ2(O,QG,Z7=Z=+*ITO+$S Q<53@2U*.SXDK
MDF\5P23-,T2;ZE6CJ:CTD GE4=^JC$M?KIKCR]N1^7A>_O6]EF0AZ5GXV8F1
M$6F/;FL"W8+4BAE$IRT71)$O2!D^$R/^OUS>2UHF>"((3&Q?E@!S>5XL+&Y.
M&"OI)$E%OL4NT79!LUC\71FZ)VE8L5&W597?'[_13Y_/I'NE>Y)D[Z80)YQV
M@V,%?+EWKN!+?>.]54*+3=(>6D"5*/O;:ZC)2._9X5_,1G/<_CV^T"JRT-)7
MR3!?*0@397(C2SB=/\.K.V^;+@R7Y/+CLQ9A:DU1(G6;&2MO9MY 5?8U49J@
M4RWE06.*BYWJ53:R_Z(K/;,CEAV0UE?$#F[>/]G<,'-JMJY_)-G!=Q9V%YII
MH?V>YW0RXRJ_CFTZZ2L;CNFT-V>6+XFO:FLN,%R7PN,:.S(JJ9K/Y18[ETMF
M3OOKP=4,$\B@LSK)[5'#E'6+S7(FJSH>4I_0C(F&_!S<I-JC=JUH]>O[5>+=
MR06Z'/C!T6SW9+U+N"Z ';I_=Z&NHR6(G;:<R.7X3'YQ'^]=U"LM6B9F/60R
M$O:VVEP$3(CC C;5!HV"H:Q"F46C8(-L[H?ZTQ*SMRG<_EBT,"<TYO,2=V(J
MG+4CB9JZ9U$0>4'82:75I=)RI$O0@\D+ I^)T5TO,2DD!MP:7"G*7%P8*XP_
MA%DF&8!,%K/G0"(3J_ILFS)@7]5E<W1ND[X%J$,4F8:F4>0QN].58RB_4(X9
M9;LY/AUF?M6&U9ZNIM0T=!8A8/)R&BR08PFTW, T'E4+&0!^=1TH&U>V[7[3
M0H,_-5HF+[ZBO :!+^8D/A-:V>@5GAYLFB;)^W$%OE#*\87B*KWPDCB02#75
M\^\+3@?JR+(60Q[O.0KOA.BD@\42KNB!K.6(;N/DEV ;?_[4*JN<1B3G-Y][
M$ML]H^6Y-EO)7VF1+I! \XF<METJE?A2<?F;8+NR""N2+C&[-%?BI1CE;U8O
MA[!3!"^K" *Q"&)/#!77;J="_^2ZUS6>!^IE/:73R-AW0#TS'@\IVX$+21J]
MD#2?,=_J!>X%(B1 V8U:\44)RT^D>H5[H>S?\MO;:],N#6N_F,OQ0F@9R%B$
MV\G^K8)F<05$M^:26V3^1+;4-A[IJ]K0)DH@(>G7+Z$^KFN6F4M8&U#ICFR^
MN8+R;Y6VY?BTI<>BX_+OTJ_+[+W9;ZQ2!B_NT8(C'MR/<35A-_#9*BF<+!N)
M0;K3[J$:8@%]$];WM')PJ-[P-9$0ES].VZG\M0BZJA$0CYS+=_-.U1#8I2>G
MI3?\-=^_TUT(RA\(@[5+AEA:X;HS4XX\8!R0NOY+^/VL5(V'!/3(L0L#)S,@
M.)U"@>4I9BN\;R.:MPN:<**78A+=1_-0&T+Z^D?//)2O[G]W-AHF2-.<2$&)
M+!$X7+/TUVK$3,-@"&TU4"KPA<S*]=U634[8D34ILV&&J'G8O:4<+V:73T'9
M57W[^ZJ^Y?^JJF_YO[;JVP;VV&JUWUS MK("W/[>I(87F+L5FAYN<:K.U4,*
MV%:= K;;6Y"-"]1C2Z8&6VE2@BVARFKYIBAFFV.CKY8__[D9VR<DD<IJ6%BM
M\KE\=5:MPSOP^77EZ^?KB]/J[?_) \/Z5.>JW^[.&S]?6\FU*74>MP'9]GI(
MZT+C>54G)TU?>7^'9=@NQ4**AHZ:N_RL6I/'?%U8+NFV:8X?\G^N&_K%%W*5
MV=J:<R?2TBN-:$/CKOK<&K>?I*ZM:+WM775IZ55/-[APESM06X7.8Z=3+_S>
MWN6"?__MY.>I+'_6[K^WMJZFX*+>%:$U.4.ET?(I1%X)/U%<JX:?T\&0"H $
MH)E(C.3K+J8\=^SH\.IMU.(S1.RE+L;HM@PUD;_;!MF."S8WU UK$I@,1TV:
M-6TW'[R@>EBOPFL]T*SYQ<"XD4T6M7EQ2"KAO2TW#L=I[)Y\Z<)!+VCN).=N
MJ,B3ODR&-=&FY<&]8N8+^M#5F^/GZ_&@J)Y)W^KJQON7.W&+3.Z_X;QV(FNR
MWB8\=]VV#0PU.9&FZ>WHC".M4X@VPCDJ%?W55F<;EP,*P] >UW^<&R"XR%P9
M]U)9T\AOKQ.Z@Q*N1;JJCIZFVP[]8&J5I57JYR[5CMR%O3D#>GJ-RD/I'HN@
MZ;%*$GA?JG/3VHA?M1?WWX[ON:&M3310?B$"1!7ICL#]@A2X%9$?'F';:&O8
MN4B:25Q\"ZR_B7Z7:U9#STZ*,3(5<FY90Z+<#$UK*.MVPZ@^$[.M6N2Z0]=^
M/:"WLJF?TQSW?G:?^VKCUZF50F[T(CL;EQAN^;"5<"I="C=PUH(Y!,19#4V3
MP_5P!EM0LD'A4K&V&E[9L^D91=_+)\:O\V+AO*-Y1M$*V.+X*;,I]D:BE1&7
MQ\B\S*M)WE5*-I68*?!BC#I(+Y7OF!"FZ9[>$*)G15YF\5VXOQ"_Z=A,A0R?
MR2\V6%\,W^C2N]\?6J1]J#X?]E0%9/P1!^)54I];IB:(10D'+4JB!*/B.]NS
M@@UQ3")];X ;LJ5U=]_BIDMT86S=IT,3]/L-,55#H6ND%;:;X_SWSS](Z^''
M]V*ZMZF3LBQ@<F)R=5F#C\I=DU"E3&N_>6GX]%$:<V@;EIVXF1$#P4Y4@F(X
M-;OB"RG^++2-NE01(^R*&+ARGF68FHG,K&:KS\7'BUH5I1)X3HN=UNT280MP
M.]G,+V5'E%:IJ?L6,9J*Y2#Q8K;$YX7%M]ZVWG8HO2[;(1$V2:1B$66!@K"X
M]LTJ!D-N^KC@1+:(@IJ(Z!8M"-<<7QF7DOITT:F6M0T&'<(, 1@><Y/;/O#2
MY@Z/9[>$66-NMU+VE6ZW4![<!E&<X4M"D2\4UMV'6\ ;^;^%-Y)I4YH,W1??
M<KXQC8YJTY)7X_/,:?FZ=7DY/$^I]7',;*1HS\RM?[5ZLDG<M,R$B]Q%2/2U
MP'A-1?YBBXF%%ML.94&428*P0UF\4]6)K%M2MZ=UKKIZA;CY)2;_8NIM2PF_
M^#5 )^EII172TZK-\=<?%_>MJ]Y9;YQDOZT97<UN[4<[2UXFVLRMQT6XBE&2
M8-4B"),@ZNG\'+5J>F%39?CY_'>EG#4&I9D<-4*GGPF#IE$V(6[B6IKAT$*>
M%W,Y7HQ1V?Z5E+U(J"160@DI*<5;*=D6MQ?<D6QMDJ431<AE^4*NQ!=6J&7]
MMFF85!K>1LQ%2<"47W"N,PF2\;77$DR2@"NGM63S:"/R!2$E&9E6M< 5P^*;
MB<NM<H]Z!\T.FE6@"??'\M0G$#R?0(AW72A3S_TJ=3L/Y<LD.]8ON4<C[@4)
M2>>F+'"KZJ$H3,2MDJ[^**?WM:]%K;C$U9^4W"8AU?L^>8D7LN VE3:>23*C
MI=-2P4DA<$8Y4]QM/.WTQ?"6B@,A%O-\,2>"$['QG) XB$S&BI_&9%I!7W#$
M\H4"F&.KY.:NVLIOT_RX<N()(B;/Y_+K9GB%GWS68J:J7I$G^HW55&\R<_3;
MN)U1[--;8C1*K5>4S IJN(1W0-H]V2*<["9J)FJ912PQU(D[?$$+<BDXXY[)
MB<7)=%N5[/#Z3?5M)KLDKD7V<)E5C2FS;IS]?-TI6Q:QIT17+&$WKIV>_3#R
M/Q^[[52/DNAQ4J3KXB[$,=V3]EB*<;/I5T;HS(NI^4"G@MHX$6\^RZ.,YP--
MH6_U6WRQ4NRGUQJOS'9*?E*&SV3SO/0F$^Y?"-$AJ6F XQU^I_&;CM]5X+.Y
M(B_$.'O;\OQ/2<J]TOS/Q%EF'6;(BWQV[7L9X69&9G*7'66%:J-&8H*5U0&(
MH?TB].;XI_+CZ_?K\N=V=I6N.*MZ2=$6QF2!*=D8U6AD.I?_ 9OST9V:S5"Z
MLO./V<S/*['CV0PS"%D];DKOOX8O^D5M@UR>SV>W^$I3?&1&7QC>@/K?8E44
M$09,#(<)J?B(N.!*B%TU')BX>L]L[RW]N"O(K+>"R,H[2]R-5YN#@3 0MK?*
MSLO?A<\L?Q<^%2WZ-#J]':J_2Z5AY[7?A=^4!A;YG)CEB]+?=7E[ SH9$;NX
M$N3?@=14_/ B(+C "]ML/L;5<G_5C?C$?&]D /B32Z> 3HS[\*M;!LFG_^UN
MQ2^UY;+95[KEXM]\WK X+F5*?"9&C_6MYXRW?R<^,0F<#,T7.VF^^_ ;\,9V
M]]__DIO)L47"[O[[LBC+[>Z_)W.#.EJ+IY0*6>"+N1POQ.ABL+O^OC3QMI8Z
MX7<M:BO<M:@VQ^;/WL7U1;Y0^]/=D&^T\C5X81':-G(-OACG&GPJ$=/L^.?7
MK*H_54?J]E^#3S<2FL_SI;S$EV+$$_ZN^[@)I:"G%&>E9%OL@NQ(MC;)TJEK
M*F;X M!0%!;G!_Y=-$SJ LUFJB;E"WPN(_%2:7G+9'<-/@8!5]U?> M>$/A"
M(26MYAF.'VT9\  _[^_],W"'[!AHA*$-QC74/K&X*_+$W1I]6>?9!SQ7)Z;:
M^<3U9;.KP@S"9/C!RH/Y079[0K()#FUC )-XO[IKA6GKA'#E-L;.97T$>."N
M#!LFL0VN8J U:1%E?P]^I,X"]I3ESG%DM<_55!T,)E76.,\2LS8._@MAS9OP
M?PX/ 1%$4XZX&[D+&Z)._@P)V)%'7.$3Z\YZQ&6YPT-WCRKJX_SM-7',_%#D
MD2>GX,BC% @N^=!2Q^1H3H_0P,I"QJ1^@W]5[GH^<8W1 (8NFW)+;7_BKF!7
MLS5?&;B\@O^EC^Y;^ WBZI^/L.XP%)A$?CAL$=CE,-J 8G#)97M;R"\3IV;T
M@X8@,WJ\+3:-)&;KN*S+C^29NU [A*NW522,A9O:''QP 6L=KP-<#$#"&^6Z
MLL23-9Q?U.SO320+)JI49*O'U33C:2TYLS*P-</D[!Z!/R8(3;#C[9Z%[B("
M.E-HC@./SG&U7P#4=W>Z/ 2[E2COUY\?YN'$0@F##LC=8?,Q-IKB<JH:X1%-
M<W0L5=3XNS60V^[O;CP@(V2:HB@UQ_KEY\<?5ZI\+F.&]K /0(SH(T<31<,=
M<N=7C>KM^257N;XZK5[5JZ?X4_WZXORTW(!?Z@WXZ[)ZU:ASUS6N4JY_YFH7
MU]_KG \U!\MCQ)'9;4/3Y($%,LO]R6N/*PK"?P]6+Y&36O9<DJ=U7JRL=-(,
M*54X;EP6VK>UG'5'<O-2R%[BSN4$=*$9$EX:%SIJ[9?4R%<T)6G0F=&82"/P
M\,.Z^(W YX9+J2'Q1'"A"!,@(ASE*S1+GQDZ7)S$J=2Y/: *L\'DM0G\%CN]
MAY]X2[XH\!6Q4<??F,:C"FKU9'0')L&Y?CT@IFP#?LK@PCVJMDHL,!/@@R%\
MYGP)9D.Y9=GHY375D^;X1&M)AC0HG7^7MK0: K5F.FC-<$.T?%2=,]R%<K*W
MTO13F5[[-?S%F13 5^<Z^+B$)5. Q._+E?%)H]H<_VA?797,7M=6-Y/J[E@)
MN7Q(_]SE$BV<D8K_C2\&@V^*86\NTU!:E!:/$"^L%R#0-M;47A9E4>VEBVDT
M]J9T2 /I+WF2&Z=[=_C.]Y\KEI7?0XM>MK*N#+T-(O<</ BK8=P26&];U4@
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MX0L2-C=8Y7[=7+=DODJY,<E 5I7J,RK/D!W_:%Y<7-^>5\^N-Y5=NNSF=U;
M$;8$B\H  R]$<NVA:>*IC4R+\&R[(%B:2X.T2[TAL@163T*F8_I%.Y)'9?)!
MB6R6+ZW=QWWQ?=K9U6+BS1 \\AMYY.KYB2-8N"I>".;O^WPNLTTZWH69&S"@
MW]QNGB+*!J.1R(:+[_6_SHT=!ZN)Z7!)*O#%4CJ>H;!H1YM#HERH<DO5:*0P
MN*G!P_IZ\>LL.[A=Q7!?M:_QDOL;5\!IDR4D>A2;S/'K.A>>TI,;4Z3?G.@
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M:9[N2]6RG<06QE6HD8>F27.S_<\RI:[.H2]L)JIAP+RR9'-$>;XCJR8W\(E
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ML,P#*LYYV7(G97%.PO;W0H["Z,F(*'[BWCFER:((.@];#^.[[P/A*G/245+
MUCP2IFR:7'H1$;"/-!6,)\>1H@:R4UG?:=X"9K33O65@6*KCW[NV;:>#_BX+
MNO4Q[A%FED]W@7%B%$Y4@XP,Q^S6 51.E-PVV'('9!4+R(&(PK@  Y!>T)P7
MOXV(,+AE?Q1FM ZP'H9%PS34XO8;\6!E4JO?L&QMQ'M^@:WV*4)H%X*AC88E
M?=]S*6P3)K7P*&:H.RZ#TPZ=!F!@]CXKNL$-!XA'&K#R>QP]&3!"&V*A3T"
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M NDV8X_7@F+I"7WM'::.WV</WS]Q3FF/%F8)8%N,R KW,,0!;0$P7>P9.+Y
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MGT3/S+3=',G>FC+HCP_5P_/]\[V/@Q_3]-;,WD^SCITN,ZPFY2D/Z)/)J&.
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M[#B <> %_> *%O0&KOD);$#Q7:-A.8X(%!/]X;^!MAKRWRK0NQ\#-EC4NL!
M_UZYJNRUNO?.+O!%V(6S&- 27AF'=M!PO" $QMY&LNC:?8K<$ FA70.+!O5L
MP]%N'5I]TW8"H_+RP2'I;8R.OS+,L.^]-D36I0'49?8"ZY4A_WIMB/G7>SAP
M7/R2XO+\TQ?+*(R(B]2]-[O7]U^N]K]?M5LGOR[::@>:=M!SS,$K \@4;BQ/
M$1E)Y]T1?&M,Q;:)ZN3EED<\%E[.0U;#F9:)A)%R_A,+=!IP()8_?[4<T"$>
MYO]>E!]4"BF7@=)N%1916$Y3LI 'U9T_TI)M;T<R6G*+I%SY8WPZ45Q63'U:
M6@=G+1LS-DIHG[A@85F74B__+61](NTM7KSF-FNQUQ;/D*GPF!5WY?5AJX)1
MMEQR"TI_/"#W/;\AG9+-GNIEY[</B[F=W6)NMS09[&(LE:3+B471WUXV]OXS
M_0U[',NFOTJIE-LK36YDGYKZEE1(>C'"BLD:^N6!KNV\HE:^'AS_8?1R&1#Z
M:@C7*5YO?M(N@8K?S14JJX,CM/\X<O.W(*;1DG(IQ%0M[N0J^_/"VBX?34><
MY(A@:89 U(>+"*VN(!TN/?2Z=$CQXT5$<U?P))<:[7V0E)BV@K-P?=\ZKE2<
MVZM/QU_ME:G@7&9>J>:*T#:&PLQ>S_?NX+CZEC,83E?H5>5313_//)=KV:AX
M(R!:UK_'".B9U__'ZD>Q42WC&US;)\P.6J_+?:-^%I[>U]O>653FHG*\(L0_
M>_9C*>\SKCDE Y=X+U?<'86NS8DHV]W<&)D M ,*96*SG]'WC+I%:4,?4QP>
M:%M*240(%GW+[QHRKQ*"0Q'E:$'[MCM&R\:%8BZV^ABY6-@!ZXXR-#K/E\KE
MZWNK4>\W3GNM#X/./#P_83VX$CH(N8RA9?V?[6WCV+:<YBOCW&Q;K^$)OT+,
MLL-"=E\;5%SYRJ@8V]M2)37M&^U50'R='E?>MD_?A6'5G- F$<4(1:2^[_5>
M&3L80!4?R!_L8$ RMF?[U_<?3AJ]VD';^K83V[+M &B<]RTM^!A_6"'E805Z
MF+83<@]>&]A \LJH^6;=;KPVSH!=>9_./-R1XJ[^JS_ES_ KWGG8J_1MJU[?
M_]IOM]\6O<"]C>KVZ[YE E]8P(;PH!X=R+1;)6ZA2$,/Z2;6HB\:WX87/(Y,
M$M1KVCUG=_?'U^\[C052K[[Z:1=W<'U_M&.W;NYNKP9^=3YU^M\ZJ";SQKHS
M_L8JQ<N&C:<;& >>WP-Q4I^"O7KQ,[_]^?.X^?W+CZ\?Y^S5  D/5X*$Y!RM
MVT1+B=)PQ&!H5!DG2/UV%T[:-=V&#7)0.9O!;"O?N;[?OPDK1\7RQ\IY>[Z5
M#Q7)S+:4O>O[VOM^]^I-<'_R?DYS:>NS:X9-&_;J9>HBQBSC\/J^ZUST:O\<
M_=BI[*X8#^S"X@[?_CA^5^G[OW[.3VC&#NI8ML1T([B)JIGT]BM1<65C8G-L
M;EA: 5104'QM;/&WX:@S&,=-'XO?:OW@_.;L<$Y&'[?)TR7J9WZZC,D6M+PU
M*ZAA]?3:$%&$.JI1+!X8&8& 6[R@O&8R^%LIY7>I-VY4<+B2+_#W^C&S>L6_
M,6OMHQWXE_5RBAD/D04RZ7:7FBFHV[$&UEJFDXGV='2W8J[6W,;=3H$V*I4=
MQ8<VBENX^79Q#R],',ZD%Y;$)MXB Z,4+I7_-TJ0)%9.Q@%68<:;?RQ3V=";
M&U0XR8U"#^BX0\9'[YPL>EA"EU22*"JBOB,L>Z NI#"0=V8S\;+1\1RL0!(+
MP2)-O*+K-2U'N%7B1EQN1&TRR28#,PC"+KL#2ZQ&6F)-4GICE>[JH?'.,>5H
M+ZZ05>8I1#I.+43*8C%@'IT'?W>\#[OV51;%1]4G67Q4N[[__&OOO7]8?7^I
M>19CBH_&L0[5(8X4$EQ<_5QS]%QS]%QS-+KFZ,(.?FZW4&?:N##0A@98S0LI
M.!I;2C*R0"(18LT$'%1UYFKB'C?B&/;A1&S#!>S"=;.7WBKF=,]W]VX;GP\.
MS2C$FKZ3"^M2GO8E%M&R+B*LVR4MQ'H.^N_%7\5\>7=4='6FTH\_5I8$,QG:
M,RL))I-@]][A&]LNM6YV.N7U),&Y&N!'$V AOU/*D@"75'8D402'>HZWN,]N
MT2;#0IJXT^A#P25:?K<XNAG7_>;<OX<[[QY%?9B3]FAEF_(G[@/UWA=&=%JN
MBE6YD,FOTY/(D 0\W/U4>>/U?WC>;J8D,EXP/1:!5//54=WYJUXJ5'/=$#[
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M=&2[+:S_)P)ZII]G^HF)'ZYIHDI \L-\ZU=H^U%U*O5I('BTR^D1T&'P7Z:
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M(U=,DW#B9,'CR5MYG6V)?[#:09XZ28U&7^=R)0]T=N^BK2(B:GA6,BJ*S^^
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MT=6M%U5CCUTN5JY0XDZ\,*^$*3FQ6D%SW&# T^-A+7: !@0-AM>Z_WRK'7$
M?!YI)M&E] %^#<O.T>/."*?>@?O"^[RUL.F/#:D#TS6;)J]IW%M('HRVCHTT
MU'N>WT.-!V\IHX0I(93TX(=8\L0G*VLA;YRS$<DA\C0KDNK%A=FHF8QD@8[4
MR-*&S$FCH*GDP4A/Q*C10U@>7,(A64H6'/!SD.EKA[7+;?@WJ,W:X<'E=NWP
M;]YY:1H>RBC*A4E"3][C,NPB*[SQ[BQ6$0UU4WWQQM;!X<7VY9N7=(B2AR+E
MP"0N8SWO0S@+K!_(@1AM6);J>:M4"Y(!])^(N!.8$]42Z'<\9$R@P=:>@5*
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M$%YCOV_!DK;>71P=D/V*ZTIN 5M&RN'(&Y=A/2"?M,\-TO$-PXOE/G#5@#I
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MZ#'<_8,;@PB['HK%+MK%ROX@3]VZ:V")EHQLVR[A&> _*:A/,#KC=DO *$0
M7/3LZ.6PCA9;:M $IS' OET/.2%.^Z8(4X5.>62$MA.TSJEW J0L&7T!-U]%
M7(27#Y/(N@N4J=+<.T\KS;WSG.9>%OD-&6*1:T8FV?2@Z+$896 ,93JY.C_6
M*6BY]X.N+.J[@Q^)0<%ZH6 L@D^&.AA4+5$<A[X5)@,$A )&!PC.6&_^&^J3
M3.T?G="]M.9"9NB4/7>""G4X60 :,,4(G0$I'U/R0GW!7;L#[!E7SGW*K96?
MJNJI<;T@_ EJ1R>PB8_62M>9%(5=!A*Q#<>,ZJ,QP#O)>=\?_Y:FOISTS1VL
M\>O900U]T%(4[M=^?WZ0O$$L/8^"TZ?J#?^&K'6.NA+9L14M2R(HIF\Y/9X.
M@)3.#;>4T,</X5'4T8TETL(@H(1"9!\@Y=M!$ )[P2Z#=;;F)*S//-Y+SKT8
M(N_)D^0B&%K=RD;W9HPS)0X:?*IH%CS\@^<@4%^#O*FT8G0P)0W&V/=N<<8C
MBJ*PRX^K@TG=AD,+N]PMS@8DAI55 6#=:PIX+)[NAQ0A"H2H"D*W_X?V9)AY
M-"S)B>'1]-*20'5JB[0MC\50*UEODOMO?1R$Y/KC>TS"!-6:36(Y3T$N)O@.
MH"NU*BP%%&'<V.8PT*[6_HO4$H<--1W'0^1"8LBFR'7(T)QRL%2UAN5V3,H9
MQ,JJQ)U% H2EX.@J/A&0F(B-BH4$VSUD;#%K):I"2_96Z*.A4==$J9BHFI\@
MY?#&R,+.0)A'= UL'()V,$*'*+P8PA\=?J$(D30&.@HN[2C446-VT%%76(2=
MD;"C>F$=JR/=V@/[, (BG;3KRL 0$ZJX]B2J5\2F7L9[23WA"'B"* ,,?K/=
MQD #/GM;63<J&MC&K"FEU26 >D1BQG@*RXC2UUQ4UH9P>H&N[P@HOREKT#B;
M.QY"D%5SFVI'%'9N+'[()0EJ8K86KE1C$J753]4?B >4I/6(U*F <71YJ)!T
M5'HXHK778!PW+!?N^;8SMMO4F*'9E/A@*M3G9@SU><T)Z7"L!SB>=!)A0LN(
M,HFB+U&&Q!3,H[2]M[@"5OJ(# 6/F?B&*<8INPIR5%D_DL[ A,-4$6H_',9-
M3D5^<^,D#25#B9P@1'""8(3P&M,<&%\IZA'-^\4PG72-]19_=EIF</03S@CQ
M%J$\)4J2QZ.KCH@(2+#$)84$DG! R8@ V^%/+"0P 0&_A0CXJCXW E"3F6E>
MX)2@L^,&F#/H]BRI\UR$QS\\6US+ID_&MS8DO#4W6XR!W)X&*G5H&P2VIM1K
MTO0:@Y.=BHX])=I]#%?:& DK#;R7ABNMHQ-D"#*=D\C>.,L'LY:M$*LIF[#7
MOEVG:G,J+.8II?^U_U+E"9>B<.<C/)I:RTD2%E^/FGF N$EKSI+/B+RK@,A;
M<\T;ZT[JCV L+&]N2EQ>9'_2HL^XO$.YK=VGE=O:?<YM94Y^XT)UQ>U*=J&Z
M1XS*X7MP-$IU$+1QGG"?&@8TB%O&1L,N --)%/0D6Q YC(,:W<Y;^9RTT /*
M4%@BNT&5P)%A[ F 4;"?7TI0?M&4*&,9-)8+%(F'W81=:FX :RMTPFXN"16*
M<9HACT*,EC:[%. AGYQ,>VZOP(@+&W4I&'53M>3B5I)#=,/^SW![9,/$2BUK
MNTQX<L(GX8EYX$K@(?RT!LJ?B !/MX1NZPJH4[E/W'/(S8J\JT+4JQ*5,! (
M4!CP5_%^+%J1'2;4WP_[$97T@W,5A=JX:U%T2XGI1:Q3"#*6BS#T*)3;'(Y;
M<4:*>G/X8,?$>-?<V,HF\<VD])SX7M53'J,7"CL[OVT*!U\.6P*[]IVEV/Q/
M_N_2Y@9C5,=&LT557*JM3#?+67.86"E/%'-C!PV+<09M=V0L'Y=!#G[4F('E
MTEHH2F^K'?N,)%2QR@N -RG+AND!0-:!&@ D42T;Q)ZVC [_",$K5@E?[;D(
M\TP]];+?F%S,J6%<Z7WC4#94."GJ$2E6Z#5L%+:<T8"O.@A=*KC5)'E!6*6W
M5'L1JSY$(>!02]>-0K+VJ*( WAW7*4,'\&MPJ+D/N9DWCF17 9Z$;_9$AL>W
MNB:%YW4+@<@ CJB#C8.XC>"@1SL5.Y&<MKL._7<'+%\_P&,1L_.X\Y1K1*E^
MX8=(H: 2T?)%5+S8)B<11%N#,\RB=8MNSG,&YSD5,$%"WQU["(0]3T$FN>&,
MGQ8[3\S*@^S,;VZPTYQPWY#ZDN6J<&3HL= [#_1\F3C=-D6-T??&=GSB/!/W
M<*RO2B\E=J5EWGB<F131+^'<\_KK9K^/2<4X++!$:_N-Y7MYU_B-!3R\79K\
MCF>*L$E"X3<"M6+> O.G#8SM^#(/;1H((B &0I@(0&RW.WW*-, MZ7J)62?&
MI:'\H0(4A0^#ST\!B(%EN*;KP;U-7W)5&FJ,?H-2 F$F\)IVV"5<!9=^W\=L
MMA^[J7 %)-2S'NF2H1HT:D4M#[V*\I"P-X.J;B+E1SO3D1/>XI4' >$XL.;Y
MB8.,>4@%;ZFP[F7VB 4Z[A;S^I]"1&]N\'4JJ=[W$A4V<,CDD' ]D"@80H:V
MN]W018&$F4P22(A5+4L9+NDSO(W1"^MR:H(H-<!3E:7:@2UGQW$I$+D-8G8%
M%>TA7F/\X9P<I6D0:@\T+X>J%TP.&//OZ#N<$9,R"02-5UG_P*X7!H-C UVT
MFV#++%;?VPP\@E#RVL@-K:7^3XV*Y-LT2-4DUJU\MH03*1P?[*E13P??"CPQ
M%X-VG@_WE,7RO"&H>[FF@04V?B-I-4<]@LD)*U032;8Z'B?.#:3TM3#;106_
M4/%4Y<>3,LB-L/JF0!78"F#;3#EZ)49^HGD7%25.!!%M?DADHB@B652&=8IN
MVXY&B22SIUAG<VO4'<Q7W.!JG$"T%4?;%"M'7'.]@C-VHCE#/'J%64<7+50)
M$@N\$,*#&D2DN50YV83M$QZ-ZQGMT*3B !%8(/M/#AV.]W6[\:<*BYF&J-<E
M@ UFCKBO52QCS0_@*QNWMBL@R;CK4U9H,)@).JF-D((VS'O +,I]X=UK"U^"
MDIL^%2PA\;MBI'P7U&-4?T73KSGMX?&,)8SE2(A=;)*)T&^"#A %FHW 3IA_
MT"N6;Q$MB&;/_PIMW](&\E 1 L,OP"-#SL. T2PREF: 2@"G#C7 BK8(0)4X
M]M9&' 0T"W$X!RXN_28(VBR&-.!%;<]<^X:[:+C:%6,TG$2-A[_'F#4@=?)K
M(^"S2/*01HF(FD 0&J(T20#TUGW/A)\@L8.X%P%3.3%-MJ3J[9KYJ QPS2?X
M3)5?VGM:^:6]Y_S2TN9HB7Z.,]'/<<G]' (4/%@B;_7)^T<KK(>FK-O^WXO"
M"S8&>V9#_GOF5=S:S7X'+RW\D2#988(%4NC[\A$@? CZ4:X;?O3B+UQG4UXA
M;[U'1/1GO_G7J"__\Z_]G=W]U\EKTKWED;7>LGH$C'W$5>"\#ORJ2R96-;^+
MN&$.&KNU+I;FFJX 7 I"]$?4Q/+1X#!<\#2\@EH0> T&#1ERX]421):ACO58
M51H9@48BUQ62H>?;C(3D,L!'L3*\WOSFQJD5->4+\$<JS0#STFN: XX.,"X@
M@7<-NN $,5KFZ*WC031@LHKX*UFJ49DT.8HT%P=,%KBY+V?:,UX+@:Q>2;L7
M=CWTVW)H!$^%P&D0Y/Y3BBIM8$$#9P*V4DO?U2*C-BNZE85!+T1HH#>DH$<T
MAB3/Q/1GW\?_A[PS/Z/2?\H[28&OP#;H0YMBB*^,;4G:SUR<EIH;B;PAN7CT
M%;; !FD+G.,(M(.]W7CO'=KIP![<E^5C"C7(1=.@T'ENJN+!P/%N<X2)@? T
M2)X,C:&B:(+/X6X,2!E+F;=D:1 %?-TVEC_J65YN;S<-&==I#*(5$U8!,#C!
M$V'178\*Z_-CML%LM<!0[(NB.\*2*Q:4R.A9'G9=:D!B_4%/XNQW[6;3L;:I
M")] B=#' 8'!/Q(0.B,?+,2-3?APG,S \LR['E=D&O\N%O-5HRX60O*NM \;
MW&AX# *!-<Q8<DT0D3&D.M'/Z1MOWYPH*(EG5EYI5HX/QI+L&_\T:I[\MNW8
M[D\-&C"&]):80,U):K+=11#3%*D5Y)I;<Z"54(B?Q3!@16<0N]4-W^[I#6>X
M)@>83?  U2AS$2#FWYH<![Y!I09K\$/Z+=&KZ"C ;%R$ "I%!*8AD8*I=07?
M.!<35>EI>&XC%?E:;$=@<:628=VP;^I=+S3HC?$%\\8;BWX!Q.%8 :MO4Q^\
MW<$P.F$!X]AEV9I-ED[+HA\AL/8 <X]>I/WE\8AAB7(!>(0JA<F[;A(..!9
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MV],];UHE?H:-+T*+/YRQUIO(CD<KW&ET]FC+#+3U6"1G1G:[M>0LEAM+S9A
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M#GX:QT30<F:T3,@CN9]C?\=)SCA!7*%B3<J9FNOB-EY8^ ((]'*,M%HL;']
MJ2(S $BKE]B^QH, <$>.[A@5&B?^=.V 8ZR>[M)7<H2/D^G\F=D):SQ5@]0%
M#6_4L1 E&RXZIE92E)3O)%#J2/BF[)\^U=MF\Z@8Q[*YC'^_$OT\;%81G7,1
MOC[ B7 MB8PH[(!-2SB*@B 2!@2GZX8XV-"6 (KX1T]"$Y0*A0IY=@)**)*6
MAAAH$;\-M@8[!*788*@FL^[808=R7PZX;O@0(G-1IR%%!'*@6#5.9]I6?RM0
M10V6411Y"K1'-,J"292_W..0I+%P9F3(4Q3+(D3MX109L@J"OI@D9SL#5HA<
M)\7I<)U"8F-'=)NJ(6 ?DJ#,,015PCQVZ-,(S"D^@AI>+&S!4WA:!OY8,][S
MFQL2%2:)%4(.N4OCE'FV!W6\& A7[R%0KXHH\&O+V9P!N/P*4O$645TEC*OM
M-[>QFG^@+!)M6V(@P5L'_W][5]:<.+*LWQWA_Z#H.'.C^Y@V2""6<\YT!(M8
MS+Z#7R8$"! &"6LQRZ^_E5FE!;,T[O'6]CQ,CVU0J2HK*RO7+QO5;][[R4F
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MPF>TJX2!#?R.,P3YF)Q%"E/7K/9\PP3 ]WN$Q,P%X3!V8-<9@?**6GU0@?^
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M&1N_\]):B*=O<?("L+/0*/:O]*"(1(&S(W<)]_PKY).L^YIA])>5\3/='2T
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M&XZ=5 RQH3V 6@8M'$DNZ+F&4]-0L*'I:)]R7^% ,22L1Y\QG*QO- 4Y+6N
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M#QVZ21,F5UVT(+>["6V*2Y%!@/ C!QS+9%UO81\<>""&2 .CTF;2B$JCC+"
M&O?3L.?LNPR:VSM%:/'9; \JLCF2[S^(B('&EH!JAVB@-'0M;_;99^CB)GHY
M'*KA 3 1LH2O0W\XHF0"^!8<XJDJ(]/30^G!'+M0JK!+ODOG&$/3&0) AF^:
M5+>F<'V/N Q0Y\D""4T, "(9*0L->JG++I0K J^ WHQXEA2G]B/LYPFMZ"20
M#>!^[*4))1(!,1YW]@E3<4Q0:1_OV!'A@0A8NWQ <U^\0GVHL/-_>GE!/A:\
M^C+LLS"BZ3Z(S><R(06&<E[E%!"_]+W_R\B=KZ'S$L)_3P%6/Q'6S:E"*)LT
M#*AK6M!(RAMJY&],'$>":#JPS/<!(Y()1"+RW4<EBL2+7P;UP5 X]S+:(%0O
M^9_%VH_(KH/02^2AZJZCC8U==%7W5@QPM-8,G8R'/H?KCR&!8@=@!Y7-P=R!
M]"#JLT0%8^Z4N)"!6:[33GDS]"W;SX%RND1 RAW%-*+Z"6IQ%([MI>7A:W++
M2:NV46@5TLD2ETRGJ^U*JU#)<;5JJ9 N2,UG/C/O^'@X.6D.M+JA+I G@?E&
M5%&%B!GJI1[7NE8<<K.,R/4>/BW\;K.F3!["-,-$!!?D$%!RJ1L>JR(U%7YK
MPJ"T@QK1";&_"#9^(:KPY05 (2SP<UK-;MJ+I=.0#WB:'3^L_F>(9;3D&0>D
M&/MP:-S2@8 #O+L#(1EP75M.8::':T[O*9IM"/J&?S145@8RS3[DO,D2>3!5
M ?004PWA+8:J.,B,#-[P\5J(Z3T@EI_RH.S*(:]T3S6&]H+L@098AT2'IQCC
MCJ  A7^DHN'NJ%]D7NZ</M#Q?N)->4YD.?RY(LOACQ!9_NB,VX*6HU3U&"B*
MAD%"\B@:-M ,TJ=8T*:4JL6 "#PY3)ASZ,"J>N+) ^ECT"FG</:9<V&CR 8+
M5.QD_B/6(P\&_F-$?BG-'4'<_Z2":/"C(:6E2FM']6A4*^3GM%0F'SRW O);
MD:<VQZ"]H< -1O33BFXIG."X$1O*$#N@)CWFKADZ1:)<^-S:%*7)4MP&%06F
MW:0=[09^\I0;KR%"TZ_<(,PRTU14TST.]<_+O/X@*#Z*CD^H>?@/9R^)@C,D
MNT=C,?A5=?3G%_FO4"CRQ4'M+;2D\N5%^)JKMY.$^5O)5J$C<<E*!OY0<G[/
M%)KI4K79;DA-+IFJMEM<.=DH2BVN46@6F]?/C0+\PK1X&>CB7YET1;=\+M%_
MV/B);"P^8N/(-9>N5EJ-:JF)+$SD>%K* ->^A\W^+3F43";C]<IBT6=472XO
M:N S'($U]IFOR"YX<%1L1>XS4#F&*N[T#G!)Y?E]B,)'7K'C1_<;F&"+TJX
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MX6/(*G)X]V(1_QS9O[G$1Q0-<.E:DOR32[Z;(^L>I\L+#^'A18^M]QKP[/N
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MNMTXVIE2+%]V9*>7FV>FA*3[7/%N\KO'K4HNZK$G5IL/"[Z2/=68J?]'A::
M@V<VJ2X3)*9&HFJO92F/7P(JDO@_'<_N/:RHD"MP=L*\W7G;+(*!?II7!!\A
M];H^ P8,Z73"@%MX5R^@<\,PX#NK"0SP08?R?I0$+&" W0L8<$18# .:WL"
M^V*59> +#"T8\$T"'/I"Y1$Q#)B&B%TCYX/W'HAUA&]O4T!])\3.[J8NZ> K
MHU@G# 3Q*.'7Q*;LU\286@X%H.90"P=G9W<OB- 2\*P-6P^[VN@ZX1O9=FS9
M=.KGI>IGC%3FI&&^'ZL3P2OM],S*J'#EZB6BIZ<7/J6)WGVF@XU4=^)49T!A
M:1VC,2'Q)=;GV8H$Q0)PP/E.4U82,)J771!11*=L]"+<(:;!K7/ZD*EA?RN
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MD@/BX6DBLL[.V^NE")D3FF:4;QGA^VZ!ANXRX\8 3O98^PL=%!!^T-S@+Q$
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MG?YWD)4MUX<<19$TX38"#N4Q <1.Q\O>/++EGI*\Z^O+Z/2@[NS-S56'B[B
MJRF3:-78#MFH&5G2>ZA.;[N_L2W F[J2.UZ?9>J8AEH2U!2>@T[J!(J-'SE-
MV]_6I$<D%HTIMMU/Y.+U+!#=F<.P/QFA2>O+%]U :"6O"R"ZRF5?K&S<Y]')
MU/%/*XN,LK"(5U^"H(BKNN(=[/O,J!^/L^NR']!_"CT:V=V=:3%$[\W2!EL_
MMK2Q'>H9YG[RT?3=<N[RG>0JD0W=5,06JI2= Q+I!'&2CP>/XU,DW&B65G<\
M)N7=%YFEPN;LNTX.]9Y&MZ#-&-MR2:L,W>_>?QI[L*D18NF.UQ&[WT&GV:6*
MOAR99%+ D$T7':Q[9+B,:\583G>R 0/Z>B=>B1:WX5Z ,+++VB10;/KO4J<'
M((:ENO)<BMU)?]&U*1*:'+/YGI/#3)-R:?5VIC==N3-=F W3AH(B"+UH>-QF
MK2)2>V4M:EJ)&C"*P'H0RE['^ G2Z6P5E;FC)V\?] 77G3()JBXWH9#5:#8]
ME&P++_+"RXOXB#,V$.-*RES/!$FBI0I^QT>]N 4Y#C*!S4C9AWY&-6-]BA<*
M_3.E'Y;IX[#?17W52\T9Y!W3W^!SU;&9+:_XB&]'\?5CF(578G"*GFO3<7J'
MIV&YKKY5)2&BLGP2RYY<:MU3TM)M_DYA7(1O&JXN$\SPYNBUI9D7#13>7M)3
MY*S?Y?<=L2Q@#ZUUYWQ$[7)0^_PQ V"/2C[^\DQJ4Z%>@1S-YKUA4=\7!Q*?
MI(!O%H@"WR;:JPVW5^L;$Q4)*P9IUE>$23*IA:2[#_&&#M?EL:X$"Y.)*^OD
M,3:%_%B47/G/_9:_H+[8G:8P*+<YD=_9/7C %MI8?W3^@4\4N_+A7K*H OT
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M>WSOPL\DC^S.X:G7570# 7L&># 5*@G>+_!@ILA]WK@VX[UL^<N9-]/?S69
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M4/#,VQ%XMJ?DMQR1KH5"73@=A*UT1L!S]K"YFN*['/_@U:N;3TAK+/<2),$
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M<07N[/D1;N<4&U:2>O5XK-O.05%9IR G[@IC:#T]<#_,=<7R^-[N1\TBBZ?
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MB:IMQ!W-=F >&3/TK,1$=Y+Z'YGQ*0)XB@*@:_]>'17^6!P!?UL;76U\!4B
M 2QB[4UF%>-3:U[^;Z]'D#E0#RMHQ1/G@2G-=Z5O27?>*7C?D1%S.RO4.B"H
M&W 6)&<A(':=L+B\B=_,4>A=Q[5! >[C!P37 2L(-MF>V]0_.XQN1Q/K\FRG
M#O)Q#)B16/-LL&+FJ9(54+JF!N9J5!7(\W+&J,=+W?;GTZB*^9 O/J>2VR=
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M\LH9\A'6TWN3::NUC$]N01/ZW:8?&9Q%B34FU710F74.1 '("^X;%DRV,_V
M R=_=A(73[/1[ BZO8%K^"^<;-DYV0G$89O1J@3A\%B.G^\E[4YIO"73D+[P
M[+X*5..3S[B<.T^B^FKCM(.E73,$7'@^G'/HC#S:P:LK2ZNU%FJ$QO_#-+6
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ME[(WHLM_/I65^W'4"\NG[ZF=4*;QNNZK. #@1UM#;1_,]=!,GR^1 8_0&<F
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M/8C$84M?4Q7[P3T9OG"[VXM1J>932$ E:G>U$IJ!VOY-A2%HPK8N@&>+N4C
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MKWL$C@/<.Q>;X+W)_@W^XA7_V0_G%41G#"=<"4B KT(1$M _F_3OY=%$:Y$
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MXR[%L:,:$<Q:Q-M$SV-^O/U6H14@W$*^+^U1M5B*WW'2;"F,"<V/<XQ['CO
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MD*^ZU,VN6=&?6YP ":$X#3@#@_"T0(1>*\9Q*-D9Y*8;/>%BG!Y^G?S8W='
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MJRC]:H!Z_U)_XQ/:Q+A&7?+$/A:ULBK<%KN"N.'\M)-D_C<PZ?3A1E'R$KR
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M[[Q?C:&#,1B(ZUXF_B1&(7;[PV#P-MV2XRKT_OQ%SZUUX@&6L5:1>+,X L=
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MB6%O4W4Y:G M;\U?BRXQOJ 1W-.$ %P10!U^80.XI^0_URY0_Q.2OS_Z(QM
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MY/KZE1&I1ZX9E]<F.!/ O?A(T=?*(X!;@XE9XST_)Q^.0  WICT0P%,-7@2
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MH(_@=<C-UNH]))^N:W#<!*0=O07_2"SI DT$"10E ^&H::>*'C@HOV@/Z".
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MNOJ&QO:.SJ[NGMZ^_O&)R:GIF=FY^378^L:?S:WMG5WXR>G9^<4EXNKZK[A
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M^O*/ZT'K-&S'#M&KK32^HA7C=*RTZK*I-G@[+QP%N),D1TW<UU.!:ZRLQL;
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M.]/10S&J_03!8X0D- 8>8ZID&OMH3J[7,TJ.CJBY31X7HSTX! 6:,?Q81>(
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M^8ES]JBR7I#TBFSQ*Y;J:"Q[;&&I?TSJ8A(-FO*+R02O$I7:WLA+*!*V^0-
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M/%H/D'FRZ<G)8KISE'?KFEP@TW%8F,4W38.]U,BKF1)C+Z-?&IZ^%@F'JDS
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MB%N#L72KJT&GXG1WAC@Q2WW\R#[SL)4GM\UXJ[%#.4VIJ='I=UOO&XNCG*/
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MK+^A9\?QSIX\A23,L^?-^%VJQ(K1=-WH>OOLY]MEQ"Z\Y^68%0UFOY'L1OF
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MK>++XIH2PMEMMVH9"C=36J92$TER3Q;F;G5#._6?^RE7KCS#A9?LG:*3NGG
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M.'J_H 1CW&@M/!TV7-Y_WX;:JA]LEE@>(4G93Y!640_977-8;);WDE,YY=$
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M!;950'JM1QAH3'$5X[P?]<@OTRE(A/0F.DARZ&!&N[_\^'J8Z+=/QP^D_SU
M;/\>L/I9!*5G!*;$0N %G<L)\:A-W@VZND714$+@\P+>\*^X7M*9V%C,BOKP
M"^A:A/3NPG#<@MYCO/)@/I4QOV>/O?!,%,=0["60<+VT=WTCB?9NLP2O5*7C
MII.#T7\=SUU_P9 GRL^">&@@Z'<KQ\^NCBW0WY>SBD4INZ.=0W%\VO29X,UE
M]3-.X#"P@_VVF1[:P7,F:F\NM!$E"?".\*L9E.+[<<L&IUK8H\!H2:D!/(4\
M7P[&TM$[(IXHD1WM1M0D"IS>"+^#FI12$'@).T]UOO-*T' \,GP*P-ZF#@4,
M9S5 -=9@X55Z?-4XXA\;0J=?>?1QM[3OM<N\$ZX>&/OO$011^=H] &N_A:G>
MP^OEYW3$!J#^XZ,\=QL37\XC2W3*T-E9%!L4J?^'Y;R9VX.)[G'^#S0-]%(2
M4ZJVF;^9DFK-;)\;9YQU]+A[V+CW]D0)9:(YNJ[3,[1;G=>$K";EFJ?I*ZD,
M*YK I-M:7XJ&V!-(^(2DJ(U]V2W_JUH,R@S#VZOAIT^L=#1'@"Z'!JTY\6\Z
MFNTX?WIL$*7^FR=.)3MB*^%-A)Q F9K25-S8%W3+TDC;1Y!0"G'-BANL?NX(
MO QO M,WA(MU/[?3!;!3MO]7 /M$+?RNV#7S-SAZOA&4J! S:A]-I!4,P/X9
M%\MO04J:B;WP3IHZ96^=EV7=S3S&C\Z^T-Q<"(!>6)JAC 1ML-!^MI:]Z;Q4
MTGYW[$JN8WQ=IBP;59")J_P?>)HYJPHN$FP;&9E8\T;+^7NB'&-7 9E$E$#(
MXXAL__ -H0+TM*R<=%*64CH_L\7W"DJS?.V8CU6=_M>J,>I9YW?BD:V P@H6
M(2Z(PS17)@&U'RXTSY:DUG1+RF4>CV*/5SGT=.N]-HJ/S/0?&T-G+(4I(BTV
MA#1D]60'.R\=M/F/I 14ZP[49+"EZH@&A[%K)OL?(YJ4'WY#(6U&Z_=4" ?
M\1^>:[)J#$B^C'NC%4C$S<WVVE%Z!'-H&PL@&'>V*]F\=JO2R9\*6NC^5=VH
MBFO""FW?<<@)!0S]TS+ 5&\S?#;SHJY/DJZ@;GK_SR#F.<Q_0E#X)3+LO4+_
M&\NA@3T[U> _[9CE,*%:A$$PE$$+>GZHP$>XR;$L@IS-]'QS#X@16!>Y_69P
M#Y 8U/]2-+*F)L?Y&H APX6V?R>4X F&QXDAJKND&[J;V\N:8@C94EJYG_76
MJ1PV%^/VKLTDY"/=![40&<$]X2E^QU55H?-YZ9_N$.A'D4&M2GV"ZMMAT)4.
M@T>"(FN+8\;30/*:YD3TRUCVN%/<WA_(\]%<520\XFVHDT>?*+_3]6<14_N!
MPR>1:"A1E 3 L84%_G2LRD/>1WHZ:\;I><W)Q!'OD#7Y/<!Y;!NT>J?[K1M,
M%>3]>NR ZW0#CY@[N<"@K1;_P4";=%.J%=OT%O2@K/80EZJ]_2GX^=*PA(<_
M_LT0#_E/+H_0.\ ]8(4!9@"I>4XNSR..S%[]YLK%7<1R;!1/MT4I=I*?'H0,
MFDP!K'E:K'ID/-M+Y(;K2Q4N6+&_G^'Y0$/I4*N8])-2BE1(PHE'!%<0N+;"
M,-K]FT-/1",!O3JW.E7WN><)3YF0_6)4EZ/V)$2E,P4SW//)NA[QD<LX$#RW
M_*:16A"[M%G1[AF*^YR/R&*=H7EUF:>W =I2#;^0&SSFXERFT+=$K7Y<:/_8
M1M+[R%=PHT<?MQ'NDHM-L"3N9N'Z(GWD N_<L<<=?\?=U''*^3'9-I%<F=KC
M<EX K@SL,S*NI+\ *=YQ,;C&Y,3"31]S=A%[.7IJ8ICS+:8.K\'MG*@+HJT#
M\=3+&G3Y6".')%-6P&A_$W=M[BN@Y4V.].FLJ2G>4"2.8%-I")=];WU(YA*@
M*$Y#@5<C8"=O#F[%RX3_KLZ]!UB"8T2"@/1L&.76Z-*Y'T<9<5TM7IN>[[<7
MW@%%G?&ZK8U*Q8T-F-9-QK-/IK ][*2FR.80CX1J#_ZL!=NB:?V9IM0QL\%+
M"''P3J:^>^/+?<>M8XG8O1:#A;R52_5B0+/("].8MPL(O0JH_"[@V+[]I]<=
MOG!.%4EU0@8?O?5EN0><O2W%[%S@NJ-!$&?DZ&P/-Z498U(YO1ST O2C&-&G
MN%@D%0,SGE7=&K/7JLY6,VZI[<A7L312B4<-R+8A!W^UYR/[G<.P*3CU FP/
MEW"?&27=*APC24I'U]^&M%!PMZ00%V;OS9J(!VN)6=L0T7[)-$5+SSZ*NQOF
MT?)ZOH[7GOH=_@>ZQ('4ZHKI=%K;/)&FKW^,JNN_!]08^P(]7ZU3\(@BF=?F
MG L(]-ZJMJ9W'+1^DN)(6_GX<32S?X^Y5]!K=3_C,3++BT/,M-KV]X+B@F:4
M^#D%7MVUADZI3W\-TN*NX^0><&C5O%:8C2R$7Z'HW1[8M4,F6])\PMS1GTN\
MQ/1.?+?J'O L$TNDZA4J_F%18$]]4E5_$]<EM1E@'C<IO71S+ZUTHZ@.<\7O
M6?QQ^TP#<Z>:K1='>$,-V6J1KYVW'U8,AI@8J)L;BJ39>(K.W%'M)O'[? =Z
M<:JVZ&$L&TE6)9M\U%+]>3IHQWF< MB\8]?\!%QFZ]'65Q[5KY'+,1-Q,$.W
MNQ!QNG54]V9YC& +\F3;Z",TOUX\2&J4>LYO<16]L9/5@,\6)$R-HIUVHL+1
MTE\<SC2^F"&OQ=TDZ/:+5A E[Q&2G66'7XBN^P3]9H*K!CEW2-P6YOO/#GVV
M43KOB.HN0!/&$\4-;[@'1-J^(.&2X]:Q6Z9<%PU AU_YK!I7M>#)>Q6 ,EYL
M!0]S9]OG"10&OZ0=&*0AMQ]9[PUW+5DAY87G=V3@(!4X*XX?(&](2R8F)DZ7
ME0_>]+OM=G#R014>E=ZB]+@B1K1II,1>23'-8Z^GF;@:-^3K%K?HGEKW &\;
MD8[Z6QL6A]_GAK-Q7R)WOQ!%HGCM\O/Q1IC!=\1!D2([%G\EAAGN7<_DPE:\
M:M6:$T^V+16Y5>*^C7W!+ %]SB!!/>62"WD!:?TD/^,H/<?SQ0ZK_'P'KV5R
MN9BSMZ$ZR=^3/P,7)?+!19EN!J92<NHS*G@/<'*E;//QX-<6ZX7;ML?L)WWI
MN6.;>4GL<A)^FXC[S)PB9$,829%2B)(9?^^IEBF*H.V,,7[^DP'ZM2G5K>Y)
MU-0JE6ZQ#WXFKH$\8C.%K;.Q%6?7Y61!_[?>,QOGIW\Z95Z0G"!)T;^M-+K/
MZL!3UJ\-L"$#\L9N=/ !4"F=UB+3=D9CI4AW^-F1QD*]R",((>3GLE5*[NID
MDT"^YVPM]!Z0^;:8:I*VD)I<F!=QQM\=+DP._Y-_81MPB'>4^5JH$V\C^I)O
MF[+I9[KO:PK=R7,O.1E7+QZEQ@H0 -<ZSW(0;;\J?-9L;=ED+;?4WQJW=2U-
MX515[[<G?"E!ZBI$%V>#1!<WK3AA-G<"!KP)&GN?5SV98T9\<5)SJ0^@_OGS
M-/UV!WT*A59B=<T3<,Y&A0S2FCJ"6CM:Y\V/NM'2#[>3]#\^P;P'$/H$UL'P
M/#^UC@NJ%4(2MY:!.-HGI/AOD\LW&WW(PO$?1&P^T03*S/Z7-M*BG7CS*5<C
M4:)U,Z5%']T-7!&%/8NS!GNZE_[^P430#-@LJP$GT[K2+$N9/D"^\B-&]''A
MESJ0O,6N[&[WKDN7.XH3L\2[DVLQVCJQ'+SFRY$#IS,47OIN@W<,#+FT(%,@
ME0/BX2%(J/_QJ*SWE&.;SAUMRKDT:"TIK$D>,X)+GG7Q2U-#>3KD,*<\43*6
MC>XG]XM-;%8%J<_NYA7"='.:(!]\YT$A=B*6-_4"^+RJ=(\&, U)8J*L .W3
M4)8#8.J^@$Y54ZV?:RAS/(E6@J;O1EP[NI"B=O[?\))&"21ERP?+DQB>F)0O
M>W$,3;:U-0T)K<JT7LB)G'/>N(W15]0OW( [BWPWP#O71+.TSDH9,*?JV+ $
M7%L,6@'B.E_Q4+(@@>O+;,K)1^2?3F E.0FU7#X>#GX>1HI4AV0G[N<B05>3
MP@2HC],63ZCK_9@9->\!Y&EMW_:CV,&#C.@37"L!,ZZ4SR::M HAL10\GQM.
MO2=.=)+8B1R""S*W)+^^'#-$GRE9\J2?/'(:M'UAV<)<D]$I\4/?0+?-&"Q?
MMY<\& L!&&Y&]G(=$S7BS=\#VG:>+=B4RE"NR["CAHE9.R] 4[XF@;.^M(NF
M%E=C&-Z5\%,I8>QZ!$^ I]QMN;7)FUXWPL2>5U'V@ ^/MTEI:S^?MA>UO((_
M*<U>J_=47!<"<>GAF)T8QPUP]-O==C"BW+9_;?B!31Y,#%2L2'#K><_B5;-(
M#WYJQC?OI_7EC^<7Y>R)1GZ+?1Z27M[]R8?RVGDD@E33UKL,=/8AL/1^%WD/
M^%Q>XZ;J%9_38AS^8UGF"M)#_O/:_<K+?;3C1J<:"480[!0_YYE$51OS6F!M
M;BP]$F'7E_](^0V>3-RK/>TI_\Z?,B!OV"EYQYRY HB2HQJH?I_\YS;U7-U8
M;Z4+$.M&%Q]9:?(@X%ZU[68<+4&B5)Z*+-3Z6HA<PM<;\8):J*O@M6V+A\;[
M\O(?%_>3_4AQ">4J6$J\?Z:GV9]GXC[7AK_V)H'GUOR"69G/:C61'U9]#W+R
M$SGN6PP<01FF+SN&-6AT#K.N=%RDTR""@GW*H;:G%\R0PZ')S]G(,GZ\'2E:
M6AYOUIU]+V?01C.KFTV5E[6XC<M[ZRUT#,[=L547FJ"/[PS"E9*K5IX8+#QR
MRA\W#GS$I^9\,WC>KH3T^/*$Q7;-.2]U56>4>/>.-DAY<D)Z9JH;3871',O5
MSR$\)_V##^YO>_W*G(7E]AL@^&2DI$RQ2!)N0P7!""<0JF!'DIU8_>=>PQRX
MV4H@UZTL>.7EO.Y*-[8'%$K#JV76U^9XNV2!PI/=VLG$,T?"H*W!=Z\@G&H>
MFM:>5S;<[8 .R2*7HJA,I7O #(P4IHS(0$4?/T#(63G8+?9LXABFZ^I*X';W
M;Y(IYYAB<>.:ET5RV_E]Y1N.?3I"@9!>X6D89D<$6Y>[7O>H'TJ#&&IOOE.K
MI*L#+%,S]H$\IVH O/VU2NG8S1:0%G?AB:A7%N5QZ8P2IS,<A\?,"W(B<.*C
M)0-H'KL?N /,\CNI\, UK^!(<(_]GOMT.(O 0BIW"/WS*5KV[73.41O?K?K6
MQTA*VU<R'O9"9]HV,?D]=$TM/TPE<>T &W2KB(P=/#GX\SM9@8?9?U^Y81'I
MQ$\=G;_IGIGYV+RI@5"T"QDDP1AZ[?ZHU ?](X&E")8GSP:.O"%\-.+)D+WI
M,MV,_.OR4EP*U9@FXC8A]IBS4M>UO BB[:Y%DM*GW"F>,%>!F#9IAWGA>2P1
ML@7D$[ K3]>.^3>=/K\%]3I#7BP- !42WV#@%_R!AV0$\39@+S(2=?+)A"K=
MD\F=LN^0@#&,5E]G&6"=,-->I<50TX2-!?7%$ATOBC-T\PR&1@/_?L>((,YQ
M2N-%U<AL7L7IBV0QF6VL7&//JL"%UV<F!GMJ>6960)5!TJ"W_G?N/>C$!EVF
MWD"VJ M/:3A+5$15O&7N1-)!2F!*J9;U+!^N?]FF!7J>2(,E>@P\RC=KE@L\
M^F)?N\I=^)OEG8YND[E4#/)*24JE#W5-:=]J L^6F*TZ5%1_F'U8XJE">54L
M"%V;,)E.*4%23&J@C6?X<&R\L,?F'F"!@W_PS:ERVO3&3M^EG*VJ-A_;_^[Q
M.P._BUH+!01TH=@KPDG+Q*470^R9TGF;[8BO8,I_P9.'(X+G8Q+A/K7_ +WY
ME<O! 37W ,TV)AJIJ55O(0D/UL)U,!N!)P:"<>(LV G*,7#RE,5Z8_/PE);^
MYZ6QS-NK].K5\SU]RGM G O"]?;[@_X^8RQ :\6@"9TX[DIG@,S(.,F_TSKL
MQ/Y&H^)_Q8S74W%'">G5KD$FY.DJ%BR- )]W^1V:15<,5'Q0J:/$Y8PY@_KX
M)[=,HL"_)(9G?F7U;[YU,</^(/**J-]3>')[ROL-TGN!<?Z'03>M+Q]6.&G4
M*N$8NC>UY1C2IW=A)OEKHV'@GW"YVZFO'ZA\#46PXMJ$\1YP!,UX]WRU;64_
M1UV4M^P&.BF%XRR0IYL<6<T6TD)=%^ O=9%-8NB V_;B'K #G/ >O0><J,3=
M-6W=Q0,:?#I&\?;(_"'>(N2+M2$=-=8$XT-O)!Y7>=O82;=ONE/B2.1[LH_1
M3OT::Q+=('D SO@*8L])K,/[7]8N:T13-$9*D5)I]R"5#^X!1%6OS.E3=F*]
M'*"2)0<KY+8DL8HH.@7.LSHN-!G/)R4R"#04.4'/M9^",5M&G"5Y;=R\"^IW
M:X33B2<//.<ZS)+?(G(MHPOKMW8W?38=P> ]0'#F<S0NA,(!4GJI" DZY%O7
M#"O2'<[_<2C#>WL<A[]Q]XBLB59FLOH50BT]#9NC-(N-@(92V"Q:F.^:ZL]'
MLA8NN E2H^=XK1B<UQ)W*4IW<O'* O M/'V; CS-U1B<?9N%$OFU^ &LA]NV
M.QXSEE#CT+M?'RPBJ^>J&'AZD9AXM./S:]>EOV")YU*=41S]'N!E7<JSQO"+
M&XH8Z56JXTLYTJE?N=T*%?-) WR90#WC"3EO]E!N;I9G%BVO2RYU)HUS*%RR
M"^7@8=_P];B.QO4)\'SA:00ST-F]7%^1KI!,V5!JC#*,I$%)B%*_]+-/[TUG
MG@(6IU*%ZI/,- G\6J 04!JS25^?Z*;ZTQ1.0!(S5D^7CGS/=Q52JK&&DG>&
MIZ[C1*3$%9*LQD1[;85H)K9=H)V>9SZ9$'Z%-.AVS])$FO1T[&DN\N"/FHZW
M)BUO])/#[7M?.V88\$P?8"1!5W8[%#]H+\E@H$Q<9IA_NHPP5R&9P*[V" UI
M#S7CLJN*SVUVA7_*^"[HOIV_J?=YY=.W6WH/F!/;N =( @$F_Q4GD]KRFPLA
M'LW*EI1IUHW:9#.P&RZQ?+Z 8GFW<O$U0XP]#*R>HI;]J?:5P]-LCIKI)7?3
M,4Q;BNTH87KD]'DS,?.F<]HG1<(2FDJ*)%< @$^X">ZHT_(V2 (1=8AC!#(?
MU]7NYV+_+>CC8"&:U%M#R+8*]O4X)H1@ZC1.6)_+#0NO3ZR&F-2F)?(8C=><
M&4JRQ_0!]Z\W+VJH7MZ1[\]&2X&*K=3':W)"&X5=OWS[X<+G\OH>X+K@*[B_
M_C;<.?F.P<J5^#IB"%VQT<-#(E0LBSZB)B+3CD-2<:;*FV.QUU4DL$FAH)"[
M/E="J$W)UPRK7B0.#:G!AL!3S%! 1JP_!YF8F;<F?GKLK&$\X/.BHV$T7&2'
MW\*/BPG26#:>S9GO9([UP>LDT%=P5K[JQKL09&Y@L< @7;LAX/J!M'=#/[4(
MQ0S?#CAW+4?P1&Q4@,AOB6@K0131<+JXQ]_)*SXH4EN\:3KN;#WA!(F<7^'=
M!3(_ .:#E5?.95W160"AH!C2NSQ?MCT#+*YCK#UEMK F#8P,X^,P)NI:4$Z#
M[B,=X[@R[(VW@MNDJ^D>O?H8MD\-YI[KG$V='<JB"25,@6J'5"*Y-T_[KC>]
MF'.01P>_&<948S^.0?LH_VQ"%0D&K3%"X"[@B2<EAES=D1AM\*/1M11 3ST2
MO+:")PJV7K\'D+ FE^CVT-W0$5OSUF+F_Q"]!^!]C02S]8K@DK?S4T85"!?C
MG%JQ,*S0B+B6VRDE5)YB*..)AE\6>G-I+^N@U&8H_^A\W>*C^9<_Y)%0X%,4
MCI,^]X3S,V\23^#$GXB PTZ9UY8;&6E)AJAD2W1,[0<H1]5!A0.B_9.AV92D
M^M/U:6MCE'"7(U)##F'02981UL)-P2P;Y#D*>N9J0T#7R]I;1G5KU%^JN-Z\
MR8&\JAI4'TZ/>,S_E;(#V'X/Z W3J$/F=S70_19LAM-/X9BPUAJ7RQ3UW.@.
M2-(J7MK'S#[^:1)KB;[MY=BIKG[''-9Y]WIJ12=Y4U/PSW?)"";>A0SVOGL
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M9#47Z9N5_Y.2FXQ4I\IUG%<W%^3,5C>M$M2+4AXP!K5A.LJ4+D,BZ^O"MU1
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MD35417+UW=DY%D:&F@C@HW,]IALG"U2"3G3%*=$1GZSKHS*#H>,.=L*#[S;
MZ \4R^B;;$(GJTOD.L6:N@L*9@6NK5[=+/P'0!= BZ;%EH'[HS2M^WQ^ES%7
MB45/Z_YBHBC5R7*5K^:R^! %(GK/L"7ZQFYIC8,2V6L:=;5GI*KR=-OTX< "
MW"*B[-(,8N65+V='EE039ADXIR<CSR4C:C;T%=*>7H0H/>WT-GZ5M<!=15'_
MT/S&RS :]\F9^#.S>*'H=WN&.V1H>Y3KRQ:A3!6C2Z.VC7HO::U=KU2J#IW5
ME3"?5W9+&DB8I<0L"X?O^0JZ++X8GR< =U+K]_KXT48EZIE@H<V,X8A@7&25
MDZ_JT'/ "9-M3HQ 1N,[W"A@_2VE\]V85EH=PXI>B3*N48EXT7[QCTE2V2E
MTL&!S8["\KG[G,1!U2B#CEG"><H4W"'BF.$VXO6V!WRFS56=&$_[I3KT$Y6I
M"V(2BPP-9DW/WH((6R:X26!L@(=76W,- :WO/JBCHM&7:Z"E=P:Z5;PEKX:Z
M&KB?"V1EZ&WIEC/<FS$2<_3 &P:E^&MOI[\S;R2M>0[W"+/[$?Q6BG'"K!JO
M2C8Y'A-CC*I;,A^C!K%>H.BV@H>'U6!0=S0GQFGS/LB"_V6$R_:7H6:;K^S*
MS/'*S,?WXO_*ZOQ?7_[TK,[_\?\%_?]&^5-SN?ZGT^S_7RG_M>,"FY*0$T_H
MI*]<OG4L(A[\HK'6ZS*IDM26"TS2X/FE5V2Y$K+T/@$9,GD-ICU0@%T&47I^
M6<;?/LM"4KT';=@Y7%)"3F# V7GX.<YOGX#^8O 7@[\8_,7@+P9_,?B+P5\,
M_F+P%X-_A$'1;R-;(X=+_@>08=@"@@<%[%1/78HCA!T6)?V-C*J3Q^]9XO/E
M?;O,>,\8[V_>N\(0ED&D^C\-EOXJ?Y6_RO]/2^T>O;%GOIYD<LA.9K Q3)E'
M4#F[M4:-Z$96DLL@D8R>/]74]Y%F3/WMBDI5)[M<B=:^KHC:.2AKF:$:3N:(
M,0@4<FQ %&JR_UYQF?LI(HF3KZ"?:8XO&&G"E\GG-_?*&>BQ'AZOCHBA1<1T
M4!-4KTV$I/KE$)A?_*AXMQ8OU*K4$2T]Z]6C#QS?Y!P\DG-:X@V3:V]''NPI
MC7,1S&7.?7WIXZ7^^0M5'4SWXZVVLH?7Z)Y#N#9$B.,@__GX+6E2=;6KT@6D
M#^NZ(FP'!:Q7^+NB"9(3_?R[W[^^D[[U%]E?9'^1_1W9(^C]!BP]M81A#&G2
MD7_FE.Y_2WF&".H2FJ<?KP*S[WQ//+8IMZ%1C+S3HQDOLMEC\G@8^_@WN5]D
M@D-GE,>\Y\?)*$!:<#V%/EFH^D)4/L_@WD7843()(Y*5BM&?^>8Q+I.RF>6J
MO.LS[<00&9S\NUE5536?JZ,G!^<Y?3Q#II>#T>\22>.@!TATJ,-+8YSV!6&<
M&\8'VX\N;NH7!;&G9AWTV6['*N\,FV=45IM@(M;;DJDK<YH:YVF-J-;=T2@\
M^YHG);&],":;J'RYEXXF6JJ3'XXEJ\\U[,A^P_S0TM1 -=2BWP#)>[I5$V65
M_ZW-PQ8%>+.O$.:-!74!CK@N.&^:1?0'\AXG4]3SO-UVDGA,1:%G@/9 ?"6]
MO>EN@56*PH=,V%4R^'--19!X8X-G(+J?$IUJDU$&>H%!@!OGCP OU2OLT@EQ
MAS-<$S]-%""3@>>C>Y%UD&6- ES]M:K4T.U,=F/ZHHJN1LXT1J1QJR'U( ZA
MLE/%-; \<&\"N7&9#VN98TCD)@,^_(??!6*9"*V\.KV2#'Z:SX@"C)R0*."(
M#$WHGV3SCU>?\4IWH';1#P6H/M?AN &:,H2T7&$!*O^E3OP?OLOG)G^LTGJQ
M,S-?K$61OF5P=8)T_;_9NRIM/F&,/:B#=[F:/J3 X73F;!ASYO_"Z!&\- I=
MHY/DX-36M*+$V(V>X/?K.,HO :V,\I[* ^#_"^+L)?>M.5.4@[VW+3IY6LO@
MZ'Y2P(P"=%" W.-J%!#SM&66H2^ ^5^H:;3<_^63_WGK\W=IJ'?@MSHHZ.\-
MDPBJ6*MP](VJ2BF_S0Q0E 6[MFTH"DY-?;S4NKC3L)]I\Y"(2"@OXFJ=9'?:
M-^.J9G<[C0TC8FQU?V)NU=NOK!M"_/Y](&.\AS;S$=HTVOE4S28%J56*2O5;
M*)2R0O:#_O>E2N:T'WXV'^#R>:]Z7MM'%Q'&ISQ[55-1;$;KM+:":!(Z3*G<
M7]K+1KAD"&4R["@,"#L,+K>T/_'9F9&FD_^].V U:U! ;.+I!.B(NDYKIV65
MQ>_XVDP$\/Q17[6((:6U* !R?C,M(^C*K><"!0RK81[]P4V-Y)@,VZ6@!61@
MWF^M@.0?74@K8X7,:5EP6-<<_V5._1FT-Q8<KS@X51%'$5<C&M!9T*/P,:3D
MW6M-5<,<_X.&"ZD>.QP)])L@CB.NVBX+#B!%D$^Y^BB@I]ADEVCM?Z-#O%;#
M!$36,@H(&OBA3[<*LJZ*]PC2#-\:59T-QLE,/(M>Q*$3FRK695E)->V15^%8
MJDJ><$NJX]O4*?_(]ZX <STSWW U[7T&$6>,-H(JK^]T4LQ U3.@D4^9H#]+
MA):@]-'Q<9G5?FF.3[&GP9-Q-SP^"S>7&W$[K4SFWOCTWJ:U9[XJ<,Y'8<<$
MFNUBMB<D40==9NZ/X1D7G1@=L>*$U7,;YR6Y#5DPZR12KR2H>IB9Z7U''Y+I
MZ)  GM\3IO:O?JHH\<D,4E9W0>M:U2S1U_Y0(7#.MV-.44!&P=8O]E_UC^Z@
M4Y-!UJ]<H8 -#N] HN,IAKWK>J1O_=&H_FSBW21_UKH_AS;JE&@TL^K:RBFU
MS)%S_M;2JOQ!PS%>_+UM3&<]AYY3ORR[].Y"+B*UT+C_I)NA_]3B""'=.<X1
MHRA9FN,PN-)]TF#%I,WYF>F.KBYF]&U:1V<"C\0>Q)[^1 F-XH@ NRET_/A#
M4J!X@:8C5%YC=\F; G D %Q@R5%(QEFK!QUF^]^W\+X1YR>!.UTCXZ9NTS1_
MU+S$*/1,4/H\TBC,&[!GQ_5,ABRY8CX+:PN<B%$W1'^<GJWG6:\D89:MAZC8
MM5,%-[PJ*=U]>Q\RY\!>M5_8N=+D310DN X'!5656"MU.L])4S\T?M5VIWPG
MUDF:INH7PZ M^+ A0:E)1;+=N(J0>_J(U$Y<=3T<>&?8:D]0F\9_GXIOCZ;\
M:%O5BY39(FZ"1 ',UTI^^&3OIG#@SM',;7O*9:4Z+7R\B)CJLR 7*M5^*-5>
M3$_*40LQ#!HNQ;(A139Y(ZU]"FRG<3"G3#(+;N@W:G5#JY ^S2 "1S_]'O4B
M;&(D1([]"RA*K'$*7 '==^B:/C*Z!ZK<I![\>(H]@GNP4AM5]Y(.6S<0RUL;
M(/]UVEBO670]Z"HP#L%WJ<Q,N!1 ^R0O<W)MQAM8KRX$_$I!N[THP'_@>KK\
MMS[]91*R71A"YA*05RDA-&_US)E!O&G$YS>!AK_:^ ^V\=]"PI&?7PH25/=Q
M/21& 7XQ-U2]_VKD/_KT\6\"!16;VK[TI"?ILX)TU7W<5=8ZCX/IB(>Q^CB(
MJGNNOH'VOF7M.*$ =]6+$TMT[_^NAWJ@B9;A,6[(RB3O*<Y!_OP6/PU!A2NH
MU:KF5*D&7J#W@(SPNHWUOWR:8_#6_2;&ZODG,C3!_VD?\/?%:8%4X$ILO6/$
MFC)E>(1'X-OD\I@ZDY16*A\4\0HSJFF[O$P"D4=VOR7DV._1Q.Z1I+C: VL2
M+O]GVFRR7_KGM.OA\P$B$7/"72EWC19L_ 5&! :$.RL[$TQFVIB4SB(P+#G0
M7Y(=*/7DEUD/'_5ST\B6C[GNVNY\>KHL#K57$UMO]EZ?KUT@]E5&0)R6BO+-
M)VR/;Y@'Q]DNT<QK** ']^",B739^XI_;AZ3HM]P]XYU:PB?D,NZ6J633<]@
M]"=#&_O9B^M01MD>$\BUB0WDOOW*FUL5=P?FJ-PC[7-K#%X"8\/HW/557VR(
M>=VR'R5CDVKRP\0\0LE YT+6:*=5W"FU#6FW,!4^5B?LCP_G?=T(7B9%RHQ0
M*H_O)H+?L- 8\L>EX;VPF&PR,?7Z<,)S:>8NVB42((/Y@GX<[7N*_!&] *(J
M9??M@%14MM6 +2]Z;/RLTFSA"V?T8Z:6)>-DI<+\3^JR^1M *UG5?U]$E9N'
M7<X5E_K@9'(...O<I\*5FGX>OE[5ZZONXU?0FI+T,61R\>%7N]N[XFA?SA#;
MTG2I9!&UC/@RML[2>^#_[<#@^;8^5LY^VH%>&:DZ26OXYH@GK2,AIW"[&'GE
M!DPG_Y1RR'DX.]1M-EB9Z:*N6[(HK^DZ4,-+/U]=^#)I$H0"5I^,@K8G0(F
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M:$Q_60W3'/]EI1=(^W>'4]@KP+1LQKI:,A/O%F^JY!3A&;J1I[CE,[/89J;
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M8DRY<MME/L9(35G&98'-(&3)$\& A/""]F^J[I>N*TW8N0W<F]$L-[<Q>+M
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MF_6Z=!T7\H0JG8!E\*>)*UD(7-M&M29\Q#P$$Y>Z!6.?W([$3/ZA6F$6@!:
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MS-/-,RLVPZ:I!BU8\YW%.:3W^=CSB@F2R 7)/I&JR;Z/%#/DU!9E"@P!PM<
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MJ5*EX>#&B- :A'D[[ZM[6BE4P<D"[-FM/E;H^]4K.#]F%#=X.!\,)/0\)1\
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M;"TR,#(Q,3(S,2YX<V102P$"% ,4    " #1@TE4/[327.L)   5;   %0
M            @ %\"@  879X;"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%
M  @ T8-)5(V;#7";$P  U54! !4              ( !FA0  &%V>&PM,C R
M,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( -&#251?=1W7PC4  &(8 P 5
M          "  6@H  !A=GAL+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" #1@TE4LVU)?SDC   K:0( %0              @ %=7@  879X;"TR,#(Q
M,3(S,5]P<F4N>&UL4$L! A0#%     @ T8-)5!X]PD?M\P  $LD'  T
M         ( !R8$  &4S-#<U7S$P<2YH=&U02P$"% ,4    " #1@TE4G'K0
M(1$'  "2'@  $               @ 'A=0$ 93,T-S5?97@S,2TQ+FAT;5!+
M 0(4 Q0    ( -&#253 T$[!(0<  %<?   0              "  2!] 0!E
M,S0W-5]E>#,Q+3(N:'1M4$L! A0#%     @ T8-)5$"R#@7@!0  J14  !
M             ( !;X0! &4S-#<U7V5X,S(M,2YH=&U02P$"% ,4    " #1
M@TE4&MAT'9\1 0"ND $ #0              @ %]B@$ :6UA9V5?,# Q+FIP
M9U!+ 0(4 Q0    ( -&#252C$@N\6 H! '%R 0 -              "  4><
E @!I;6%G95\P,#(N:G!G4$L%!@     +  L M@(  ,JF P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
